# Top 100 PICO-like extracts for lijecnicki vjesnik-139-365_cleaned.json

1. [outcome] score 14 ✅ BINGO (PIO)
Smjernice Guidelines SMJERNICE ZA DIJAGNOZU, LIJEČENJE I PRAĆENJE BOLESNIKA OBOLJELIH OD RAKA PLUĆA NEMALIH STANICA
GUIDELINES FOR DIAGNOSIS, TREATMENT AND MONITORING PATIENTS WITH NON-SMALL CELL LUNG CANCER MIROSLAV SAMARŽIJA, MARKO
JAKOPOVIĆ, MARIJO BOBAN, LIDIJA BOŠKOVIĆ, INGRID BELAC LOVASIĆ, ANTONIO JURETIĆ, DAMIR GUGIĆ, JASNA RADIĆ, SVEN
SEIWERTH, SNJEŽANA TOMIĆ, KSENIJA LUČIN, SANJA PLEŠTINA, MIHOVIL ROGLIĆ, JOŠKO JURIČIĆ, SILVANA SMOJVER JEŽEK, DINKO
STANČIĆ-ROKOTOV, IVICAMAŽURANIĆ, SUZANA KUKULJ, KREŠIMIR DOLIĆ, DRAGAN ARAR, MELITA KUKULJAN, EDUARD VRDOLJAK*
Deskriptori: Karcinom pluća nemalih stanica – dijagnoza, liječenje, patologija; Tumorski stadij; Smjernice; Hrvatska
Sažetak. Rak pluća najučestalija je zloćudna bolest u muškaraca, a pri vrhu je učestalosti i u žena. Među oboljelima 85%
čine bolesnici s rakom pluća nemalih stanica. S obzirom na agresivnu prirodu ove bolesti i lošu prognozu ako se ne
dijagnosticira u ranom stadiju bolesti, vrlo je važno defi nirati i provoditi standardizirani pristup u dijagnostici,
liječenju i praćenju ovih bolesnika. Metode liječenja uključuju kirurgiju, kemoterapiju, radioterapiju, ciljanu biološku
terapiju i imunoterapiju ovisno o stadiju bolesti, biološkim obilježjima tumora i općem stanju bolesnika. Descriptors: C
arcinnoma, non-small-cell lung – diagnosis, pathology, therapy; Neoplasm staging; Practice guidelines as topic; Croatia
Summary. Lung cancer is the most common male cancer, and one of the most common female cancers. Non-small cell lung
cancers account for 85% of lung cancers. Due to the aggressiveness of the disease and bad prognosis if it is not
diagnosed early, it is important to defi ne and implement standardized approach for diagnostics, treatment and
monitoring of these patients. Treatment modalities include surgery, chemotherapy, radiotherapy, targeted biolo

2. [population] score 13 ✅ BINGO (PIO)
Smjernice Guidelines SMJERNICE ZA DIJAGNOZU, LIJEČENJE I PRAĆENJE BOLESNIKA OBOLJELIH OD RAKA PLUĆA NEMALIH STANICA
GUIDELINES FOR DIAGNOSIS, TREATMENT AND MONITORING PATIENTS WITH NON-SMALL CELL LUNG CANCER MIROSLAV SAMARŽIJA, MARKO
JAKOPOVIĆ, MARIJO BOBAN, LIDIJA BOŠKOVIĆ, INGRID BELAC LOVASIĆ, ANTONIO JURETIĆ, DAMIR GUGIĆ, JASNA RADIĆ, SVEN
SEIWERTH, SNJEŽANA TOMIĆ, KSENIJA LUČIN, SANJA PLEŠTINA, MIHOVIL ROGLIĆ, JOŠKO JURIČIĆ, SILVANA SMOJVER JEŽEK, DINKO
STANČIĆ-ROKOTOV, IVICAMAŽURANIĆ, SUZANA KUKULJ, KREŠIMIR DOLIĆ, DRAGAN ARAR, MELITA KUKULJAN, EDUARD VRDOLJAK*
Deskriptori: Karcinom pluća nemalih stanica – dijagnoza, liječenje, patologija; Tumorski stadij; Smjernice; Hrvatska
Sažetak. Rak pluća najučestalija je zloćudna bolest u muškaraca, a pri vrhu je učestalosti i u žena. Među oboljelima 85%
čine bolesnici s rakom pluća nemalih stanica. S obzirom na agresivnu prirodu ove bolesti i lošu prognozu ako se ne
dijagnosticira u ranom stadiju bolesti, vrlo je važno defi nirati i provoditi standardizirani pristup u dijagnostici,
liječenju i praćenju ovih bolesnika. Metode liječenja uključuju kirurgiju, kemoterapiju, radioterapiju, ciljanu biološku
terapiju i imunoterapiju ovisno o stadiju bolesti, biološkim obilježjima tumora i općem stanju bolesnika. Descriptors: C
arcinnoma, non-small-cell lung – diagnosis, pathology, therapy; Neoplasm staging; Practice guidelines as topic; Croatia
Summary. Lung cancer is the most common male cancer, and one of the most common female cancers. Non-small cell lung
cancers account for 85% of lung cancers. Due to the aggressiveness of the disease and bad prognosis if it is not
diagnosed early, it is important to defi ne and implement standardized approach for diagnostics, treatment and
monitoring of these patients. Treatment modalities include surgery, chemothera

3. [outcome] score 9
Smjernice Guidelines SMJERNICE ZA DIJAGNOZU, LIJEČENJE I PRAĆENJE BOLESNIKA OBOLJELIH OD RAKA PLUĆA NEMALIH STANICA
GUIDELINES FOR DIAGNOSIS, TREATMENT AND MONITORING PATIENTS WITH NON-SMALL CELL LUNG CANCER MIROSLAV SAMARŽIJA, MARKO
JAKOPOVIĆ, MARIJO BOBAN, LIDIJA BOŠKOVIĆ, INGRID BELAC LOVASIĆ, ANTONIO JURETIĆ, DAMIR GUGIĆ, JASNA RADIĆ, SVEN
SEIWERTH, SNJEŽANA TOMIĆ, KSENIJA LUČIN, SANJA PLEŠTINA, MIHOVIL ROGLIĆ, JOŠKO JURIČIĆ, SILVANA SMOJVER JEŽEK, DINKO
STANČIĆ-ROKOTOV, IVICAMAŽURANIĆ, SUZANA KUKULJ, KREŠIMIR DOLIĆ, DRAGAN ARAR, MELITA KUKULJAN, EDUARD VRDOLJAK*
Deskriptori: Karcinom pluća nemalih stanica – dijagnoza, liječenje, patologija; Tumorski stadij; Smjernice; Hrvatska
Sažetak. Rak pluća najučestalija je zloćudna bolest u muškaraca, a pri vrhu je učestalosti i u žena. Među oboljelima 85%
čine bolesnici s rakom pluća nemalih stanica. S obzirom na agresivnu prirodu ove bolesti i lošu prognozu ako se ne
dijagnosticira u ranom stadiju bolesti, vrlo je važno defi nirati i provoditi standardizirani pristup u dijagnostici,
liječenju i praćenju ovih bolesnika. Metode liječenja uključuju kirurgiju, kemoterapiju, radioterapiju, ciljanu biološku
terapiju i imunoterapiju ovisno o stadiju bolesti, biološkim obilježjima tumora i općem stanju bolesnika. Descriptors: C
arcinnoma, non-small-cell lung – diagnosis, pathology, therapy; Neoplasm staging; Practice guidelines as topic; Croatia
Summary. Lung cancer is the most common male cancer, and one of the most common female cancers. Non-small cell lung
cancers account for 85% of lung cancers. Due to the aggressiveness of the disease and bad prognosis if it is not
diagnosed early, it is important to defi ne and implement standardized approach for diagnostics, treatment and
monitoring of these patients. Treatment modalities include surgery, chemotherapy, radiotherapy, targeted biologic
therapy and immunotherapy according to the stage, specifi c tumour histological subtype and patient condition. Liječ
Vjesn 2017;139:365–371 Smjernice za dijagnozu, liječenje i praćenje bolesnika * Klinika za plućne bolesti Jordanovac,
Medicinski fakultet Sveučilišta oboljelih od raka pluća nemalih stanica napravilo je Hrvat- u Zagrebu, KBC Zagreb
(akademik Miroslav Samaržija, dr. med.; prof. sko onkološko društvo Hrvatskoga liječničkog zbora, a re- dr. sc. Marko
Jakopović, dr. med.; doc. dr. sc. Sanja Pleština, dr. med.; prim. zultat su angažmana i suradnje vodećih stručnjaka u
Hrvat- Mihovil Roglić, dr. med.; prof. dr. sc. Dinko Stančić-Rokotov, dr. med.; prof. dr. sc. Ivica Mažuranić, dr. med.;
doc. dr. sc. Suzana Kukulj, dr. med.), skoj na područjima onkologije, pulmologije, kirurgije, pato- Klinika za
onkologiju i radioterapiju, Medicinski fakultet Sveučilišta u logije, radiologije i citologije. Izrada uputa nije fi
nancijski Splitu, KBC Split (doc. dr. sc. Marijo Boban, dr. med.; mr. sc. Lidija potpomognuta. Osnovni ciljevi ovih
smjernica jesu pobolj- Bošković, dr. med.; prof. dr. sc. Eduard Vrdoljak, dr. med.), Klinika za radioterapiju i
onkologiju, Medicinski fakultet Sveučilišta u Rijeci,

4. [intervention] score 8 ✅ BINGO (PIO)
Smjernice Guidelines SMJERNICE ZA DIJAGNOZU, LIJEČENJE I PRAĆENJE BOLESNIKA OBOLJELIH OD RAKA PLUĆA NEMALIH STANICA
GUIDELINES FOR DIAGNOSIS, TREATMENT AND MONITORING PATIENTS WITH NON-SMALL CELL LUNG CANCER MIROSLAV SAMARŽIJA, MARKO
JAKOPOVIĆ, MARIJO BOBAN, LIDIJA BOŠKOVIĆ, INGRID BELAC LOVASIĆ, ANTONIO JURETIĆ, DAMIR GUGIĆ, JASNA RADIĆ, SVEN
SEIWERTH, SNJEŽANA TOMIĆ, KSENIJA LUČIN, SANJA PLEŠTINA, MIHOVIL ROGLIĆ, JOŠKO JURIČIĆ, SILVANA SMOJVER JEŽEK, DINKO
STANČIĆ-ROKOTOV, IVICAMAŽURANIĆ, SUZANA KUKULJ, KREŠIMIR DOLIĆ, DRAGAN ARAR, MELITA KUKULJAN, EDUARD VRDOLJAK*
Deskriptori: Karcinom pluća nemalih stanica – dijagnoza, liječenje, patologija; Tumorski stadij; Smjernice; Hrvatska
Sažetak. Rak pluća najučestalija je zloćudna bolest u muškaraca, a pri vrhu je učestalosti i u žena. Među oboljelima 85%
čine bolesnici s rakom pluća nemalih stanica. S obzirom na agresivnu prirodu ove bolesti i lošu prognozu ako se ne
dijagnosticira u ranom stadiju bolesti, vrlo je važno defi nirati i provoditi standardizirani pristup u dijagnostici,
liječenju i praćenju ovih bolesnika. Metode liječenja uključuju kirurgiju, kemoterapiju, radioterapiju, ciljanu biološku
terapiju i imunoterapiju ovisno o stadiju bolesti, biološkim obilježjima tumora i općem stanju bolesnika. Descriptors: C
arcinnoma, non-small-cell lung – diagnosis, pathology, therapy; Neoplasm staging; Practice guidelines as topic; Croatia
Summary. Lung cancer is the most common male cancer, and one of the most common female cancers. Non-small cell lung
cancers account for 85% of lung cancers. Due to the aggressiveness of the disease and bad prognosis if it is not
diagnosed early, it is important to defi ne and implement standardized approach for diagnostics, treatment and
monitoring of these patients. Treatment modalities inc

5. [outcome] score 8
započeti i bez sastanka multidiscipli- medicinu i citologiju, Medicinski fakultet Sveučilišta u Splitu, KBC narnog tima
samo u hitnim stanjima te sukladno organiza- Split (prof. dr. sc. Snježana Tomić, dr. med.), Zavod za opću patologiju i
ciji pojedinih klinika, a s poštovanjem pravila dobre klinič- patološku anatomiju, Medicinski fakultet Sveučilišta u
Rijeci, KBC Rijeka (prof. dr. sc. Ksenija Lučin, dr. med.), Klinika za kirurgiju, Medi- ke prakse. cinski fakultet
Sveučilišta u Splitu, KBC Split (Joško Juričić, dr. med.), Klinički zavod za dijagnostičku i intervencijsku radiologiju,
Medi- Incidencija cinski fakultet Sveučilišta u Splitu, KBC Split (doc. dr. sc. Krešimir Dolić, dr. med.), Klinika za
plućne bolesti, Medicinski fakultet Rak pluća najučestalija je zloćudna bolest u muškaraca, a Sveučilišta u Splitu, KBC
Split (Dragan Arar, dr. med.), Klinički zavod pri vrhu je učestalosti i u žena. Istodobno je i vodeći uzrok za
radiologiju, Medicinski fakultet Sveučilišta u Rijeci, Fakultet smrti među svim zloćudnim bolestima. U Hrvatskoj se na
zdravstvenih studija Sveučilišta u Rijeci, KBC Rijeka (doc. dr. sc. Meli- ta Kukuljan, dr. med.) godinu dijagnosticira
više od 2900 novih bolesnika s rakom Adresa za dopisivanje: Prof. dr. sc. E. Vrdoljak, Klinika za onkologiju i pluća, od
kojih 85% čine bolesnici s rakom pluća nemalih radioterapiju, KBC Split, Spinčićeva 1, 21000 Split; e-mail: edo.vrdo-
stanica. Incidencija raka pluća u Hrvatskoj jest 68/100.000 ljak@gmail.com stanovnika (M 103, Ž 35,5).1 Primljeno 26.
srpnja 2017., prihvaćeno 30. listopada 2017. Tablica – Table 1. TNM-klasifi kacija raka pluća nemalih stanica / Non-
small cell lung cancer TNM classifi cation Deskriptori T, N i M 8. izdanja TNM-klasifi kacije raka pluća / T, N and M
descriptors for the eighth edition of TNM classifi cation for lung cacer T: primarni tumor / T: primary tumor Tx ne može
se procijeniti prisutnost primarnog tumora ili tumor koji je dokazan prisutnošću zloćudnih stanica u sputumu ili ispirku
bronha, ali se ne može vizualizirati slikovnim metodama ili bronhoskopijom / primary tumor cannot be assessed or tumor
proven by presence of malignant cells in sputum or bronchial washings but not visualized by imaging or bronchoscopy T0
bez dokaza primarnog tumora / no evidence of primary tumor Tis k arcinom in situ / carcinoma in situ T1 tumor ≤ 3 cm u
najvećem promjeru okružen plućima ili visceralnom pleurom bez bronhoskopskog dokaza invazije proksimalno od lobarnog
bron- ha (npr., tumor nije vidljiv u glavnom bronhu) / tumor ≤ 3 cm in greatest dimension surrounded by lung or visceral
pleura without bronchoscopic evidence of invasion more proximal than the lobar bronchus (i.e., not in the main bronchus)
T1a(mi) minimalno invazivni karcinom / minimally invasive adenocarcinom T1a tumor ≤ 1 cm u najvećem promjeru / tumor ≤ 1
cm in greatest dimension T1b tumor > 1 cm, ali ≤ 2 cm u najvećem promjeru / tumor > 1 cm but ≤ 2 cm in greatest
dimension T1c tumor > 2 cm, ali ≤ 3 cm u najvećem promjeru / tumor > 2 cm but ≤ 3 cm in greatest dimension T2 tumor > 3
cm, ali ≤ 5 cm ili tumor s bilo kojom od navedenih značajka: zahvaća glavni bronh neovisno o udaljenosti od karine, ali
ne zahvaća karinu, invadira visceralnu pleuru, povezan je s atelektazom ili opstruktivnim pneumonitisom koji se širi u
hila

6. [intervention] score 2
Smjernice Guidelines SMJERNICE ZA DIJAGNOZU, LIJEČENJE I PRAĆENJE BOLESNIKA OBOLJELIH OD RAKA PLUĆA NEMALIH STANICA
GUIDELINES FOR DIAGNOSIS, TREATMENT AND MONITORING PATIENTS WITH NON-SMALL CELL LUNG CANCER MIROSLAV SAMARŽIJA, MARKO
JAKOPOVIĆ, MARIJO BOBAN, LIDIJA BOŠKOVIĆ, INGRID BELAC LOVASIĆ, ANTONIO JURETIĆ, DAMIR GUGIĆ, JASNA RADIĆ, SVEN
SEIWERTH, SNJEŽANA TOMIĆ, KSENIJA LUČIN, SANJA PLEŠTINA, MIHOVIL ROGLIĆ, JOŠKO JURIČIĆ, SILVANA SMOJVER JEŽEK, DINKO
STANČIĆ-ROKOTOV, IVICAMAŽURANIĆ, SUZANA KUKULJ, KREŠIMIR DOLIĆ, DRAGAN ARAR, MELITA KUKULJAN, EDUARD VRDOLJAK*
Deskriptori: Karcinom pluća nemalih stanica – dijagnoza, liječenje, patologija; Tumorski stadij; Smjernice; Hrvatska
Sažetak. Rak pluća najučestalija je zloćudna bolest u muškaraca, a pri vrhu je učestalosti i u žena. Među oboljelima 85%
čine bolesnici s rakom pluća nemalih stanica. S obzirom na agresivnu prirodu ove bolesti i lošu prognozu ako se ne
dijagnosticira u ranom stadiju bolesti, vrlo je važno defi nirati i provoditi standardizirani pristup u dijagnostici,
liječenju i praćenju ovih bolesnika. Metode liječenja uključuju kirurgiju, kemoterapiju, radioterapiju, ciljanu biološku
terapiju i imunoterapiju ovisno o stadiju bolesti, biološkim obilježjima tumora i općem stanju bolesnika. Descriptors: C
arcinnoma, non-small-cell lung – diagnosis, pathology, therapy; Neoplasm staging; Practice guidelines as topic; Croatia
Summary. Lung cancer is the most common male cancer, and one of the most common female cancers. Non-small cell lung
cancers account for 85% of lung cancers. Due to the aggressiveness of the disease and bad prognosis if it is not
diagnosed early, it is important to defi ne and implement standardized approach for diagnostics, treatment and
monitoring of these patients. Treatment modalities include surgery, chemotherapy, radiotherapy, targeted biologic
therapy and immunotherapy according to the stage, specifi c tumour histological subtype and patient condition. Liječ
Vjesn 2017;139:365–371 Smjernice za dijagnozu, liječenje i praćenje bolesnika * Klinika za plućne bolesti Jordanovac,
Medicinski fakultet Sveučilišta oboljelih od raka pluća nemalih stanica napravilo je Hrvat- u Zagrebu, KBC Zagreb
(akademik Miroslav Samaržija, dr. med.; prof. sko onkološko društvo Hrvatskoga liječničkog zbora, a re- dr. sc. Marko
Jakopović, dr. med.; doc. dr. sc. Sanja Pleština, dr. med.; prim. zultat su angažmana i suradnje vodećih stručnjaka u
Hrvat- Mihovil Roglić, dr. med.; prof. dr. sc. Dinko Stančić-Rokotov, dr. med.; prof. dr. sc. Ivica Mažuranić, dr. med.;
doc. dr. sc. Suzana Kukulj, dr. med.), skoj na područjima onkologije, pulmologije, kirurgije, pato- Klinika za
onkologiju i radioterapiju, Medicinski fakultet Sveučilišta u logije, radiologije i citologije. Izrada uputa nije fi
nancijski Splitu, KBC Split (doc. dr. sc. Marijo Boban, dr. med.; mr. sc. Lidija potpomognuta. Osnovni ciljevi ovih
smjernica jesu pobolj- Bošković, dr. med.; prof. dr. sc. Eduard Vrdoljak, dr. med.), Kli

7. [outcome] score -33 ✅ BINGO (PIO)
IIIA non-small cell lung cancer. J Clin On- prema preporuci multidisciplinarnog tima). col 2012;30:172–8. 8. Gilligan D,
Nicolson M, Smith I i sur. Preoperative chemotherapy in Diseminirana/neresektabilna lokalno uznapredovala patients with
resectable non-small cell lung cancer: results of the MRC bolest – pauza u liječenju, praćenje radi pravodobne
LU22/NVALT 2/EORTC 08012 multicentre randomised trial and up- date of systematic review. Lancet 2007;369:1929–37.
detekcije progresije bolesti 9. NSCLC Meta-analysis Collaborative Group. Preoperative chemothera- Klinički pregled, KKS,
DKS, SE i osnovne biokemijske py for non-small-cell lung cancer: a systematic review and meta-analy- pretrage krvi
svakih 8 – 12 tjedana prvih 12 mjeseci, svaka sis of individual participant data. Lancet 2014;383(9928):1561–71. 10.
Higgins K, Chino JP, Marks LB i sur. Preoperative chemotherapy ver- 3 – 6 mjeseci 2. i 3. godinu, zatim svakih 4 – 8
mjeseci tije- sus preoperative chemoradiotherapy for stage III (N2) non-small-cell kom 4. i 5. godine, potom svakih 6 –
12 mjeseci. Praćenje lung cancer. Int J Radiat Oncol Biol Phys 2009;75(5):1462–7. 11. Albain KS, Swann RS, Rusch VW i
sur. Radiotherapy plus chemothera- 32. Scagliotti GV, Hanna N, Fossella F i sur. The differential effi cacy of py with
or without surgical resection for stage III non-small cell lung pemetrexed according to NSCLC histology: a review of two
phase III cancer: a phase III randomised controlled trial. Lancet 2009;374: studies. Oncologist 2009;14:253–63. 379–86.
33. Scagliotti GV, Parikh P, von Pawel J i sur. Phase III study comparing 12. Thomas M, Rübe C, Hoffknecht P i sur.
Effect of preoperative chemo- cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemo- radiation in addition
to preoperative chemotherapy: a randomised trial therapy-naive patients with advanced-stage non-small-cell lung cancer.
in stage III non-small cell lung cancer. Lancet Oncol 2008;9:636–48. J Clin Oncol 2008;26:3543–51. 13. Furuse K, Fukuoka
M, Kawahara M i sur. Phase III study of concurrent 34. Paz-Ares LG, de Marinis F, Dediu M i sur. PARAMOUNT: final
overall versus sequential thoracic radiotherapy in combination with mito- survival results of the phase III study of
maintenance pemetrexed ver- mycin, vindesine, and cisplatin in unresectable stage III non-small-cell sus placebo
immediately after induction treatment with pemetrexed lung cancer. J Clin Oncol 1999;17:2692–9. plus cisplatin for
advanced nonsquamous non-small-cell lung cancer. J 14. Curran WJ Jr, Paulus R, Langer CJ i sur. Sequential vs.
concurrent Clin Oncol 2013;31:2895–902. chemoradiation for stage III non-small cell lung cancer: randomized 35. Sandler
A, Gray R, Perry MC i sur. Paclitaxel-carboplatin alone or with phase III trial RTOG 9410. J Natl Cancer Inst
2011;103(19):1452–60. bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 15. Fournel P, Robinet G,
Thomas P i sur. Randomized phase III trial of 36. Reck M, von Pawel J, Zatloukal P i sur. Phase III trial of cisplatin
plus sequential chemoradiotherapy compared with concurrent chemoradio- gemcitabine with either placebo or bevacizumab as
fi rst-line therapy therapy in locally advanced non-small-cell lung cancer: Groupe Lyon- for nonsquamous non-small cell
lung cancer: AVAiL.

8. [outcome] score -33 ✅ BINGO (ICO)
Rübe C, Hoffknecht P i sur. Effect of preoperative chemo- cisplatin plus gemcitabine with cisplatin plus pemetrexed in
chemo- radiation in addition to preoperative chemotherapy: a randomised trial therapy-naive patients with advanced-stage
non-small-cell lung cancer. in stage III non-small cell lung cancer. Lancet Oncol 2008;9:636–48. J Clin Oncol
2008;26:3543–51. 13. Furuse K, Fukuoka M, Kawahara M i sur. Phase III study of concurrent 34. Paz-Ares LG, de Marinis F,
Dediu M i sur. PARAMOUNT: final overall versus sequential thoracic radiotherapy in combination with mito- survival
results of the phase III study of maintenance pemetrexed ver- mycin, vindesine, and cisplatin in unresectable stage III
non-small-cell sus placebo immediately after induction treatment with pemetrexed lung cancer. J Clin Oncol
1999;17:2692–9. plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J 14. Curran WJ Jr, Paulus R, Langer
CJ i sur. Sequential vs. concurrent Clin Oncol 2013;31:2895–902. chemoradiation for stage III non-small cell lung
cancer: randomized 35. Sandler A, Gray R, Perry MC i sur. Paclitaxel-carboplatin alone or with phase III trial RTOG
9410. J Natl Cancer Inst 2011;103(19):1452–60. bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 15.
Fournel P, Robinet G, Thomas P i sur. Randomized phase III trial of 36. Reck M, von Pawel J, Zatloukal P i sur. Phase
III trial of cisplatin plus sequential chemoradiotherapy compared with concurrent chemoradio- gemcitabine with either
placebo or bevacizumab as fi rst-line therapy therapy in locally advanced non-small-cell lung cancer: Groupe Lyon- for
nonsquamous non-small cell lung cancer: AVAiL. J Clin Oncol Saint-Etienne d’Oncologie Thoracique-Groupe Français de
Pneumo- Cancérologie NPC 95-01 Study. J Clin Oncol 2005;23:5910–7. 37. Sandler A, Yi J, Dahlberg S i sur. Treatment
outcomes by tumor histol- 16. Aupérin A, Le Péchoux C, Rolland E i sur. Meta-analysis of concomi- ogy in Eastern
Cooperative Group Study E4599 of bevacizumab with tant versus sequential radiochemotherapy in locally advanced non-
paclitaxel/carboplatin for advanced non-small cell lung cancer. J Tho- small cell lung cancer. J Clin Oncol
2010;28:2181–90. rac Oncol 2010;5:1416–23. 17. Brunelli A, Charloux A, Bolliger CT i sur. ERS/ESTS clinical guide- 38.
Masters GA, Temin S, Christopher G i sur. Systemic Therapy for Stage lines on fitness for radical therapy in lung cancer
patients (surgery and IV Non-Small-Cell Lung Cancer: American Society of Clinical On- chemo-radiotherapy). Eur Respir J
2009;34:17–41. cology Clinical Practice Guideline Update. J Clin Oncol 2015;33: 18. Rusch VW, Giroux DJ, Kraut MJ i sur.
Induction chemoradiation and 3488–515. surgical resection for superior sulcus non-small cell lung carcinomas: 39. Santos
FN, de Castria TB, Cruz MR, Riera R. Chemotherapy for ad- long-term results of Southwest Oncology Group Trial 9416 –
(Inter- vanced non-small cell lung cancer in the elderly population. Cochrane group Trial 0160). J Clin Oncol
2007;25:313–8. Database Syst Rev 2015;(10):CD010463. 19. Hancock JG, Rosen JE, Antonicelli A i sur. Impact of adjuvant
treat- 40. Novello S, Barlesi F, Califano R i sur. Metastatic non-small-cell lung ment for microscopic residual disease
after non-small cell lung cancer cancer: ESMO Clini

9. [outcome] score -33 ✅ BINGO (PIO)
oracic radiotherapy in combination with mito- survival results of the phase III study of maintenance pemetrexed ver-
mycin, vindesine, and cisplatin in unresectable stage III non-small-cell sus placebo immediately after induction
treatment with pemetrexed lung cancer. J Clin Oncol 1999;17:2692–9. plus cisplatin for advanced nonsquamous non-small-
cell lung cancer. J 14. Curran WJ Jr, Paulus R, Langer CJ i sur. Sequential vs. concurrent Clin Oncol 2013;31:2895–902.
chemoradiation for stage III non-small cell lung cancer: randomized 35. Sandler A, Gray R, Perry MC i sur. Paclitaxel-
carboplatin alone or with phase III trial RTOG 9410. J Natl Cancer Inst 2011;103(19):1452–60. bevacizumab for non-small-
cell lung cancer. N Engl J Med 2006;355: 15. Fournel P, Robinet G, Thomas P i sur. Randomized phase III trial of 36.
Reck M, von Pawel J, Zatloukal P i sur. Phase III trial of cisplatin plus sequential chemoradiotherapy compared with
concurrent chemoradio- gemcitabine with either placebo or bevacizumab as fi rst-line therapy therapy in locally advanced
non-small-cell lung cancer: Groupe Lyon- for nonsquamous non-small cell lung cancer: AVAiL. J Clin Oncol Saint-Etienne
d’Oncologie Thoracique-Groupe Français de Pneumo- Cancérologie NPC 95-01 Study. J Clin Oncol 2005;23:5910–7. 37. Sandler
A, Yi J, Dahlberg S i sur. Treatment outcomes by tumor histol- 16. Aupérin A, Le Péchoux C, Rolland E i sur. Meta-
analysis of concomi- ogy in Eastern Cooperative Group Study E4599 of bevacizumab with tant versus sequential
radiochemotherapy in locally advanced non- paclitaxel/carboplatin for advanced non-small cell lung cancer. J Tho- small
cell lung cancer. J Clin Oncol 2010;28:2181–90. rac Oncol 2010;5:1416–23. 17. Brunelli A, Charloux A, Bolliger CT i sur.
ERS/ESTS clinical guide- 38. Masters GA, Temin S, Christopher G i sur. Systemic Therapy for Stage lines on fitness for
radical therapy in lung cancer patients (surgery and IV Non-Small-Cell Lung Cancer: American Society of Clinical On-
chemo-radiotherapy). Eur Respir J 2009;34:17–41. cology Clinical Practice Guideline Update. J Clin Oncol 2015;33: 18.
Rusch VW, Giroux DJ, Kraut MJ i sur. Induction chemoradiation and 3488–515. surgical resection for superior sulcus non-
small cell lung carcinomas: 39. Santos FN, de Castria TB, Cruz MR, Riera R. Chemotherapy for ad- long-term results of
Southwest Oncology Group Trial 9416 – (Inter- vanced non-small cell lung cancer in the elderly population. Cochrane
group Trial 0160). J Clin Oncol 2007;25:313–8. Database Syst Rev 2015;(10):CD010463. 19. Hancock JG, Rosen JE,
Antonicelli A i sur. Impact of adjuvant treat- 40. Novello S, Barlesi F, Califano R i sur. Metastatic non-small-cell
lung ment for microscopic residual disease after non-small cell lung cancer cancer: ESMO Clinical Practice Guidelines
for diagnosis, treatment surgery. Ann Thorac Surg 2015;99(2):406–13. and follow-up. Ann Oncol 2016;27:1–27. 20.
Douillard JY, Rosell R, De Lena M i sur. Impact of postoperative radia- 41. von Plessen C, Bergman B, Andresen O i sur.
Palliative chemotherapy tion therapy on survival in patients with complete resection and stage I, beyond three courses
conveys no survival or consistent quality-of-life II, or IIIA non-small-cell lungcancer treated with adjuvant chemother-
benefi ts in advanc

10. [outcome] score -33 ✅ BINGO (PICO)
II trial of 63. Rittmeyer A, Barlesi F, Waterkamp D i sur. Atezolizumab versus docetaxel versus vinorelbine or
ifosfamide in patients with advanced docetaxel in patients with previously treated non-small-cell lung cancer non-small-
cell lung cancer previously treated with platinum-containing (OAK): a phase 3, open-label, multicentre randomised
controlled trial. chemotherapy regimens. The TAX 320 Non Small Cell Lung Cancer Lancet 2017;389:255–65. Study Group. J
Clin Oncol 2000;18:2354–62. 64. Mok TS, Yi-Long Wu YL, Ahn MJ i sur. Osimertinib or platinum–peme- 56. Sheperd FA,
Dancey J, Ramlau R i sur. Prospective randomized trial of trexed in EGFR T790M–positive lung cancer. N Engl J Med 2017;
docetaxel versus best suportive care in patients with non small cell lung 376:629–40. cancer previously treated with
platinum-based chemotherapy. J Clin 65. Larkins E, Blumenthal GM, Chen H i sur. FDA Approval: Alectinib for Oncol
2000;18:2095–103. the treatment of metastatic, ALK-positive non-small cell lung cancer 57. Hanna N, Sheperd FA, Fossella
FV i sur. Randomized phase III trial of following crizotinib. Clin Cancer Res 2016;22:5171–6. pemetrexed versus
docetaxel in patients with non-small-cell lung 66. Khozin S, Blumenthal GM, Zhang L i sur. FDA approval: ceritinib for
cancer previously treated with chemotherapy. J Clin Oncol 2004;22: the treatment of metastatic anaplastic lymphoma
kinase-positive non- 1589–97. small cell lung cancer. Clin Cancer Res 2015;21(11):2436–9. 58. Nagano T, Kim YH, Goto K i
sur. Re-challenge chemotherapy for re- 67. Shepherd FA, Pereira JR, Ciuleanu T i sur. Erlotinib in Previously lapsed
non-small-cell lung cancer. Lung Cancer 2010;69(3):315–8. Treated Non-Small-Cell Lung Cancer. N Engl J Med 2005;353: 59.
Reck M, Kaiser R, Mellemgaard A i sur. Docetaxel plus nintedanib ver- 123–32. sus docetaxel plus placebo in patients
with previously treated non- 68. Tsao MN, Lloyd N, Wong RK i sur. Whole brain radiotherapy for the small-cell lung
cancer (LUME-Lung 1): a phase 3, double-blind, ran- treatment of newly diagnosed multiple brain metastases. Cochrane Da-
domised controlled trial. Lancet 2014;15:143–55. tabase Syst Rev 2012;4:CD003869. 60. Borghaei H, Paz-Ares L, Horn L i
sur. Nivolumab versus Docetaxel in 69. Temel JS, Greer JA, Muzikansky A i sur. Early palliative care for pa- Advanced
Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med tients with metastatic non-small-cell lung cancer. N Engl J Med
2010; 61. Brahmer J, Reckamp KL, Baas P i sur. Nivolumab versus docetaxel in 70. Vansteenkiste J, Crinò L, Dooms C i
sur. 2nd ESMO Consensus Con- advanced squamous-cell non-small-cell lung cancer. N Engl J Med ference on Lung Cancer:
early-stage non-small-cell lung cancer con- 2015;373(2):123–35. sensus on diagnosis, treatment and follow-up. Ann Oncol
2014;25: 62. Herbst RS, Baas P, Kim DW i sur. Pembrolizumab versus docetaxel for 1462–74. previously treated,
PD-L1-positive, advanced non-small-cell lung can- 71. Samaržija M, Gugić D, Radić J i sur. Kliničke upute za dijagnozu,
cer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; liječenje i praćenje bolesnika oboljelih od karcinoma
pluća nemalih 387(10027):1540–50. stanica. Liječ Vjesn 2011;133:361–5.

11. [intervention] score -34 ✅ BINGO (PIO)
60). J Clin Oncol 2007;25:313–8. Database Syst Rev 2015;(10):CD010463. 19. Hancock JG, Rosen JE, Antonicelli A i sur.
Impact of adjuvant treat- 40. Novello S, Barlesi F, Califano R i sur. Metastatic non-small-cell lung ment for
microscopic residual disease after non-small cell lung cancer cancer: ESMO Clinical Practice Guidelines for diagnosis,
treatment surgery. Ann Thorac Surg 2015;99(2):406–13. and follow-up. Ann Oncol 2016;27:1–27. 20. Douillard JY, Rosell R,
De Lena M i sur. Impact of postoperative radia- 41. von Plessen C, Bergman B, Andresen O i sur. Palliative chemotherapy
tion therapy on survival in patients with complete resection and stage I, beyond three courses conveys no survival or
consistent quality-of-life II, or IIIA non-small-cell lungcancer treated with adjuvant chemother- benefi ts in advanced
non small-cell lung cancer. Br J Cancer 2006; apy: the adjuvant Navelbine International Trialist Association (ANITA)
95:966–73. Randomized Trial. Int J Radiat Oncol Biol Phys 2008:72;696–701. 42. Park JO, Kim SW, Ahn JS i sur. Phase III
trial of two versus four addi- 21. Bradley JD, Paulus R, Graham MV i sur. Phase II trial of postoperative tional cycles
in patients who are nonprogressive after two cycles of adjuvant paclitaxel/carboplatin and thoracic radiotherapy in
resected platinum-based chemotherapy in non small-cell lung cancer. J Clin stage II and IIIA non-small-cell lung cancer:
promising long-term Oncol 2007;25:5233–9. results of the Radiation Therapy Oncology Group–RTOG 9705. J Clin 43. Rosell
R, Carceremy E, Gervais R i sur. Erlotinib versus standard che- Oncol 2005:343;3480–7. motherapy as first-line treatment
for European patients with advanced 22. Butts CA, Ding K, Seymour L i sur. Randomized phase III trial of EGFR mutation-
positive non-small-cell lung cancer (EURTAC): a vinorelbine plus cisplatin compared with observation in completely
multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; resected stage IB and II non-small cell lung
cancer: updated survival 13:239–46. analysis of JBR-10. J Clin Oncol 2009;28:29–34. 44. Yang JC, Wu YL, Schuler M i sur.
Afatinib versus cisplatin-based che- 23. Douillard JY, Rosell R, De Lena M i sur. Adjuvant vinorelbine plus motherapy
for EGFR mutation-positive lung adenocarcinoma (LUX- cisplatin versus observation in patients with completely resected
stage Lung 3 and LUX-Lung 6): analysis of overall survival data from two IB–IIIA non-small-cell lung cancer (Adjuvant
Navelbine International randomised, phase 3 trials. Lancet Oncol 2015;16(2):141–51. Trialist Association [ANITA]): a
randomised controlled trial. Lancet 45. Mok TS, Wu JL, Thongprasert S i sur. Gefi tinib or carboplatin-pacli- Oncol
2006;7:719–27. taxel in pulmonary adenocarcinoma. N Engl J Med 2009:3;361(10): 24. Pignon JP, Tribodet H, Scagliotti GV
i sur. Lung adjuvant cisplatin 46. Zhou C, Wu JL, Chen G i sur. Erlotinib versus chemotherapy as fi rst- evaluation: a
pooled analysis by the LACE Collaborative Group. J Clin line treatment for patients with advanced EGFR mutation-positive
Oncol 2008;26:3552–9. non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, 25. Strauss GM, Herndon JE 2nd,
Maddaus MA i sur. Adjuvant paclitaxel open-label, randomised, phase 3 study. Lancet Oncol 2011;12(8): plus carbo

12. [outcome] score -34 ✅ BINGO (PIO)
10;28:2181–90. rac Oncol 2010;5:1416–23. 17. Brunelli A, Charloux A, Bolliger CT i sur. ERS/ESTS clinical guide- 38.
Masters GA, Temin S, Christopher G i sur. Systemic Therapy for Stage lines on fitness for radical therapy in lung cancer
patients (surgery and IV Non-Small-Cell Lung Cancer: American Society of Clinical On- chemo-radiotherapy). Eur Respir J
2009;34:17–41. cology Clinical Practice Guideline Update. J Clin Oncol 2015;33: 18. Rusch VW, Giroux DJ, Kraut MJ i sur.
Induction chemoradiation and 3488–515. surgical resection for superior sulcus non-small cell lung carcinomas: 39. Santos
FN, de Castria TB, Cruz MR, Riera R. Chemotherapy for ad- long-term results of Southwest Oncology Group Trial 9416 –
(Inter- vanced non-small cell lung cancer in the elderly population. Cochrane group Trial 0160). J Clin Oncol
2007;25:313–8. Database Syst Rev 2015;(10):CD010463. 19. Hancock JG, Rosen JE, Antonicelli A i sur. Impact of adjuvant
treat- 40. Novello S, Barlesi F, Califano R i sur. Metastatic non-small-cell lung ment for microscopic residual disease
after non-small cell lung cancer cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment surgery. Ann Thorac
Surg 2015;99(2):406–13. and follow-up. Ann Oncol 2016;27:1–27. 20. Douillard JY, Rosell R, De Lena M i sur. Impact of
postoperative radia- 41. von Plessen C, Bergman B, Andresen O i sur. Palliative chemotherapy tion therapy on survival in
patients with complete resection and stage I, beyond three courses conveys no survival or consistent quality-of-life II,
or IIIA non-small-cell lungcancer treated with adjuvant chemother- benefi ts in advanced non small-cell lung cancer. Br
J Cancer 2006; apy: the adjuvant Navelbine International Trialist Association (ANITA) 95:966–73. Randomized Trial. Int J
Radiat Oncol Biol Phys 2008:72;696–701. 42. Park JO, Kim SW, Ahn JS i sur. Phase III trial of two versus four addi- 21.
Bradley JD, Paulus R, Graham MV i sur. Phase II trial of postoperative tional cycles in patients who are nonprogressive
after two cycles of adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected platinum-based chemotherapy in
non small-cell lung cancer. J Clin stage II and IIIA non-small-cell lung cancer: promising long-term Oncol
2007;25:5233–9. results of the Radiation Therapy Oncology Group–RTOG 9705. J Clin 43. Rosell R, Carceremy E, Gervais R i
sur. Erlotinib versus standard che- Oncol 2005:343;3480–7. motherapy as first-line treatment for European patients with
advanced 22. Butts CA, Ding K, Seymour L i sur. Randomized phase III trial of EGFR mutation-positive non-small-cell lung
cancer (EURTAC): a vinorelbine plus cisplatin compared with observation in completely multicentre, open-label,
randomised phase 3 trial. Lancet Oncol 2012; resected stage IB and II non-small cell lung cancer: updated survival
13:239–46. analysis of JBR-10. J Clin Oncol 2009;28:29–34. 44. Yang JC, Wu YL, Schuler M i sur. Afatinib versus
cisplatin-based che- 23. Douillard JY, Rosell R, De Lena M i sur. Adjuvant vinorelbine plus motherapy for EGFR mutation-
positive lung adenocarcinoma (LUX- cisplatin versus observation in patients with completely resected stage Lung 3 and
LUX-Lung 6): analysis of overall survival data from two IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine Intern

13. [outcome] score -34 ✅ BINGO (PIO)
515. surgical resection for superior sulcus non-small cell lung carcinomas: 39. Santos FN, de Castria TB, Cruz MR, Riera
R. Chemotherapy for ad- long-term results of Southwest Oncology Group Trial 9416 – (Inter- vanced non-small cell lung
cancer in the elderly population. Cochrane group Trial 0160). J Clin Oncol 2007;25:313–8. Database Syst Rev
2015;(10):CD010463. 19. Hancock JG, Rosen JE, Antonicelli A i sur. Impact of adjuvant treat- 40. Novello S, Barlesi F,
Califano R i sur. Metastatic non-small-cell lung ment for microscopic residual disease after non-small cell lung cancer
cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment surgery. Ann Thorac Surg 2015;99(2):406–13. and
follow-up. Ann Oncol 2016;27:1–27. 20. Douillard JY, Rosell R, De Lena M i sur. Impact of postoperative radia- 41. von
Plessen C, Bergman B, Andresen O i sur. Palliative chemotherapy tion therapy on survival in patients with complete
resection and stage I, beyond three courses conveys no survival or consistent quality-of-life II, or IIIA non-small-cell
lungcancer treated with adjuvant chemother- benefi ts in advanced non small-cell lung cancer. Br J Cancer 2006; apy: the
adjuvant Navelbine International Trialist Association (ANITA) 95:966–73. Randomized Trial. Int J Radiat Oncol Biol Phys
2008:72;696–701. 42. Park JO, Kim SW, Ahn JS i sur. Phase III trial of two versus four addi- 21. Bradley JD, Paulus R,
Graham MV i sur. Phase II trial of postoperative tional cycles in patients who are nonprogressive after two cycles of
adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected platinum-based chemotherapy in non small-cell lung
cancer. J Clin stage II and IIIA non-small-cell lung cancer: promising long-term Oncol 2007;25:5233–9. results of the
Radiation Therapy Oncology Group–RTOG 9705. J Clin 43. Rosell R, Carceremy E, Gervais R i sur. Erlotinib versus standard
che- Oncol 2005:343;3480–7. motherapy as first-line treatment for European patients with advanced 22. Butts CA, Ding K,
Seymour L i sur. Randomized phase III trial of EGFR mutation-positive non-small-cell lung cancer (EURTAC): a vinorelbine
plus cisplatin compared with observation in completely multicentre, open-label, randomised phase 3 trial. Lancet Oncol
2012; resected stage IB and II non-small cell lung cancer: updated survival 13:239–46. analysis of JBR-10. J Clin Oncol
2009;28:29–34. 44. Yang JC, Wu YL, Schuler M i sur. Afatinib versus cisplatin-based che- 23. Douillard JY, Rosell R, De
Lena M i sur. Adjuvant vinorelbine plus motherapy for EGFR mutation-positive lung adenocarcinoma (LUX- cisplatin versus
observation in patients with completely resected stage Lung 3 and LUX-Lung 6): analysis of overall survival data from
two IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International randomised, phase 3 trials. Lancet Oncol
2015;16(2):141–51. Trialist Association [ANITA]): a randomised controlled trial. Lancet 45. Mok TS, Wu JL, Thongprasert
S i sur. Gefi tinib or carboplatin-pacli- Oncol 2006;7:719–27. taxel in pulmonary adenocarcinoma. N Engl J Med
2009:3;361(10): 24. Pignon JP, Tribodet H, Scagliotti GV i sur. Lung adjuvant cisplatin 46. Zhou C, Wu JL, Chen G i sur.
Erlotinib versus chemotherapy as fi rst- evaluation: a pooled analysis by the LACE Collaborative Group. J Clin li

14. [population] score -35 ✅ BINGO (PIO)
TACT 1. J Clin Oncol 2004;22:777–84. 29. Jiang J, Liang H, Zhou X i sur. A meta-analysis of randomized con- 51. Herbst
RS, Giaccone G, Schiller JH i sur. Gefi tinib in combination with trolled trials comparing carboplatin-based to
cisplatin-based chemo- paclitaxel and carboplatin in advanced non-small-cell lung cancer: a therapy in advanced non-
small cell lung cancer. Lung Cancer 2007;57: phase III trial–INTACT 2. J Clin Oncol 2004;22:785–94. 348–58. 52.
Gatzemeier U, Pluzanska A, Szczesna A i sur. Phase III study of erlo- 30. Smit EF, van Meerbeeck JP, Lianes P i sur.
Three-arm randomized tinib in combination with cisplatin and gemcitabine in advanced non- study of two cisplatin-based
regimens and paclitaxel plus gemcitabine small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J in
advanced non-small-cell lung cancer: a phase III trial of the Euro- Clin Oncol 2007;25:1545–52. pean Organization for
Research and Treatment of Cancer Lung Cancer 53. Shaw AT, Kim DW, Nakagawa K i sur. Crizotinib versus chemothe-
Group–EORTC 08975. J Clin Oncol 2003;21:3909–17. rapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368: 31.
Schiller JH, Harrington D, Belani CP i sur. Comparison of four chemo- 2385–94. therapy regimens for advanced non-small-
cell lung cancer. N Engl J 54. Solomon BJ, Mok T, Kim DW i sur. First-line crizotinib versus chemo- Med 2002;346:92–8.
therapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167–77. 55. Fossella FV, DeVore R, Kerr RN i sur. Randomized
phase III trial of 63. Rittmeyer A, Barlesi F, Waterkamp D i sur. Atezolizumab versus docetaxel versus vinorelbine or
ifosfamide in patients with advanced docetaxel in patients with previously treated non-small-cell lung cancer non-small-
cell lung cancer previously treated with platinum-containing (OAK): a phase 3, open-label, multicentre randomised
controlled trial. chemotherapy regimens. The TAX 320 Non Small Cell Lung Cancer Lancet 2017;389:255–65. Study Group. J
Clin Oncol 2000;18:2354–62. 64. Mok TS, Yi-Long Wu YL, Ahn MJ i sur. Osimertinib or platinum–peme- 56. Sheperd FA,
Dancey J, Ramlau R i sur. Prospective randomized trial of trexed in EGFR T790M–positive lung cancer. N Engl J Med 2017;
docetaxel versus best suportive care in patients with non small cell lung 376:629–40. cancer previously treated with
platinum-based chemotherapy. J Clin 65. Larkins E, Blumenthal GM, Chen H i sur. FDA Approval: Alectinib for Oncol
2000;18:2095–103. the treatment of metastatic, ALK-positive non-small cell lung cancer 57. Hanna N, Sheperd FA, Fossella
FV i sur. Randomized phase III trial of following crizotinib. Clin Cancer Res 2016;22:5171–6. pemetrexed versus
docetaxel in patients with non-small-cell lung 66. Khozin S, Blumenthal GM, Zhang L i sur. FDA approval: ceritinib for
cancer previously treated with chemotherapy. J Clin Oncol 2004;22: the treatment of metastatic anaplastic lymphoma
kinase-positive non- 1589–97. small cell lung cancer. Clin Cancer Res 2015;21(11):2436–9. 58. Nagano T, Kim YH, Goto K i
sur. Re-challenge chemotherapy for re- 67. Shepherd FA, Pereira JR, Ciuleanu T i sur. Erlotinib in Previously lapsed
non-small-cell lung cancer. Lung Cancer 2010;69(3):315–8. Treated Non-Small-Cell Lung Cancer. N Engl J Med 2005;353: 59.
Reck M, Kaiser R, Mellemgaa

15. [intervention] score -35 ✅ BINGO (ICO)
mjeseci, svaka sis of individual participant data. Lancet 2014;383(9928):1561–71. 10. Higgins K, Chino JP, Marks LB i
sur. Preoperative chemotherapy ver- 3 – 6 mjeseci 2. i 3. godinu, zatim svakih 4 – 8 mjeseci tije- sus preoperative
chemoradiotherapy for stage III (N2) non-small-cell kom 4. i 5. godine, potom svakih 6 – 12 mjeseci. Praćenje lung
cancer. Int J Radiat Oncol Biol Phys 2009;75(5):1462–7. 11. Albain KS, Swann RS, Rusch VW i sur. Radiotherapy plus
chemothera- 32. Scagliotti GV, Hanna N, Fossella F i sur. The differential effi cacy of py with or without surgical
resection for stage III non-small cell lung pemetrexed according to NSCLC histology: a review of two phase III cancer: a
phase III randomised controlled trial. Lancet 2009;374: studies. Oncologist 2009;14:253–63. 379–86. 33. Scagliotti GV,
Parikh P, von Pawel J i sur. Phase III study comparing 12. Thomas M, Rübe C, Hoffknecht P i sur. Effect of preoperative
chemo- cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemo- radiation in addition to preoperative
chemotherapy: a randomised trial therapy-naive patients with advanced-stage non-small-cell lung cancer. in stage III
non-small cell lung cancer. Lancet Oncol 2008;9:636–48. J Clin Oncol 2008;26:3543–51. 13. Furuse K, Fukuoka M, Kawahara
M i sur. Phase III study of concurrent 34. Paz-Ares LG, de Marinis F, Dediu M i sur. PARAMOUNT: final overall versus
sequential thoracic radiotherapy in combination with mito- survival results of the phase III study of maintenance
pemetrexed ver- mycin, vindesine, and cisplatin in unresectable stage III non-small-cell sus placebo immediately after
induction treatment with pemetrexed lung cancer. J Clin Oncol 1999;17:2692–9. plus cisplatin for advanced nonsquamous
non-small-cell lung cancer. J 14. Curran WJ Jr, Paulus R, Langer CJ i sur. Sequential vs. concurrent Clin Oncol
2013;31:2895–902. chemoradiation for stage III non-small cell lung cancer: randomized 35. Sandler A, Gray R, Perry MC i
sur. Paclitaxel-carboplatin alone or with phase III trial RTOG 9410. J Natl Cancer Inst 2011;103(19):1452–60.
bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 15. Fournel P, Robinet G, Thomas P i sur. Randomized
phase III trial of 36. Reck M, von Pawel J, Zatloukal P i sur. Phase III trial of cisplatin plus sequential
chemoradiotherapy compared with concurrent chemoradio- gemcitabine with either placebo or bevacizumab as fi rst-line
therapy therapy in locally advanced non-small-cell lung cancer: Groupe Lyon- for nonsquamous non-small cell lung cancer:
AVAiL. J Clin Oncol Saint-Etienne d’Oncologie Thoracique-Groupe Français de Pneumo- Cancérologie NPC 95-01 Study. J Clin
Oncol 2005;23:5910–7. 37. Sandler A, Yi J, Dahlberg S i sur. Treatment outcomes by tumor histol- 16. Aupérin A, Le
Péchoux C, Rolland E i sur. Meta-analysis of concomi- ogy in Eastern Cooperative Group Study E4599 of bevacizumab with
tant versus sequential radiochemotherapy in locally advanced non- paclitaxel/carboplatin for advanced non-small cell
lung cancer. J Tho- small cell lung cancer. J Clin Oncol 2010;28:2181–90. rac Oncol 2010;5:1416–23. 17. Brunelli A,
Charloux A, Bolliger CT i sur. ERS/ESTS clinical guide- 38. Masters GA, Temin S, Christopher G i sur. Systemic Therapy
for Stage lines on fitness for radic

16. [intervention] score -35 ✅ BINGO (PIO)
l-cell lung cancer: a phase III trial of the Euro- Clin Oncol 2007;25:1545–52. pean Organization for Research and
Treatment of Cancer Lung Cancer 53. Shaw AT, Kim DW, Nakagawa K i sur. Crizotinib versus chemothe- Group–EORTC 08975. J
Clin Oncol 2003;21:3909–17. rapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368: 31. Schiller JH,
Harrington D, Belani CP i sur. Comparison of four chemo- 2385–94. therapy regimens for advanced non-small-cell lung
cancer. N Engl J 54. Solomon BJ, Mok T, Kim DW i sur. First-line crizotinib versus chemo- Med 2002;346:92–8. therapy in
ALK-positive lung cancer. N Engl J Med 2014;371:2167–77. 55. Fossella FV, DeVore R, Kerr RN i sur. Randomized phase III
trial of 63. Rittmeyer A, Barlesi F, Waterkamp D i sur. Atezolizumab versus docetaxel versus vinorelbine or ifosfamide
in patients with advanced docetaxel in patients with previously treated non-small-cell lung cancer non-small-cell lung
cancer previously treated with platinum-containing (OAK): a phase 3, open-label, multicentre randomised controlled
trial. chemotherapy regimens. The TAX 320 Non Small Cell Lung Cancer Lancet 2017;389:255–65. Study Group. J Clin Oncol
2000;18:2354–62. 64. Mok TS, Yi-Long Wu YL, Ahn MJ i sur. Osimertinib or platinum–peme- 56. Sheperd FA, Dancey J, Ramlau
R i sur. Prospective randomized trial of trexed in EGFR T790M–positive lung cancer. N Engl J Med 2017; docetaxel versus
best suportive care in patients with non small cell lung 376:629–40. cancer previously treated with platinum-based
chemotherapy. J Clin 65. Larkins E, Blumenthal GM, Chen H i sur. FDA Approval: Alectinib for Oncol 2000;18:2095–103. the
treatment of metastatic, ALK-positive non-small cell lung cancer 57. Hanna N, Sheperd FA, Fossella FV i sur. Randomized
phase III trial of following crizotinib. Clin Cancer Res 2016;22:5171–6. pemetrexed versus docetaxel in patients with
non-small-cell lung 66. Khozin S, Blumenthal GM, Zhang L i sur. FDA approval: ceritinib for cancer previously treated
with chemotherapy. J Clin Oncol 2004;22: the treatment of metastatic anaplastic lymphoma kinase-positive non- 1589–97.
small cell lung cancer. Clin Cancer Res 2015;21(11):2436–9. 58. Nagano T, Kim YH, Goto K i sur. Re-challenge
chemotherapy for re- 67. Shepherd FA, Pereira JR, Ciuleanu T i sur. Erlotinib in Previously lapsed non-small-cell lung
cancer. Lung Cancer 2010;69(3):315–8. Treated Non-Small-Cell Lung Cancer. N Engl J Med 2005;353: 59. Reck M, Kaiser R,
Mellemgaard A i sur. Docetaxel plus nintedanib ver- 123–32. sus docetaxel plus placebo in patients with previously
treated non- 68. Tsao MN, Lloyd N, Wong RK i sur. Whole brain radiotherapy for the small-cell lung cancer (LUME-Lung 1):
a phase 3, double-blind, ran- treatment of newly diagnosed multiple brain metastases. Cochrane Da- domised controlled
trial. Lancet 2014;15:143–55. tabase Syst Rev 2012;4:CD003869. 60. Borghaei H, Paz-Ares L, Horn L i sur. Nivolumab
versus Docetaxel in 69. Temel JS, Greer JA, Muzikansky A i sur. Early palliative care for pa- Advanced Nonsquamous Non-
Small-Cell Lung Cancer. N Engl J Med tients with metastatic non-small-cell lung cancer. N Engl J Med 2010; 61. Brahmer
J, Reckamp KL, Baas P i sur. Nivolumab versus docetaxel in 70. Vansteenkiste J, Crinò L, Dooms C i sur. 2nd ESMO
Consensus Con- ad

17. [intervention] score -35 ✅ BINGO (PICO)
TAX 320 Non Small Cell Lung Cancer Lancet 2017;389:255–65. Study Group. J Clin Oncol 2000;18:2354–62. 64. Mok TS, Yi-
Long Wu YL, Ahn MJ i sur. Osimertinib or platinum–peme- 56. Sheperd FA, Dancey J, Ramlau R i sur. Prospective randomized
trial of trexed in EGFR T790M–positive lung cancer. N Engl J Med 2017; docetaxel versus best suportive care in patients
with non small cell lung 376:629–40. cancer previously treated with platinum-based chemotherapy. J Clin 65. Larkins E,
Blumenthal GM, Chen H i sur. FDA Approval: Alectinib for Oncol 2000;18:2095–103. the treatment of metastatic, ALK-
positive non-small cell lung cancer 57. Hanna N, Sheperd FA, Fossella FV i sur. Randomized phase III trial of following
crizotinib. Clin Cancer Res 2016;22:5171–6. pemetrexed versus docetaxel in patients with non-small-cell lung 66. Khozin
S, Blumenthal GM, Zhang L i sur. FDA approval: ceritinib for cancer previously treated with chemotherapy. J Clin Oncol
2004;22: the treatment of metastatic anaplastic lymphoma kinase-positive non- 1589–97. small cell lung cancer. Clin
Cancer Res 2015;21(11):2436–9. 58. Nagano T, Kim YH, Goto K i sur. Re-challenge chemotherapy for re- 67. Shepherd FA,
Pereira JR, Ciuleanu T i sur. Erlotinib in Previously lapsed non-small-cell lung cancer. Lung Cancer 2010;69(3):315–8.
Treated Non-Small-Cell Lung Cancer. N Engl J Med 2005;353: 59. Reck M, Kaiser R, Mellemgaard A i sur. Docetaxel plus
nintedanib ver- 123–32. sus docetaxel plus placebo in patients with previously treated non- 68. Tsao MN, Lloyd N, Wong
RK i sur. Whole brain radiotherapy for the small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, ran- treatment
of newly diagnosed multiple brain metastases. Cochrane Da- domised controlled trial. Lancet 2014;15:143–55. tabase Syst
Rev 2012;4:CD003869. 60. Borghaei H, Paz-Ares L, Horn L i sur. Nivolumab versus Docetaxel in 69. Temel JS, Greer JA,
Muzikansky A i sur. Early palliative care for pa- Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med tients
with metastatic non-small-cell lung cancer. N Engl J Med 2010; 61. Brahmer J, Reckamp KL, Baas P i sur. Nivolumab versus
docetaxel in 70. Vansteenkiste J, Crinò L, Dooms C i sur. 2nd ESMO Consensus Con- advanced squamous-cell non-small-cell
lung cancer. N Engl J Med ference on Lung Cancer: early-stage non-small-cell lung cancer con- 2015;373(2):123–35. sensus
on diagnosis, treatment and follow-up. Ann Oncol 2014;25: 62. Herbst RS, Baas P, Kim DW i sur. Pembrolizumab versus
docetaxel for 1462–74. previously treated, PD-L1-positive, advanced non-small-cell lung can- 71. Samaržija M, Gugić D,
Radić J i sur. Kliničke upute za dijagnozu, cer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; liječenje i
praćenje bolesnika oboljelih od karcinoma pluća nemalih 387(10027):1540–50. stanica. Liječ Vjesn 2011;133:361–5.

18. [outcome] score -35 ✅ BINGO (PIO)
of the Euro- Clin Oncol 2007;25:1545–52. pean Organization for Research and Treatment of Cancer Lung Cancer 53. Shaw AT,
Kim DW, Nakagawa K i sur. Crizotinib versus chemothe- Group–EORTC 08975. J Clin Oncol 2003;21:3909–17. rapy in advanced
ALK-positive lung cancer. N Engl J Med 2013;368: 31. Schiller JH, Harrington D, Belani CP i sur. Comparison of four
chemo- 2385–94. therapy regimens for advanced non-small-cell lung cancer. N Engl J 54. Solomon BJ, Mok T, Kim DW i sur.
First-line crizotinib versus chemo- Med 2002;346:92–8. therapy in ALK-positive lung cancer. N Engl J Med
2014;371:2167–77. 55. Fossella FV, DeVore R, Kerr RN i sur. Randomized phase III trial of 63. Rittmeyer A, Barlesi F,
Waterkamp D i sur. Atezolizumab versus docetaxel versus vinorelbine or ifosfamide in patients with advanced docetaxel in
patients with previously treated non-small-cell lung cancer non-small-cell lung cancer previously treated with platinum-
containing (OAK): a phase 3, open-label, multicentre randomised controlled trial. chemotherapy regimens. The TAX 320 Non
Small Cell Lung Cancer Lancet 2017;389:255–65. Study Group. J Clin Oncol 2000;18:2354–62. 64. Mok TS, Yi-Long Wu YL, Ahn
MJ i sur. Osimertinib or platinum–peme- 56. Sheperd FA, Dancey J, Ramlau R i sur. Prospective randomized trial of trexed
in EGFR T790M–positive lung cancer. N Engl J Med 2017; docetaxel versus best suportive care in patients with non small
cell lung 376:629–40. cancer previously treated with platinum-based chemotherapy. J Clin 65. Larkins E, Blumenthal GM,
Chen H i sur. FDA Approval: Alectinib for Oncol 2000;18:2095–103. the treatment of metastatic, ALK-positive non-small
cell lung cancer 57. Hanna N, Sheperd FA, Fossella FV i sur. Randomized phase III trial of following crizotinib. Clin
Cancer Res 2016;22:5171–6. pemetrexed versus docetaxel in patients with non-small-cell lung 66. Khozin S, Blumenthal GM,
Zhang L i sur. FDA approval: ceritinib for cancer previously treated with chemotherapy. J Clin Oncol 2004;22: the
treatment of metastatic anaplastic lymphoma kinase-positive non- 1589–97. small cell lung cancer. Clin Cancer Res
2015;21(11):2436–9. 58. Nagano T, Kim YH, Goto K i sur. Re-challenge chemotherapy for re- 67. Shepherd FA, Pereira JR,
Ciuleanu T i sur. Erlotinib in Previously lapsed non-small-cell lung cancer. Lung Cancer 2010;69(3):315–8. Treated Non-
Small-Cell Lung Cancer. N Engl J Med 2005;353: 59. Reck M, Kaiser R, Mellemgaard A i sur. Docetaxel plus nintedanib ver-
123–32. sus docetaxel plus placebo in patients with previously treated non- 68. Tsao MN, Lloyd N, Wong RK i sur. Whole
brain radiotherapy for the small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, ran- treatment of newly
diagnosed multiple brain metastases. Cochrane Da- domised controlled trial. Lancet 2014;15:143–55. tabase Syst Rev
2012;4:CD003869. 60. Borghaei H, Paz-Ares L, Horn L i sur. Nivolumab versus Docetaxel in 69. Temel JS, Greer JA,
Muzikansky A i sur. Early palliative care for pa- Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med tients
with metastatic non-small-cell lung cancer. N Engl J Med 2010; 61. Brahmer J, Reckamp KL, Baas P i sur. Nivolumab versus
docetaxel in 70. Vansteenkiste J, Crinò L, Dooms C i sur. 2nd ESMO Consensus Con- advanced squamous-cell non-small-cell
lung cancer. N Engl

19. [outcome] score -35 ✅ BINGO (PIO)
ults of the Radiation Therapy Oncology Group–RTOG 9705. J Clin 43. Rosell R, Carceremy E, Gervais R i sur. Erlotinib
versus standard che- Oncol 2005:343;3480–7. motherapy as first-line treatment for European patients with advanced 22.
Butts CA, Ding K, Seymour L i sur. Randomized phase III trial of EGFR mutation-positive non-small-cell lung cancer
(EURTAC): a vinorelbine plus cisplatin compared with observation in completely multicentre, open-label, randomised phase
3 trial. Lancet Oncol 2012; resected stage IB and II non-small cell lung cancer: updated survival 13:239–46. analysis of
JBR-10. J Clin Oncol 2009;28:29–34. 44. Yang JC, Wu YL, Schuler M i sur. Afatinib versus cisplatin-based che- 23.
Douillard JY, Rosell R, De Lena M i sur. Adjuvant vinorelbine plus motherapy for EGFR mutation-positive lung
adenocarcinoma (LUX- cisplatin versus observation in patients with completely resected stage Lung 3 and LUX-Lung 6):
analysis of overall survival data from two IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International
randomised, phase 3 trials. Lancet Oncol 2015;16(2):141–51. Trialist Association [ANITA]): a randomised controlled
trial. Lancet 45. Mok TS, Wu JL, Thongprasert S i sur. Gefi tinib or carboplatin-pacli- Oncol 2006;7:719–27. taxel in
pulmonary adenocarcinoma. N Engl J Med 2009:3;361(10): 24. Pignon JP, Tribodet H, Scagliotti GV i sur. Lung adjuvant
cisplatin 46. Zhou C, Wu JL, Chen G i sur. Erlotinib versus chemotherapy as fi rst- evaluation: a pooled analysis by the
LACE Collaborative Group. J Clin line treatment for patients with advanced EGFR mutation-positive Oncol 2008;26:3552–9.
non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, 25. Strauss GM, Herndon JE 2nd, Maddaus MA i sur.
Adjuvant paclitaxel open-label, randomised, phase 3 study. Lancet Oncol 2011;12(8): plus carboplatin compared with
observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, 47. Gridelli C, De
Marinis F, Di Maio M i sur. Gefi tinib as fi rst-line treat- Radiation Therapy Oncology Group, and North Central Cancer
Treat- ment for patients with advanced non-small-cell lung cancer with acti- ment Group Study Groups. J Clin Oncol
2008;26(31):5043–51. vating epidermal growth factor receptor mutation: Review of the evi- 26. Sederholm C, Hillerdal G,
Lambert K i sur. Phase III trial of gem- dence. Lung Cancer 2011;71(3):249–57. citabine plus carboplatin versus single-
agent gemcitabine in the treat- 48. Lee CK, Brown C, Gralla RJ i sur. Impact of EGFR inhibitor in non- ment of locally
advanced or metastatic non-small-cell lung cancer. The small cell lung cancer on progression-free and overall survival:
a meta- Swedish Lung Cancer Study Group. J Clin Oncol 2005;23:8380–8. analysis. J Natl Cancer Inst 2013;105:595–605. 27.
Delbaldo C, Michiels S, Syz N i sur. Benefi ts of adding a drug to a single 49. Seto T, Kato T, Nishio M i sur.
Erlotinib alone or with bevacizumab as agent or a 2-agent chemotherapy regimen in advanced non-small-cell fi rst-line
therapy in patients with advanced non-squamous non-small- lung cancer. A meta analysis. JAMA 2004;292:470–84. cell lung
cancer harbouring EGFR mutations (JO25567): an open-la- 28. Pujol JL, Barlesi F, Daures JP i sur. Should chemotherapy
combina- bel, randomised

20. [population] score -36 ✅ BINGO (PIO)
irana/neresektabilna lokalno uznapredovala patients with resectable non-small cell lung cancer: results of the MRC
bolest – pauza u liječenju, praćenje radi pravodobne LU22/NVALT 2/EORTC 08012 multicentre randomised trial and up- date
of systematic review. Lancet 2007;369:1929–37. detekcije progresije bolesti 9. NSCLC Meta-analysis Collaborative Group.
Preoperative chemothera- Klinički pregled, KKS, DKS, SE i osnovne biokemijske py for non-small-cell lung cancer: a
systematic review and meta-analy- pretrage krvi svakih 8 – 12 tjedana prvih 12 mjeseci, svaka sis of individual
participant data. Lancet 2014;383(9928):1561–71. 10. Higgins K, Chino JP, Marks LB i sur. Preoperative chemotherapy ver-
3 – 6 mjeseci 2. i 3. godinu, zatim svakih 4 – 8 mjeseci tije- sus preoperative chemoradiotherapy for stage III (N2)
non-small-cell kom 4. i 5. godine, potom svakih 6 – 12 mjeseci. Praćenje lung cancer. Int J Radiat Oncol Biol Phys
2009;75(5):1462–7. 11. Albain KS, Swann RS, Rusch VW i sur. Radiotherapy plus chemothera- 32. Scagliotti GV, Hanna N,
Fossella F i sur. The differential effi cacy of py with or without surgical resection for stage III non-small cell lung
pemetrexed according to NSCLC histology: a review of two phase III cancer: a phase III randomised controlled trial.
Lancet 2009;374: studies. Oncologist 2009;14:253–63. 379–86. 33. Scagliotti GV, Parikh P, von Pawel J i sur. Phase III
study comparing 12. Thomas M, Rübe C, Hoffknecht P i sur. Effect of preoperative chemo- cisplatin plus gemcitabine with
cisplatin plus pemetrexed in chemo- radiation in addition to preoperative chemotherapy: a randomised trial therapy-naive
patients with advanced-stage non-small-cell lung cancer. in stage III non-small cell lung cancer. Lancet Oncol
2008;9:636–48. J Clin Oncol 2008;26:3543–51. 13. Furuse K, Fukuoka M, Kawahara M i sur. Phase III study of concurrent
34. Paz-Ares LG, de Marinis F, Dediu M i sur. PARAMOUNT: final overall versus sequential thoracic radiotherapy in
combination with mito- survival results of the phase III study of maintenance pemetrexed ver- mycin, vindesine, and
cisplatin in unresectable stage III non-small-cell sus placebo immediately after induction treatment with pemetrexed
lung cancer. J Clin Oncol 1999;17:2692–9. plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J 14.
Curran WJ Jr, Paulus R, Langer CJ i sur. Sequential vs. concurrent Clin Oncol 2013;31:2895–902. chemoradiation for stage
III non-small cell lung cancer: randomized 35. Sandler A, Gray R, Perry MC i sur. Paclitaxel-carboplatin alone or with
phase III trial RTOG 9410. J Natl Cancer Inst 2011;103(19):1452–60. bevacizumab for non-small-cell lung cancer. N Engl J
Med 2006;355: 15. Fournel P, Robinet G, Thomas P i sur. Randomized phase III trial of 36. Reck M, von Pawel J, Zatloukal
P i sur. Phase III trial of cisplatin plus sequential chemoradiotherapy compared with concurrent chemoradio- gemcitabine
with either placebo or bevacizumab as fi rst-line therapy therapy in locally advanced non-small-cell lung cancer: Groupe
Lyon- for nonsquamous non-small cell lung cancer: AVAiL. J Clin Oncol Saint-Etienne d’Oncologie Thoracique-Groupe
Français de Pneumo- Cancérologie NPC 95-01 Study. J Clin Oncol 2005;23:5910–7. 37. Sandler A, Yi J, Dahlberg S i sur.
Treatment

21. [population] score -36 ✅ BINGO (PIO)
ooperative Group Study E4599 of bevacizumab with tant versus sequential radiochemotherapy in locally advanced non-
paclitaxel/carboplatin for advanced non-small cell lung cancer. J Tho- small cell lung cancer. J Clin Oncol
2010;28:2181–90. rac Oncol 2010;5:1416–23. 17. Brunelli A, Charloux A, Bolliger CT i sur. ERS/ESTS clinical guide- 38.
Masters GA, Temin S, Christopher G i sur. Systemic Therapy for Stage lines on fitness for radical therapy in lung cancer
patients (surgery and IV Non-Small-Cell Lung Cancer: American Society of Clinical On- chemo-radiotherapy). Eur Respir J
2009;34:17–41. cology Clinical Practice Guideline Update. J Clin Oncol 2015;33: 18. Rusch VW, Giroux DJ, Kraut MJ i sur.
Induction chemoradiation and 3488–515. surgical resection for superior sulcus non-small cell lung carcinomas: 39. Santos
FN, de Castria TB, Cruz MR, Riera R. Chemotherapy for ad- long-term results of Southwest Oncology Group Trial 9416 –
(Inter- vanced non-small cell lung cancer in the elderly population. Cochrane group Trial 0160). J Clin Oncol
2007;25:313–8. Database Syst Rev 2015;(10):CD010463. 19. Hancock JG, Rosen JE, Antonicelli A i sur. Impact of adjuvant
treat- 40. Novello S, Barlesi F, Califano R i sur. Metastatic non-small-cell lung ment for microscopic residual disease
after non-small cell lung cancer cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment surgery. Ann Thorac
Surg 2015;99(2):406–13. and follow-up. Ann Oncol 2016;27:1–27. 20. Douillard JY, Rosell R, De Lena M i sur. Impact of
postoperative radia- 41. von Plessen C, Bergman B, Andresen O i sur. Palliative chemotherapy tion therapy on survival in
patients with complete resection and stage I, beyond three courses conveys no survival or consistent quality-of-life II,
or IIIA non-small-cell lungcancer treated with adjuvant chemother- benefi ts in advanced non small-cell lung cancer. Br
J Cancer 2006; apy: the adjuvant Navelbine International Trialist Association (ANITA) 95:966–73. Randomized Trial. Int J
Radiat Oncol Biol Phys 2008:72;696–701. 42. Park JO, Kim SW, Ahn JS i sur. Phase III trial of two versus four addi- 21.
Bradley JD, Paulus R, Graham MV i sur. Phase II trial of postoperative tional cycles in patients who are nonprogressive
after two cycles of adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected platinum-based chemotherapy in
non small-cell lung cancer. J Clin stage II and IIIA non-small-cell lung cancer: promising long-term Oncol
2007;25:5233–9. results of the Radiation Therapy Oncology Group–RTOG 9705. J Clin 43. Rosell R, Carceremy E, Gervais R i
sur. Erlotinib versus standard che- Oncol 2005:343;3480–7. motherapy as first-line treatment for European patients with
advanced 22. Butts CA, Ding K, Seymour L i sur. Randomized phase III trial of EGFR mutation-positive non-small-cell lung
cancer (EURTAC): a vinorelbine plus cisplatin compared with observation in completely multicentre, open-label,
randomised phase 3 trial. Lancet Oncol 2012; resected stage IB and II non-small cell lung cancer: updated survival
13:239–46. analysis of JBR-10. J Clin Oncol 2009;28:29–34. 44. Yang JC, Wu YL, Schuler M i sur. Afatinib versus
cisplatin-based che- 23. Douillard JY, Rosell R, De Lena M i sur. Adjuvant vinorelbine plus motherapy for EGFR mutation-
positive

22. [population] score -36 ✅ BINGO (PIO)
5:313–8. Database Syst Rev 2015;(10):CD010463. 19. Hancock JG, Rosen JE, Antonicelli A i sur. Impact of adjuvant treat-
40. Novello S, Barlesi F, Califano R i sur. Metastatic non-small-cell lung ment for microscopic residual disease after
non-small cell lung cancer cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment surgery. Ann Thorac Surg
2015;99(2):406–13. and follow-up. Ann Oncol 2016;27:1–27. 20. Douillard JY, Rosell R, De Lena M i sur. Impact of
postoperative radia- 41. von Plessen C, Bergman B, Andresen O i sur. Palliative chemotherapy tion therapy on survival in
patients with complete resection and stage I, beyond three courses conveys no survival or consistent quality-of-life II,
or IIIA non-small-cell lungcancer treated with adjuvant chemother- benefi ts in advanced non small-cell lung cancer. Br
J Cancer 2006; apy: the adjuvant Navelbine International Trialist Association (ANITA) 95:966–73. Randomized Trial. Int J
Radiat Oncol Biol Phys 2008:72;696–701. 42. Park JO, Kim SW, Ahn JS i sur. Phase III trial of two versus four addi- 21.
Bradley JD, Paulus R, Graham MV i sur. Phase II trial of postoperative tional cycles in patients who are nonprogressive
after two cycles of adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected platinum-based chemotherapy in
non small-cell lung cancer. J Clin stage II and IIIA non-small-cell lung cancer: promising long-term Oncol
2007;25:5233–9. results of the Radiation Therapy Oncology Group–RTOG 9705. J Clin 43. Rosell R, Carceremy E, Gervais R i
sur. Erlotinib versus standard che- Oncol 2005:343;3480–7. motherapy as first-line treatment for European patients with
advanced 22. Butts CA, Ding K, Seymour L i sur. Randomized phase III trial of EGFR mutation-positive non-small-cell lung
cancer (EURTAC): a vinorelbine plus cisplatin compared with observation in completely multicentre, open-label,
randomised phase 3 trial. Lancet Oncol 2012; resected stage IB and II non-small cell lung cancer: updated survival
13:239–46. analysis of JBR-10. J Clin Oncol 2009;28:29–34. 44. Yang JC, Wu YL, Schuler M i sur. Afatinib versus
cisplatin-based che- 23. Douillard JY, Rosell R, De Lena M i sur. Adjuvant vinorelbine plus motherapy for EGFR mutation-
positive lung adenocarcinoma (LUX- cisplatin versus observation in patients with completely resected stage Lung 3 and
LUX-Lung 6): analysis of overall survival data from two IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine
International randomised, phase 3 trials. Lancet Oncol 2015;16(2):141–51. Trialist Association [ANITA]): a randomised
controlled trial. Lancet 45. Mok TS, Wu JL, Thongprasert S i sur. Gefi tinib or carboplatin-pacli- Oncol 2006;7:719–27.
taxel in pulmonary adenocarcinoma. N Engl J Med 2009:3;361(10): 24. Pignon JP, Tribodet H, Scagliotti GV i sur. Lung
adjuvant cisplatin 46. Zhou C, Wu JL, Chen G i sur. Erlotinib versus chemotherapy as fi rst- evaluation: a pooled
analysis by the LACE Collaborative Group. J Clin line treatment for patients with advanced EGFR mutation-positive Oncol
2008;26:3552–9. non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, 25. Strauss GM, Herndon JE 2nd, Maddaus
MA i sur. Adjuvant paclitaxel open-label, randomised, phase 3 study. Lancet Oncol 2011;12(8): plus carboplatin compared
with o

23. [population] score -36 ✅ BINGO (PIO)
and IIIA non-small-cell lung cancer: promising long-term Oncol 2007;25:5233–9. results of the Radiation Therapy Oncology
Group–RTOG 9705. J Clin 43. Rosell R, Carceremy E, Gervais R i sur. Erlotinib versus standard che- Oncol
2005:343;3480–7. motherapy as first-line treatment for European patients with advanced 22. Butts CA, Ding K, Seymour L i
sur. Randomized phase III trial of EGFR mutation-positive non-small-cell lung cancer (EURTAC): a vinorelbine plus
cisplatin compared with observation in completely multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012;
resected stage IB and II non-small cell lung cancer: updated survival 13:239–46. analysis of JBR-10. J Clin Oncol
2009;28:29–34. 44. Yang JC, Wu YL, Schuler M i sur. Afatinib versus cisplatin-based che- 23. Douillard JY, Rosell R, De
Lena M i sur. Adjuvant vinorelbine plus motherapy for EGFR mutation-positive lung adenocarcinoma (LUX- cisplatin versus
observation in patients with completely resected stage Lung 3 and LUX-Lung 6): analysis of overall survival data from
two IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International randomised, phase 3 trials. Lancet Oncol
2015;16(2):141–51. Trialist Association [ANITA]): a randomised controlled trial. Lancet 45. Mok TS, Wu JL, Thongprasert
S i sur. Gefi tinib or carboplatin-pacli- Oncol 2006;7:719–27. taxel in pulmonary adenocarcinoma. N Engl J Med
2009:3;361(10): 24. Pignon JP, Tribodet H, Scagliotti GV i sur. Lung adjuvant cisplatin 46. Zhou C, Wu JL, Chen G i sur.
Erlotinib versus chemotherapy as fi rst- evaluation: a pooled analysis by the LACE Collaborative Group. J Clin line
treatment for patients with advanced EGFR mutation-positive Oncol 2008;26:3552–9. non-small-cell lung cancer (OPTIMAL,
CTONG-0802): a multicentre, 25. Strauss GM, Herndon JE 2nd, Maddaus MA i sur. Adjuvant paclitaxel open-label,
randomised, phase 3 study. Lancet Oncol 2011;12(8): plus carboplatin compared with observation in stage IB non-small-
cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, 47. Gridelli C, De Marinis F, Di Maio M i sur. Gefi
tinib as fi rst-line treat- Radiation Therapy Oncology Group, and North Central Cancer Treat- ment for patients with
advanced non-small-cell lung cancer with acti- ment Group Study Groups. J Clin Oncol 2008;26(31):5043–51. vating
epidermal growth factor receptor mutation: Review of the evi- 26. Sederholm C, Hillerdal G, Lambert K i sur. Phase III
trial of gem- dence. Lung Cancer 2011;71(3):249–57. citabine plus carboplatin versus single-agent gemcitabine in the
treat- 48. Lee CK, Brown C, Gralla RJ i sur. Impact of EGFR inhibitor in non- ment of locally advanced or metastatic
non-small-cell lung cancer. The small cell lung cancer on progression-free and overall survival: a meta- Swedish Lung
Cancer Study Group. J Clin Oncol 2005;23:8380–8. analysis. J Natl Cancer Inst 2013;105:595–605. 27. Delbaldo C, Michiels
S, Syz N i sur. Benefi ts of adding a drug to a single 49. Seto T, Kato T, Nishio M i sur. Erlotinib alone or with
bevacizumab as agent or a 2-agent chemotherapy regimen in advanced non-small-cell fi rst-line therapy in patients with
advanced non-squamous non-small- lung cancer. A meta analysis. JAMA 2004;292:470–84. cell lung cancer harbouring EGFR
mutations (JO25567): an open-la-

24. [population] score -36 ✅ BINGO (PIO)
trial. Lancet Oncol 2012; resected stage IB and II non-small cell lung cancer: updated survival 13:239–46. analysis of
JBR-10. J Clin Oncol 2009;28:29–34. 44. Yang JC, Wu YL, Schuler M i sur. Afatinib versus cisplatin-based che- 23.
Douillard JY, Rosell R, De Lena M i sur. Adjuvant vinorelbine plus motherapy for EGFR mutation-positive lung
adenocarcinoma (LUX- cisplatin versus observation in patients with completely resected stage Lung 3 and LUX-Lung 6):
analysis of overall survival data from two IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International
randomised, phase 3 trials. Lancet Oncol 2015;16(2):141–51. Trialist Association [ANITA]): a randomised controlled
trial. Lancet 45. Mok TS, Wu JL, Thongprasert S i sur. Gefi tinib or carboplatin-pacli- Oncol 2006;7:719–27. taxel in
pulmonary adenocarcinoma. N Engl J Med 2009:3;361(10): 24. Pignon JP, Tribodet H, Scagliotti GV i sur. Lung adjuvant
cisplatin 46. Zhou C, Wu JL, Chen G i sur. Erlotinib versus chemotherapy as fi rst- evaluation: a pooled analysis by the
LACE Collaborative Group. J Clin line treatment for patients with advanced EGFR mutation-positive Oncol 2008;26:3552–9.
non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, 25. Strauss GM, Herndon JE 2nd, Maddaus MA i sur.
Adjuvant paclitaxel open-label, randomised, phase 3 study. Lancet Oncol 2011;12(8): plus carboplatin compared with
observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, 47. Gridelli C, De
Marinis F, Di Maio M i sur. Gefi tinib as fi rst-line treat- Radiation Therapy Oncology Group, and North Central Cancer
Treat- ment for patients with advanced non-small-cell lung cancer with acti- ment Group Study Groups. J Clin Oncol
2008;26(31):5043–51. vating epidermal growth factor receptor mutation: Review of the evi- 26. Sederholm C, Hillerdal G,
Lambert K i sur. Phase III trial of gem- dence. Lung Cancer 2011;71(3):249–57. citabine plus carboplatin versus single-
agent gemcitabine in the treat- 48. Lee CK, Brown C, Gralla RJ i sur. Impact of EGFR inhibitor in non- ment of locally
advanced or metastatic non-small-cell lung cancer. The small cell lung cancer on progression-free and overall survival:
a meta- Swedish Lung Cancer Study Group. J Clin Oncol 2005;23:8380–8. analysis. J Natl Cancer Inst 2013;105:595–605. 27.
Delbaldo C, Michiels S, Syz N i sur. Benefi ts of adding a drug to a single 49. Seto T, Kato T, Nishio M i sur.
Erlotinib alone or with bevacizumab as agent or a 2-agent chemotherapy regimen in advanced non-small-cell fi rst-line
therapy in patients with advanced non-squamous non-small- lung cancer. A meta analysis. JAMA 2004;292:470–84. cell lung
cancer harbouring EGFR mutations (JO25567): an open-la- 28. Pujol JL, Barlesi F, Daures JP i sur. Should chemotherapy
combina- bel, randomised, multicentre, phase 2 study. Lancet 2014;15:1236–44. tions for advanced non-small cell lung
cancer be platinum-based? A 50. Giaccone G, Herbst RS, Manegold C i sur. Gefi tinib in combination meta analysis of
phased III randomized trials. Lung Cancer 2006;51: with gemcitabine and cisplatin in advanced non-small-cell lung
cancer: 335–45. a phase III trial–INTACT 1. J Clin Oncol 2004;22:777–84. 29. Jiang J, Liang H, Zhou X i sur. A meta-
analysis of randomized con- 5

25. [population] score -36 ✅ BINGO (PIO)
ou C, Wu JL, Chen G i sur. Erlotinib versus chemotherapy as fi rst- evaluation: a pooled analysis by the LACE
Collaborative Group. J Clin line treatment for patients with advanced EGFR mutation-positive Oncol 2008;26:3552–9. non-
small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, 25. Strauss GM, Herndon JE 2nd, Maddaus MA i sur. Adjuvant
paclitaxel open-label, randomised, phase 3 study. Lancet Oncol 2011;12(8): plus carboplatin compared with observation in
stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, 47. Gridelli C, De Marinis F, Di
Maio M i sur. Gefi tinib as fi rst-line treat- Radiation Therapy Oncology Group, and North Central Cancer Treat- ment
for patients with advanced non-small-cell lung cancer with acti- ment Group Study Groups. J Clin Oncol
2008;26(31):5043–51. vating epidermal growth factor receptor mutation: Review of the evi- 26. Sederholm C, Hillerdal G,
Lambert K i sur. Phase III trial of gem- dence. Lung Cancer 2011;71(3):249–57. citabine plus carboplatin versus single-
agent gemcitabine in the treat- 48. Lee CK, Brown C, Gralla RJ i sur. Impact of EGFR inhibitor in non- ment of locally
advanced or metastatic non-small-cell lung cancer. The small cell lung cancer on progression-free and overall survival:
a meta- Swedish Lung Cancer Study Group. J Clin Oncol 2005;23:8380–8. analysis. J Natl Cancer Inst 2013;105:595–605. 27.
Delbaldo C, Michiels S, Syz N i sur. Benefi ts of adding a drug to a single 49. Seto T, Kato T, Nishio M i sur.
Erlotinib alone or with bevacizumab as agent or a 2-agent chemotherapy regimen in advanced non-small-cell fi rst-line
therapy in patients with advanced non-squamous non-small- lung cancer. A meta analysis. JAMA 2004;292:470–84. cell lung
cancer harbouring EGFR mutations (JO25567): an open-la- 28. Pujol JL, Barlesi F, Daures JP i sur. Should chemotherapy
combina- bel, randomised, multicentre, phase 2 study. Lancet 2014;15:1236–44. tions for advanced non-small cell lung
cancer be platinum-based? A 50. Giaccone G, Herbst RS, Manegold C i sur. Gefi tinib in combination meta analysis of
phased III randomized trials. Lung Cancer 2006;51: with gemcitabine and cisplatin in advanced non-small-cell lung
cancer: 335–45. a phase III trial–INTACT 1. J Clin Oncol 2004;22:777–84. 29. Jiang J, Liang H, Zhou X i sur. A meta-
analysis of randomized con- 51. Herbst RS, Giaccone G, Schiller JH i sur. Gefi tinib in combination with trolled trials
comparing carboplatin-based to cisplatin-based chemo- paclitaxel and carboplatin in advanced non-small-cell lung cancer:
a therapy in advanced non-small cell lung cancer. Lung Cancer 2007;57: phase III trial–INTACT 2. J Clin Oncol
2004;22:785–94. 348–58. 52. Gatzemeier U, Pluzanska A, Szczesna A i sur. Phase III study of erlo- 30. Smit EF, van
Meerbeeck JP, Lianes P i sur. Three-arm randomized tinib in combination with cisplatin and gemcitabine in advanced non-
study of two cisplatin-based regimens and paclitaxel plus gemcitabine small-cell lung cancer: the Tarceva Lung Cancer
Investigation Trial. J in advanced non-small-cell lung cancer: a phase III trial of the Euro- Clin Oncol
2007;25:1545–52. pean Organization for Research and Treatment of Cancer Lung Cancer 53. Shaw AT, Kim DW, Nakagawa K i
sur. Crizotinib versus chemothe- Group–EO

26. [population] score -36 ✅ BINGO (PIO)
ion with cisplatin and gemcitabine in advanced non- study of two cisplatin-based regimens and paclitaxel plus
gemcitabine small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J in advanced non-small-cell lung
cancer: a phase III trial of the Euro- Clin Oncol 2007;25:1545–52. pean Organization for Research and Treatment of
Cancer Lung Cancer 53. Shaw AT, Kim DW, Nakagawa K i sur. Crizotinib versus chemothe- Group–EORTC 08975. J Clin Oncol
2003;21:3909–17. rapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368: 31. Schiller JH, Harrington D, Belani
CP i sur. Comparison of four chemo- 2385–94. therapy regimens for advanced non-small-cell lung cancer. N Engl J 54.
Solomon BJ, Mok T, Kim DW i sur. First-line crizotinib versus chemo- Med 2002;346:92–8. therapy in ALK-positive lung
cancer. N Engl J Med 2014;371:2167–77. 55. Fossella FV, DeVore R, Kerr RN i sur. Randomized phase III trial of 63.
Rittmeyer A, Barlesi F, Waterkamp D i sur. Atezolizumab versus docetaxel versus vinorelbine or ifosfamide in patients
with advanced docetaxel in patients with previously treated non-small-cell lung cancer non-small-cell lung cancer
previously treated with platinum-containing (OAK): a phase 3, open-label, multicentre randomised controlled trial.
chemotherapy regimens. The TAX 320 Non Small Cell Lung Cancer Lancet 2017;389:255–65. Study Group. J Clin Oncol
2000;18:2354–62. 64. Mok TS, Yi-Long Wu YL, Ahn MJ i sur. Osimertinib or platinum–peme- 56. Sheperd FA, Dancey J, Ramlau
R i sur. Prospective randomized trial of trexed in EGFR T790M–positive lung cancer. N Engl J Med 2017; docetaxel versus
best suportive care in patients with non small cell lung 376:629–40. cancer previously treated with platinum-based
chemotherapy. J Clin 65. Larkins E, Blumenthal GM, Chen H i sur. FDA Approval: Alectinib for Oncol 2000;18:2095–103. the
treatment of metastatic, ALK-positive non-small cell lung cancer 57. Hanna N, Sheperd FA, Fossella FV i sur. Randomized
phase III trial of following crizotinib. Clin Cancer Res 2016;22:5171–6. pemetrexed versus docetaxel in patients with
non-small-cell lung 66. Khozin S, Blumenthal GM, Zhang L i sur. FDA approval: ceritinib for cancer previously treated
with chemotherapy. J Clin Oncol 2004;22: the treatment of metastatic anaplastic lymphoma kinase-positive non- 1589–97.
small cell lung cancer. Clin Cancer Res 2015;21(11):2436–9. 58. Nagano T, Kim YH, Goto K i sur. Re-challenge
chemotherapy for re- 67. Shepherd FA, Pereira JR, Ciuleanu T i sur. Erlotinib in Previously lapsed non-small-cell lung
cancer. Lung Cancer 2010;69(3):315–8. Treated Non-Small-Cell Lung Cancer. N Engl J Med 2005;353: 59. Reck M, Kaiser R,
Mellemgaard A i sur. Docetaxel plus nintedanib ver- 123–32. sus docetaxel plus placebo in patients with previously
treated non- 68. Tsao MN, Lloyd N, Wong RK i sur. Whole brain radiotherapy for the small-cell lung cancer (LUME-Lung 1):
a phase 3, double-blind, ran- treatment of newly diagnosed multiple brain metastases. Cochrane Da- domised controlled
trial. Lancet 2014;15:143–55. tabase Syst Rev 2012;4:CD003869. 60. Borghaei H, Paz-Ares L, Horn L i sur. Nivolumab
versus Docetaxel in 69. Temel JS, Greer JA, Muzikansky A i sur. Early palliative care for pa- Advanced Nonsquamous Non-
Small-Cell Lung Cancer. N Engl J Me

27. [population] score -36 ✅ BINGO (PICO)
cancer non-small-cell lung cancer previously treated with platinum-containing (OAK): a phase 3, open-label, multicentre
randomised controlled trial. chemotherapy regimens. The TAX 320 Non Small Cell Lung Cancer Lancet 2017;389:255–65. Study
Group. J Clin Oncol 2000;18:2354–62. 64. Mok TS, Yi-Long Wu YL, Ahn MJ i sur. Osimertinib or platinum–peme- 56. Sheperd
FA, Dancey J, Ramlau R i sur. Prospective randomized trial of trexed in EGFR T790M–positive lung cancer. N Engl J Med
2017; docetaxel versus best suportive care in patients with non small cell lung 376:629–40. cancer previously treated
with platinum-based chemotherapy. J Clin 65. Larkins E, Blumenthal GM, Chen H i sur. FDA Approval: Alectinib for Oncol
2000;18:2095–103. the treatment of metastatic, ALK-positive non-small cell lung cancer 57. Hanna N, Sheperd FA, Fossella
FV i sur. Randomized phase III trial of following crizotinib. Clin Cancer Res 2016;22:5171–6. pemetrexed versus
docetaxel in patients with non-small-cell lung 66. Khozin S, Blumenthal GM, Zhang L i sur. FDA approval: ceritinib for
cancer previously treated with chemotherapy. J Clin Oncol 2004;22: the treatment of metastatic anaplastic lymphoma
kinase-positive non- 1589–97. small cell lung cancer. Clin Cancer Res 2015;21(11):2436–9. 58. Nagano T, Kim YH, Goto K i
sur. Re-challenge chemotherapy for re- 67. Shepherd FA, Pereira JR, Ciuleanu T i sur. Erlotinib in Previously lapsed
non-small-cell lung cancer. Lung Cancer 2010;69(3):315–8. Treated Non-Small-Cell Lung Cancer. N Engl J Med 2005;353: 59.
Reck M, Kaiser R, Mellemgaard A i sur. Docetaxel plus nintedanib ver- 123–32. sus docetaxel plus placebo in patients
with previously treated non- 68. Tsao MN, Lloyd N, Wong RK i sur. Whole brain radiotherapy for the small-cell lung
cancer (LUME-Lung 1): a phase 3, double-blind, ran- treatment of newly diagnosed multiple brain metastases. Cochrane Da-
domised controlled trial. Lancet 2014;15:143–55. tabase Syst Rev 2012;4:CD003869. 60. Borghaei H, Paz-Ares L, Horn L i
sur. Nivolumab versus Docetaxel in 69. Temel JS, Greer JA, Muzikansky A i sur. Early palliative care for pa- Advanced
Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med tients with metastatic non-small-cell lung cancer. N Engl J Med
2010; 61. Brahmer J, Reckamp KL, Baas P i sur. Nivolumab versus docetaxel in 70. Vansteenkiste J, Crinò L, Dooms C i
sur. 2nd ESMO Consensus Con- advanced squamous-cell non-small-cell lung cancer. N Engl J Med ference on Lung Cancer:
early-stage non-small-cell lung cancer con- 2015;373(2):123–35. sensus on diagnosis, treatment and follow-up. Ann Oncol
2014;25: 62. Herbst RS, Baas P, Kim DW i sur. Pembrolizumab versus docetaxel for 1462–74. previously treated,
PD-L1-positive, advanced non-small-cell lung can- 71. Samaržija M, Gugić D, Radić J i sur. Kliničke upute za dijagnozu,
cer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; liječenje i praćenje bolesnika oboljelih od karcinoma
pluća nemalih 387(10027):1540–50. stanica. Liječ Vjesn 2011;133:361–5.

28. [outcome] score -38
ddaus MA i sur. Adjuvant paclitaxel open-label, randomised, phase 3 study. Lancet Oncol 2011;12(8): plus carboplatin
compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, 47.
Gridelli C, De Marinis F, Di Maio M i sur. Gefi tinib as fi rst-line treat- Radiation Therapy Oncology Group, and North
Central Cancer Treat- ment for patients with advanced non-small-cell lung cancer with acti- ment Group Study Groups. J
Clin Oncol 2008;26(31):5043–51. vating epidermal growth factor receptor mutation: Review of the evi- 26. Sederholm C,
Hillerdal G, Lambert K i sur. Phase III trial of gem- dence. Lung Cancer 2011;71(3):249–57. citabine plus carboplatin
versus single-agent gemcitabine in the treat- 48. Lee CK, Brown C, Gralla RJ i sur. Impact of EGFR inhibitor in non-
ment of locally advanced or metastatic non-small-cell lung cancer. The small cell lung cancer on progression-free and
overall survival: a meta- Swedish Lung Cancer Study Group. J Clin Oncol 2005;23:8380–8. analysis. J Natl Cancer Inst
2013;105:595–605. 27. Delbaldo C, Michiels S, Syz N i sur. Benefi ts of adding a drug to a single 49. Seto T, Kato T,
Nishio M i sur. Erlotinib alone or with bevacizumab as agent or a 2-agent chemotherapy regimen in advanced non-small-
cell fi rst-line therapy in patients with advanced non-squamous non-small- lung cancer. A meta analysis. JAMA
2004;292:470–84. cell lung cancer harbouring EGFR mutations (JO25567): an open-la- 28. Pujol JL, Barlesi F, Daures JP i
sur. Should chemotherapy combina- bel, randomised, multicentre, phase 2 study. Lancet 2014;15:1236–44. tions for
advanced non-small cell lung cancer be platinum-based? A 50. Giaccone G, Herbst RS, Manegold C i sur. Gefi tinib in
combination meta analysis of phased III randomized trials. Lung Cancer 2006;51: with gemcitabine and cisplatin in
advanced non-small-cell lung cancer: 335–45. a phase III trial–INTACT 1. J Clin Oncol 2004;22:777–84. 29. Jiang J, Liang
H, Zhou X i sur. A meta-analysis of randomized con- 51. Herbst RS, Giaccone G, Schiller JH i sur. Gefi tinib in
combination with trolled trials comparing carboplatin-based to cisplatin-based chemo- paclitaxel and carboplatin in
advanced non-small-cell lung cancer: a therapy in advanced non-small cell lung cancer. Lung Cancer 2007;57: phase III
trial–INTACT 2. J Clin Oncol 2004;22:785–94. 348–58. 52. Gatzemeier U, Pluzanska A, Szczesna A i sur. Phase III study of
erlo- 30. Smit EF, van Meerbeeck JP, Lianes P i sur. Three-arm randomized tinib in combination with cisplatin and
gemcitabine in advanced non- study of two cisplatin-based regimens and paclitaxel plus gemcitabine small-cell lung
cancer: the Tarceva Lung Cancer Investigation Trial. J in advanced non-small-cell lung cancer: a phase III trial of the
Euro- Clin Oncol 2007;25:1545–52. pean Organization for Research and Treatment of Cancer Lung Cancer 53. Shaw AT, Kim
DW, Nakagawa K i sur. Crizotinib versus chemothe- Group–EORTC 08975. J Clin Oncol 2003;21:3909–17. rapy in advanced ALK-
positive lung cancer. N Engl J Med 2013;368: 31. Schiller JH, Harrington D, Belani CP i sur. Comparison of four chemo-
2385–94. therapy regimens for advanced non-small-cell lung cancer. N Engl J 54. Solomon BJ, Mok T, Kim DW i sur. First-
line crizotinib versus chemo- Med 2002;346

29. [intervention] score -39 ✅ BINGO (PIO)
ncologie Thoracique-Groupe Français de Pneumo- Cancérologie NPC 95-01 Study. J Clin Oncol 2005;23:5910–7. 37. Sandler A,
Yi J, Dahlberg S i sur. Treatment outcomes by tumor histol- 16. Aupérin A, Le Péchoux C, Rolland E i sur. Meta-analysis
of concomi- ogy in Eastern Cooperative Group Study E4599 of bevacizumab with tant versus sequential radiochemotherapy in
locally advanced non- paclitaxel/carboplatin for advanced non-small cell lung cancer. J Tho- small cell lung cancer. J
Clin Oncol 2010;28:2181–90. rac Oncol 2010;5:1416–23. 17. Brunelli A, Charloux A, Bolliger CT i sur. ERS/ESTS clinical
guide- 38. Masters GA, Temin S, Christopher G i sur. Systemic Therapy for Stage lines on fitness for radical therapy in
lung cancer patients (surgery and IV Non-Small-Cell Lung Cancer: American Society of Clinical On- chemo-radiotherapy).
Eur Respir J 2009;34:17–41. cology Clinical Practice Guideline Update. J Clin Oncol 2015;33: 18. Rusch VW, Giroux DJ,
Kraut MJ i sur. Induction chemoradiation and 3488–515. surgical resection for superior sulcus non-small cell lung
carcinomas: 39. Santos FN, de Castria TB, Cruz MR, Riera R. Chemotherapy for ad- long-term results of Southwest Oncology
Group Trial 9416 – (Inter- vanced non-small cell lung cancer in the elderly population. Cochrane group Trial 0160). J
Clin Oncol 2007;25:313–8. Database Syst Rev 2015;(10):CD010463. 19. Hancock JG, Rosen JE, Antonicelli A i sur. Impact of
adjuvant treat- 40. Novello S, Barlesi F, Califano R i sur. Metastatic non-small-cell lung ment for microscopic residual
disease after non-small cell lung cancer cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment surgery. Ann
Thorac Surg 2015;99(2):406–13. and follow-up. Ann Oncol 2016;27:1–27. 20. Douillard JY, Rosell R, De Lena M i sur.
Impact of postoperative radia- 41. von Plessen C, Bergman B, Andresen O i sur. Palliative chemotherapy tion therapy on
survival in patients with complete resection and stage I, beyond three courses conveys no survival or consistent
quality-of-life II, or IIIA non-small-cell lungcancer treated with adjuvant chemother- benefi ts in advanced non small-
cell lung cancer. Br J Cancer 2006; apy: the adjuvant Navelbine International Trialist Association (ANITA) 95:966–73.
Randomized Trial. Int J Radiat Oncol Biol Phys 2008:72;696–701. 42. Park JO, Kim SW, Ahn JS i sur. Phase III trial of
two versus four addi- 21. Bradley JD, Paulus R, Graham MV i sur. Phase II trial of postoperative tional cycles in
patients who are nonprogressive after two cycles of adjuvant paclitaxel/carboplatin and thoracic radiotherapy in
resected platinum-based chemotherapy in non small-cell lung cancer. J Clin stage II and IIIA non-small-cell lung cancer:
promising long-term Oncol 2007;25:5233–9. results of the Radiation Therapy Oncology Group–RTOG 9705. J Clin 43. Rosell
R, Carceremy E, Gervais R i sur. Erlotinib versus standard che- Oncol 2005:343;3480–7. motherapy as first-line treatment
for European patients with advanced 22. Butts CA, Ding K, Seymour L i sur. Randomized phase III trial of EGFR mutation-
positive non-small-cell lung cancer (EURTAC): a vinorelbine plus cisplatin compared with observation in completely
multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; resected stage IB and II non-small cell lu

30. [intervention] score -39 ✅ BINGO (PIO)
carboplatin-pacli- Oncol 2006;7:719–27. taxel in pulmonary adenocarcinoma. N Engl J Med 2009:3;361(10): 24. Pignon JP,
Tribodet H, Scagliotti GV i sur. Lung adjuvant cisplatin 46. Zhou C, Wu JL, Chen G i sur. Erlotinib versus chemotherapy
as fi rst- evaluation: a pooled analysis by the LACE Collaborative Group. J Clin line treatment for patients with
advanced EGFR mutation-positive Oncol 2008;26:3552–9. non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre,
25. Strauss GM, Herndon JE 2nd, Maddaus MA i sur. Adjuvant paclitaxel open-label, randomised, phase 3 study. Lancet
Oncol 2011;12(8): plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the
Cancer and Leukemia Group B, 47. Gridelli C, De Marinis F, Di Maio M i sur. Gefi tinib as fi rst-line treat- Radiation
Therapy Oncology Group, and North Central Cancer Treat- ment for patients with advanced non-small-cell lung cancer with
acti- ment Group Study Groups. J Clin Oncol 2008;26(31):5043–51. vating epidermal growth factor receptor mutation:
Review of the evi- 26. Sederholm C, Hillerdal G, Lambert K i sur. Phase III trial of gem- dence. Lung Cancer
2011;71(3):249–57. citabine plus carboplatin versus single-agent gemcitabine in the treat- 48. Lee CK, Brown C, Gralla
RJ i sur. Impact of EGFR inhibitor in non- ment of locally advanced or metastatic non-small-cell lung cancer. The small
cell lung cancer on progression-free and overall survival: a meta- Swedish Lung Cancer Study Group. J Clin Oncol
2005;23:8380–8. analysis. J Natl Cancer Inst 2013;105:595–605. 27. Delbaldo C, Michiels S, Syz N i sur. Benefi ts of
adding a drug to a single 49. Seto T, Kato T, Nishio M i sur. Erlotinib alone or with bevacizumab as agent or a 2-agent
chemotherapy regimen in advanced non-small-cell fi rst-line therapy in patients with advanced non-squamous non-small-
lung cancer. A meta analysis. JAMA 2004;292:470–84. cell lung cancer harbouring EGFR mutations (JO25567): an open-la-
28. Pujol JL, Barlesi F, Daures JP i sur. Should chemotherapy combina- bel, randomised, multicentre, phase 2 study.
Lancet 2014;15:1236–44. tions for advanced non-small cell lung cancer be platinum-based? A 50. Giaccone G, Herbst RS,
Manegold C i sur. Gefi tinib in combination meta analysis of phased III randomized trials. Lung Cancer 2006;51: with
gemcitabine and cisplatin in advanced non-small-cell lung cancer: 335–45. a phase III trial–INTACT 1. J Clin Oncol
2004;22:777–84. 29. Jiang J, Liang H, Zhou X i sur. A meta-analysis of randomized con- 51. Herbst RS, Giaccone G,
Schiller JH i sur. Gefi tinib in combination with trolled trials comparing carboplatin-based to cisplatin-based chemo-
paclitaxel and carboplatin in advanced non-small-cell lung cancer: a therapy in advanced non-small cell lung cancer.
Lung Cancer 2007;57: phase III trial–INTACT 2. J Clin Oncol 2004;22:785–94. 348–58. 52. Gatzemeier U, Pluzanska A,
Szczesna A i sur. Phase III study of erlo- 30. Smit EF, van Meerbeeck JP, Lianes P i sur. Three-arm randomized tinib in
combination with cisplatin and gemcitabine in advanced non- study of two cisplatin-based regimens and paclitaxel plus
gemcitabine small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J in advanced non-small-cell lung
cancer: a phase III tri

31. [intervention] score -39 ✅ BINGO (PIO)
lacebo immediately after induction treatment with pemetrexed lung cancer. J Clin Oncol 1999;17:2692–9. plus cisplatin
for advanced nonsquamous non-small-cell lung cancer. J 14. Curran WJ Jr, Paulus R, Langer CJ i sur. Sequential vs.
concurrent Clin Oncol 2013;31:2895–902. chemoradiation for stage III non-small cell lung cancer: randomized 35. Sandler
A, Gray R, Perry MC i sur. Paclitaxel-carboplatin alone or with phase III trial RTOG 9410. J Natl Cancer Inst
2011;103(19):1452–60. bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 15. Fournel P, Robinet G,
Thomas P i sur. Randomized phase III trial of 36. Reck M, von Pawel J, Zatloukal P i sur. Phase III trial of cisplatin
plus sequential chemoradiotherapy compared with concurrent chemoradio- gemcitabine with either placebo or bevacizumab as
fi rst-line therapy therapy in locally advanced non-small-cell lung cancer: Groupe Lyon- for nonsquamous non-small cell
lung cancer: AVAiL. J Clin Oncol Saint-Etienne d’Oncologie Thoracique-Groupe Français de Pneumo- Cancérologie NPC 95-01
Study. J Clin Oncol 2005;23:5910–7. 37. Sandler A, Yi J, Dahlberg S i sur. Treatment outcomes by tumor histol- 16.
Aupérin A, Le Péchoux C, Rolland E i sur. Meta-analysis of concomi- ogy in Eastern Cooperative Group Study E4599 of
bevacizumab with tant versus sequential radiochemotherapy in locally advanced non- paclitaxel/carboplatin for advanced
non-small cell lung cancer. J Tho- small cell lung cancer. J Clin Oncol 2010;28:2181–90. rac Oncol 2010;5:1416–23. 17.
Brunelli A, Charloux A, Bolliger CT i sur. ERS/ESTS clinical guide- 38. Masters GA, Temin S, Christopher G i sur.
Systemic Therapy for Stage lines on fitness for radical therapy in lung cancer patients (surgery and IV Non-Small-Cell
Lung Cancer: American Society of Clinical On- chemo-radiotherapy). Eur Respir J 2009;34:17–41. cology Clinical Practice
Guideline Update. J Clin Oncol 2015;33: 18. Rusch VW, Giroux DJ, Kraut MJ i sur. Induction chemoradiation and 3488–515.
surgical resection for superior sulcus non-small cell lung carcinomas: 39. Santos FN, de Castria TB, Cruz MR, Riera R.
Chemotherapy for ad- long-term results of Southwest Oncology Group Trial 9416 – (Inter- vanced non-small cell lung
cancer in the elderly population. Cochrane group Trial 0160). J Clin Oncol 2007;25:313–8. Database Syst Rev
2015;(10):CD010463. 19. Hancock JG, Rosen JE, Antonicelli A i sur. Impact of adjuvant treat- 40. Novello S, Barlesi F,
Califano R i sur. Metastatic non-small-cell lung ment for microscopic residual disease after non-small cell lung cancer
cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment surgery. Ann Thorac Surg 2015;99(2):406–13. and
follow-up. Ann Oncol 2016;27:1–27. 20. Douillard JY, Rosell R, De Lena M i sur. Impact of postoperative radia- 41. von
Plessen C, Bergman B, Andresen O i sur. Palliative chemotherapy tion therapy on survival in patients with complete
resection and stage I, beyond three courses conveys no survival or consistent quality-of-life II, or IIIA non-small-cell
lungcancer treated with adjuvant chemother- benefi ts in advanced non small-cell lung cancer. Br J Cancer 2006; apy: the
adjuvant Navelbine International Trialist Association (ANITA) 95:966–73. Randomized Trial. Int J Radiat Oncol Biol Phys
2008:72;696–701

32. [outcome] score -39
specifi čna terapija IIB – Dokaz proizašao iz barem jedne pseudoeksperimen- talne studije drugog tipa Endoskopske
minimalno invazivne metode mogu biti ko- III – Dokaz iz neeksperimentalnih deskriptivnih studija, risne kod opstrukcije
dišnih putova (terapija laserom, po- poput usporednih studija, korelacijskih studija ili pri- stavljanje stenta,
krioterapija, brahiterapija). Postavljanje kaza bolesnika stenta katkad se rabi kod sindroma gornje šuplje vene, a IV –
Dokaz proizašao iz izvješća ili mišljenja odbora struč- pleurodeza ili postavljanje torakalnog drena kod recidivira-
njaka ili iz kliničkog iskustva nedvojbenog autoriteta jućih pleuralnih izljeva. ili obojega Suportivna terapija Ove su
smjernice nadopuna kliničkih uputa za dijagnozu, Kod svih bolesnika s uznapredovalim karcinomom pluća liječenje i
praćenje bolesnika oboljelih od raka pluća nema- savjetuje se što prije započeti primjenom suportivne tera- lih stanica
objavljenih 2011. godini.71 pije.69 Klinička istraživanja L I T E R A T U R A Savjetuje se uključenje što većeg broja
bolesnika s karci- 1. Incidencija raka u Hrvatskoj 2014. Bilten br. 39. Zagreb: Hrvatski zavod za javno zdravstvo; 2016.
nomom pluća u klinička istraživanja. 2. Goldstraw P, Chansky K, Crowley J i sur. The IASLC Lung Cancer Staging Project:
Proposals for Revision of the TNM Stage Groupings Preporuke za kontrolu i praćenje in the Forthcoming (Eighth) Edition
of the TNM Classifi cation for Lung Cancer. J Thorac Oncol 2016;11(1):39–51. Nakon radikalnoga kirurškog zahvata 3.
Ginsberg RJ, Rubinstein LV. Randomised trial of lobectomy versus /adjuvantnog liječenja70 limited resection for T1 N0
non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995;60: 615–22. Klinički pregled, KKS, DKS, SE i
osnovne biokemijske 4. Scott WJ, Howington J, Feigenberg S i sur. Treatment of non-small cel pretrage krvi napraviti
svaka 3 do 4 mjeseca prve 2 godine, lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines
(2. izd.). Chest 2007;132:234S–42S. svakih 6 mjeseci od 3. do 5. godine, potom 1x na godinu. CT 5. Darling GE, Allen MS,
Decker PA i sur. Randomized trial of mediasti- pluća (rendgensko snimanje) svakih 6 mjeseci prve 2 godine, nal lymph
node sampling versus complete lymphadenectomy during zatim 1x na godinu. CT (UZ) abdomena 1x na go dinu. pulmonary
resection in the patient with N0 or N1 (less than hilar) Ostale pretrage prema kliničkoj indikaciji (PET samo non-small
cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg
2011;141(3): prema preporuci multidisciplinarnog tima). 6. Baumann P, Nyman J, Hoyer M i sur. Outcome in a prospective
phase Diseminirana/neresektabilna lokalno uznapredovala II trial of medically inoperable stage I non-small-cell lung
cancer pa- bolest u fazi aktivnog liječenja tients treated with stereotactic body radiotherapy. J Clin Oncol 2009;
Kontrola učinka liječenja svakih 6 – 8 tjedana (rendgen- 27:3290–6. 7. Scagliotti GV, Pastorino U, Vansteenkiste JF i
sur. Randomized phase ska snimka/CT pluća, UZ/CT abdomena).41 Ostale pretra- III study of surgery alone or surgery plus
preoperative cisplatin and ge prema kliničkoj indikaciji (PET nije indiciran, iznimno gemcitabine in stages IB to IIIA
non-small cell lung cancer.

33. [outcome] score -39
0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995;60: 615–22. Klinički pregled, KKS, DKS, SE i
osnovne biokemijske 4. Scott WJ, Howington J, Feigenberg S i sur. Treatment of non-small cel pretrage krvi napraviti
svaka 3 do 4 mjeseca prve 2 godine, lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines
(2. izd.). Chest 2007;132:234S–42S. svakih 6 mjeseci od 3. do 5. godine, potom 1x na godinu. CT 5. Darling GE, Allen MS,
Decker PA i sur. Randomized trial of mediasti- pluća (rendgensko snimanje) svakih 6 mjeseci prve 2 godine, nal lymph
node sampling versus complete lymphadenectomy during zatim 1x na godinu. CT (UZ) abdomena 1x na go dinu. pulmonary
resection in the patient with N0 or N1 (less than hilar) Ostale pretrage prema kliničkoj indikaciji (PET samo non-small
cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg
2011;141(3): prema preporuci multidisciplinarnog tima). 6. Baumann P, Nyman J, Hoyer M i sur. Outcome in a prospective
phase Diseminirana/neresektabilna lokalno uznapredovala II trial of medically inoperable stage I non-small-cell lung
cancer pa- bolest u fazi aktivnog liječenja tients treated with stereotactic body radiotherapy. J Clin Oncol 2009;
Kontrola učinka liječenja svakih 6 – 8 tjedana (rendgen- 27:3290–6. 7. Scagliotti GV, Pastorino U, Vansteenkiste JF i
sur. Randomized phase ska snimka/CT pluća, UZ/CT abdomena).41 Ostale pretra- III study of surgery alone or surgery plus
preoperative cisplatin and ge prema kliničkoj indikaciji (PET nije indiciran, iznimno gemcitabine in stages IB to IIIA
non-small cell lung cancer. J Clin On- prema preporuci multidisciplinarnog tima). col 2012;30:172–8. 8. Gilligan D,
Nicolson M, Smith I i sur. Preoperative chemotherapy in Diseminirana/neresektabilna lokalno uznapredovala patients with
resectable non-small cell lung cancer: results of the MRC bolest – pauza u liječenju, praćenje radi pravodobne
LU22/NVALT 2/EORTC 08012 multicentre randomised trial and up- date of systematic review. Lancet 2007;369:1929–37.
detekcije progresije bolesti 9. NSCLC Meta-analysis Collaborative Group. Preoperative chemothera- Klinički pregled, KKS,
DKS, SE i osnovne biokemijske py for non-small-cell lung cancer: a systematic review and meta-analy- pretrage krvi
svakih 8 – 12 tjedana prvih 12 mjeseci, svaka sis of individual participant data. Lancet 2014;383(9928):1561–71. 10.
Higgins K, Chino JP, Marks LB i sur. Preoperative chemotherapy ver- 3 – 6 mjeseci 2. i 3. godinu, zatim svakih 4 – 8
mjeseci tije- sus preoperative chemoradiotherapy for stage III (N2) non-small-cell kom 4. i 5. godine, potom svakih 6 –
12 mjeseci. Praćenje lung cancer. Int J Radiat Oncol Biol Phys 2009;75(5):1462–7. 11. Albain KS, Swann RS, Rusch VW i
sur. Radiotherapy plus chemothera- 32. Scagliotti GV, Hanna N, Fossella F i sur. The differential effi cacy of py with
or without surgical resection for stage III non-small cell lung pemetrexed according to NSCLC histology: a review of two
phase III cancer: a phase III randomised controlled trial. Lancet 2009;374: studies. Oncologist 2009;14:253–63. 379–86.
33. Scagliotti GV, Parikh P, von Pawel J i sur. Phase III study comparing 12. Thomas M, Rübe C, Hoffknecht P i sur.
Effect of preoperative chemo- c

34. [outcome] score -39
N2) non-small-cell kom 4. i 5. godine, potom svakih 6 – 12 mjeseci. Praćenje lung cancer. Int J Radiat Oncol Biol Phys
2009;75(5):1462–7. 11. Albain KS, Swann RS, Rusch VW i sur. Radiotherapy plus chemothera- 32. Scagliotti GV, Hanna N,
Fossella F i sur. The differential effi cacy of py with or without surgical resection for stage III non-small cell lung
pemetrexed according to NSCLC histology: a review of two phase III cancer: a phase III randomised controlled trial.
Lancet 2009;374: studies. Oncologist 2009;14:253–63. 379–86. 33. Scagliotti GV, Parikh P, von Pawel J i sur. Phase III
study comparing 12. Thomas M, Rübe C, Hoffknecht P i sur. Effect of preoperative chemo- cisplatin plus gemcitabine with
cisplatin plus pemetrexed in chemo- radiation in addition to preoperative chemotherapy: a randomised trial therapy-naive
patients with advanced-stage non-small-cell lung cancer. in stage III non-small cell lung cancer. Lancet Oncol
2008;9:636–48. J Clin Oncol 2008;26:3543–51. 13. Furuse K, Fukuoka M, Kawahara M i sur. Phase III study of concurrent
34. Paz-Ares LG, de Marinis F, Dediu M i sur. PARAMOUNT: final overall versus sequential thoracic radiotherapy in
combination with mito- survival results of the phase III study of maintenance pemetrexed ver- mycin, vindesine, and
cisplatin in unresectable stage III non-small-cell sus placebo immediately after induction treatment with pemetrexed
lung cancer. J Clin Oncol 1999;17:2692–9. plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J 14.
Curran WJ Jr, Paulus R, Langer CJ i sur. Sequential vs. concurrent Clin Oncol 2013;31:2895–902. chemoradiation for stage
III non-small cell lung cancer: randomized 35. Sandler A, Gray R, Perry MC i sur. Paclitaxel-carboplatin alone or with
phase III trial RTOG 9410. J Natl Cancer Inst 2011;103(19):1452–60. bevacizumab for non-small-cell lung cancer. N Engl J
Med 2006;355: 15. Fournel P, Robinet G, Thomas P i sur. Randomized phase III trial of 36. Reck M, von Pawel J, Zatloukal
P i sur. Phase III trial of cisplatin plus sequential chemoradiotherapy compared with concurrent chemoradio- gemcitabine
with either placebo or bevacizumab as fi rst-line therapy therapy in locally advanced non-small-cell lung cancer: Groupe
Lyon- for nonsquamous non-small cell lung cancer: AVAiL. J Clin Oncol Saint-Etienne d’Oncologie Thoracique-Groupe
Français de Pneumo- Cancérologie NPC 95-01 Study. J Clin Oncol 2005;23:5910–7. 37. Sandler A, Yi J, Dahlberg S i sur.
Treatment outcomes by tumor histol- 16. Aupérin A, Le Péchoux C, Rolland E i sur. Meta-analysis of concomi- ogy in
Eastern Cooperative Group Study E4599 of bevacizumab with tant versus sequential radiochemotherapy in locally advanced
non- paclitaxel/carboplatin for advanced non-small cell lung cancer. J Tho- small cell lung cancer. J Clin Oncol
2010;28:2181–90. rac Oncol 2010;5:1416–23. 17. Brunelli A, Charloux A, Bolliger CT i sur. ERS/ESTS clinical guide- 38.
Masters GA, Temin S, Christopher G i sur. Systemic Therapy for Stage lines on fitness for radical therapy in lung cancer
patients (surgery and IV Non-Small-Cell Lung Cancer: American Society of Clinical On- chemo-radiotherapy). Eur Respir J
2009;34:17–41. cology Clinical Practice Guideline Update. J Clin Oncol 2015;33: 18. Rusch VW, Giroux DJ, Kraut MJ i sur.
Induction chemor

35. [outcome] score -39
. Randomized trial of mediasti- pluća (rendgensko snimanje) svakih 6 mjeseci prve 2 godine, nal lymph node sampling
versus complete lymphadenectomy during zatim 1x na godinu. CT (UZ) abdomena 1x na go dinu. pulmonary resection in the
patient with N0 or N1 (less than hilar) Ostale pretrage prema kliničkoj indikaciji (PET samo non-small cell carcinoma:
results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg 2011;141(3): prema
preporuci multidisciplinarnog tima). 6. Baumann P, Nyman J, Hoyer M i sur. Outcome in a prospective phase
Diseminirana/neresektabilna lokalno uznapredovala II trial of medically inoperable stage I non-small-cell lung cancer
pa- bolest u fazi aktivnog liječenja tients treated with stereotactic body radiotherapy. J Clin Oncol 2009; Kontrola
učinka liječenja svakih 6 – 8 tjedana (rendgen- 27:3290–6. 7. Scagliotti GV, Pastorino U, Vansteenkiste JF i sur.
Randomized phase ska snimka/CT pluća, UZ/CT abdomena).41 Ostale pretra- III study of surgery alone or surgery plus
preoperative cisplatin and ge prema kliničkoj indikaciji (PET nije indiciran, iznimno gemcitabine in stages IB to IIIA
non-small cell lung cancer. J Clin On- prema preporuci multidisciplinarnog tima). col 2012;30:172–8. 8. Gilligan D,
Nicolson M, Smith I i sur. Preoperative chemotherapy in Diseminirana/neresektabilna lokalno uznapredovala patients with
resectable non-small cell lung cancer: results of the MRC bolest – pauza u liječenju, praćenje radi pravodobne
LU22/NVALT 2/EORTC 08012 multicentre randomised trial and up- date of systematic review. Lancet 2007;369:1929–37.
detekcije progresije bolesti 9. NSCLC Meta-analysis Collaborative Group. Preoperative chemothera- Klinički pregled, KKS,
DKS, SE i osnovne biokemijske py for non-small-cell lung cancer: a systematic review and meta-analy- pretrage krvi
svakih 8 – 12 tjedana prvih 12 mjeseci, svaka sis of individual participant data. Lancet 2014;383(9928):1561–71. 10.
Higgins K, Chino JP, Marks LB i sur. Preoperative chemotherapy ver- 3 – 6 mjeseci 2. i 3. godinu, zatim svakih 4 – 8
mjeseci tije- sus preoperative chemoradiotherapy for stage III (N2) non-small-cell kom 4. i 5. godine, potom svakih 6 –
12 mjeseci. Praćenje lung cancer. Int J Radiat Oncol Biol Phys 2009;75(5):1462–7. 11. Albain KS, Swann RS, Rusch VW i
sur. Radiotherapy plus chemothera- 32. Scagliotti GV, Hanna N, Fossella F i sur. The differential effi cacy of py with
or without surgical resection for stage III non-small cell lung pemetrexed according to NSCLC histology: a review of two
phase III cancer: a phase III randomised controlled trial. Lancet 2009;374: studies. Oncologist 2009;14:253–63. 379–86.
33. Scagliotti GV, Parikh P, von Pawel J i sur. Phase III study comparing 12. Thomas M, Rübe C, Hoffknecht P i sur.
Effect of preoperative chemo- cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemo- radiation in addition
to preoperative chemotherapy: a randomised trial therapy-naive patients with advanced-stage non-small-cell lung cancer.
in stage III non-small cell lung cancer. Lancet Oncol 2008;9:636–48. J Clin Oncol 2008;26:3543–51. 13. Furuse K, Fukuoka
M, Kawahara M i sur. Phase III study of concurrent 34. Paz-Ares LG, de Marinis F, Dediu M i sur. PARAMOUNT: final
overall versus sequential th

36. [outcome] score -39
M i sur. Adjuvant vinorelbine plus motherapy for EGFR mutation-positive lung adenocarcinoma (LUX- cisplatin versus
observation in patients with completely resected stage Lung 3 and LUX-Lung 6): analysis of overall survival data from
two IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International randomised, phase 3 trials. Lancet Oncol
2015;16(2):141–51. Trialist Association [ANITA]): a randomised controlled trial. Lancet 45. Mok TS, Wu JL, Thongprasert
S i sur. Gefi tinib or carboplatin-pacli- Oncol 2006;7:719–27. taxel in pulmonary adenocarcinoma. N Engl J Med
2009:3;361(10): 24. Pignon JP, Tribodet H, Scagliotti GV i sur. Lung adjuvant cisplatin 46. Zhou C, Wu JL, Chen G i sur.
Erlotinib versus chemotherapy as fi rst- evaluation: a pooled analysis by the LACE Collaborative Group. J Clin line
treatment for patients with advanced EGFR mutation-positive Oncol 2008;26:3552–9. non-small-cell lung cancer (OPTIMAL,
CTONG-0802): a multicentre, 25. Strauss GM, Herndon JE 2nd, Maddaus MA i sur. Adjuvant paclitaxel open-label,
randomised, phase 3 study. Lancet Oncol 2011;12(8): plus carboplatin compared with observation in stage IB non-small-
cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, 47. Gridelli C, De Marinis F, Di Maio M i sur. Gefi
tinib as fi rst-line treat- Radiation Therapy Oncology Group, and North Central Cancer Treat- ment for patients with
advanced non-small-cell lung cancer with acti- ment Group Study Groups. J Clin Oncol 2008;26(31):5043–51. vating
epidermal growth factor receptor mutation: Review of the evi- 26. Sederholm C, Hillerdal G, Lambert K i sur. Phase III
trial of gem- dence. Lung Cancer 2011;71(3):249–57. citabine plus carboplatin versus single-agent gemcitabine in the
treat- 48. Lee CK, Brown C, Gralla RJ i sur. Impact of EGFR inhibitor in non- ment of locally advanced or metastatic
non-small-cell lung cancer. The small cell lung cancer on progression-free and overall survival: a meta- Swedish Lung
Cancer Study Group. J Clin Oncol 2005;23:8380–8. analysis. J Natl Cancer Inst 2013;105:595–605. 27. Delbaldo C, Michiels
S, Syz N i sur. Benefi ts of adding a drug to a single 49. Seto T, Kato T, Nishio M i sur. Erlotinib alone or with
bevacizumab as agent or a 2-agent chemotherapy regimen in advanced non-small-cell fi rst-line therapy in patients with
advanced non-squamous non-small- lung cancer. A meta analysis. JAMA 2004;292:470–84. cell lung cancer harbouring EGFR
mutations (JO25567): an open-la- 28. Pujol JL, Barlesi F, Daures JP i sur. Should chemotherapy combina- bel, randomised,
multicentre, phase 2 study. Lancet 2014;15:1236–44. tions for advanced non-small cell lung cancer be platinum-based? A
50. Giaccone G, Herbst RS, Manegold C i sur. Gefi tinib in combination meta analysis of phased III randomized trials.
Lung Cancer 2006;51: with gemcitabine and cisplatin in advanced non-small-cell lung cancer: 335–45. a phase III
trial–INTACT 1. J Clin Oncol 2004;22:777–84. 29. Jiang J, Liang H, Zhou X i sur. A meta-analysis of randomized con- 51.
Herbst RS, Giaccone G, Schiller JH i sur. Gefi tinib in combination with trolled trials comparing carboplatin-based to
cisplatin-based chemo- paclitaxel and carboplatin in advanced non-small-cell lung cancer: a therapy in advanced non-
small cell lung cancer. Lung Can

37. [intervention] score -40 ✅ BINGO (PIO)
rapy in Diseminirana/neresektabilna lokalno uznapredovala patients with resectable non-small cell lung cancer: results
of the MRC bolest – pauza u liječenju, praćenje radi pravodobne LU22/NVALT 2/EORTC 08012 multicentre randomised trial
and up- date of systematic review. Lancet 2007;369:1929–37. detekcije progresije bolesti 9. NSCLC Meta-analysis
Collaborative Group. Preoperative chemothera- Klinički pregled, KKS, DKS, SE i osnovne biokemijske py for non-small-cell
lung cancer: a systematic review and meta-analy- pretrage krvi svakih 8 – 12 tjedana prvih 12 mjeseci, svaka sis of
individual participant data. Lancet 2014;383(9928):1561–71. 10. Higgins K, Chino JP, Marks LB i sur. Preoperative
chemotherapy ver- 3 – 6 mjeseci 2. i 3. godinu, zatim svakih 4 – 8 mjeseci tije- sus preoperative chemoradiotherapy for
stage III (N2) non-small-cell kom 4. i 5. godine, potom svakih 6 – 12 mjeseci. Praćenje lung cancer. Int J Radiat Oncol
Biol Phys 2009;75(5):1462–7. 11. Albain KS, Swann RS, Rusch VW i sur. Radiotherapy plus chemothera- 32. Scagliotti GV,
Hanna N, Fossella F i sur. The differential effi cacy of py with or without surgical resection for stage III non-small
cell lung pemetrexed according to NSCLC histology: a review of two phase III cancer: a phase III randomised controlled
trial. Lancet 2009;374: studies. Oncologist 2009;14:253–63. 379–86. 33. Scagliotti GV, Parikh P, von Pawel J i sur.
Phase III study comparing 12. Thomas M, Rübe C, Hoffknecht P i sur. Effect of preoperative chemo- cisplatin plus
gemcitabine with cisplatin plus pemetrexed in chemo- radiation in addition to preoperative chemotherapy: a randomised
trial therapy-naive patients with advanced-stage non-small-cell lung cancer. in stage III non-small cell lung cancer.
Lancet Oncol 2008;9:636–48. J Clin Oncol 2008;26:3543–51. 13. Furuse K, Fukuoka M, Kawahara M i sur. Phase III study of
concurrent 34. Paz-Ares LG, de Marinis F, Dediu M i sur. PARAMOUNT: final overall versus sequential thoracic
radiotherapy in combination with mito- survival results of the phase III study of maintenance pemetrexed ver- mycin,
vindesine, and cisplatin in unresectable stage III non-small-cell sus placebo immediately after induction treatment with
pemetrexed lung cancer. J Clin Oncol 1999;17:2692–9. plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
J 14. Curran WJ Jr, Paulus R, Langer CJ i sur. Sequential vs. concurrent Clin Oncol 2013;31:2895–902. chemoradiation for
stage III non-small cell lung cancer: randomized 35. Sandler A, Gray R, Perry MC i sur. Paclitaxel-carboplatin alone or
with phase III trial RTOG 9410. J Natl Cancer Inst 2011;103(19):1452–60. bevacizumab for non-small-cell lung cancer. N
Engl J Med 2006;355: 15. Fournel P, Robinet G, Thomas P i sur. Randomized phase III trial of 36. Reck M, von Pawel J,
Zatloukal P i sur. Phase III trial of cisplatin plus sequential chemoradiotherapy compared with concurrent chemoradio-
gemcitabine with either placebo or bevacizumab as fi rst-line therapy therapy in locally advanced non-small-cell lung
cancer: Groupe Lyon- for nonsquamous non-small cell lung cancer: AVAiL. J Clin Oncol Saint-Etienne d’Oncologie
Thoracique-Groupe Français de Pneumo- Cancérologie NPC 95-01 Study. J Clin Oncol 2005;23:5910–7. 37. Sandler A, Yi J,
Dahlberg S i

38. [comparator] score -40 ✅ BINGO (PICO)
-cell lung cancer non-small-cell lung cancer previously treated with platinum-containing (OAK): a phase 3, open-label,
multicentre randomised controlled trial. chemotherapy regimens. The TAX 320 Non Small Cell Lung Cancer Lancet
2017;389:255–65. Study Group. J Clin Oncol 2000;18:2354–62. 64. Mok TS, Yi-Long Wu YL, Ahn MJ i sur. Osimertinib or
platinum–peme- 56. Sheperd FA, Dancey J, Ramlau R i sur. Prospective randomized trial of trexed in EGFR T790M–positive
lung cancer. N Engl J Med 2017; docetaxel versus best suportive care in patients with non small cell lung 376:629–40.
cancer previously treated with platinum-based chemotherapy. J Clin 65. Larkins E, Blumenthal GM, Chen H i sur. FDA
Approval: Alectinib for Oncol 2000;18:2095–103. the treatment of metastatic, ALK-positive non-small cell lung cancer 57.
Hanna N, Sheperd FA, Fossella FV i sur. Randomized phase III trial of following crizotinib. Clin Cancer Res
2016;22:5171–6. pemetrexed versus docetaxel in patients with non-small-cell lung 66. Khozin S, Blumenthal GM, Zhang L i
sur. FDA approval: ceritinib for cancer previously treated with chemotherapy. J Clin Oncol 2004;22: the treatment of
metastatic anaplastic lymphoma kinase-positive non- 1589–97. small cell lung cancer. Clin Cancer Res 2015;21(11):2436–9.
58. Nagano T, Kim YH, Goto K i sur. Re-challenge chemotherapy for re- 67. Shepherd FA, Pereira JR, Ciuleanu T i sur.
Erlotinib in Previously lapsed non-small-cell lung cancer. Lung Cancer 2010;69(3):315–8. Treated Non-Small-Cell Lung
Cancer. N Engl J Med 2005;353: 59. Reck M, Kaiser R, Mellemgaard A i sur. Docetaxel plus nintedanib ver- 123–32. sus
docetaxel plus placebo in patients with previously treated non- 68. Tsao MN, Lloyd N, Wong RK i sur. Whole brain
radiotherapy for the small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, ran- treatment of newly diagnosed
multiple brain metastases. Cochrane Da- domised controlled trial. Lancet 2014;15:143–55. tabase Syst Rev
2012;4:CD003869. 60. Borghaei H, Paz-Ares L, Horn L i sur. Nivolumab versus Docetaxel in 69. Temel JS, Greer JA,
Muzikansky A i sur. Early palliative care for pa- Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med tients
with metastatic non-small-cell lung cancer. N Engl J Med 2010; 61. Brahmer J, Reckamp KL, Baas P i sur. Nivolumab versus
docetaxel in 70. Vansteenkiste J, Crinò L, Dooms C i sur. 2nd ESMO Consensus Con- advanced squamous-cell non-small-cell
lung cancer. N Engl J Med ference on Lung Cancer: early-stage non-small-cell lung cancer con- 2015;373(2):123–35. sensus
on diagnosis, treatment and follow-up. Ann Oncol 2014;25: 62. Herbst RS, Baas P, Kim DW i sur. Pembrolizumab versus
docetaxel for 1462–74. previously treated, PD-L1-positive, advanced non-small-cell lung can- 71. Samaržija M, Gugić D,
Radić J i sur. Kliničke upute za dijagnozu, cer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; liječenje i
praćenje bolesnika oboljelih od karcinoma pluća nemalih 387(10027):1540–50. stanica. Liječ Vjesn 2011;133:361–5.

39. [outcome] score -40
gnosis, treatment surgery. Ann Thorac Surg 2015;99(2):406–13. and follow-up. Ann Oncol 2016;27:1–27. 20. Douillard JY,
Rosell R, De Lena M i sur. Impact of postoperative radia- 41. von Plessen C, Bergman B, Andresen O i sur. Palliative
chemotherapy tion therapy on survival in patients with complete resection and stage I, beyond three courses conveys no
survival or consistent quality-of-life II, or IIIA non-small-cell lungcancer treated with adjuvant chemother- benefi ts
in advanced non small-cell lung cancer. Br J Cancer 2006; apy: the adjuvant Navelbine International Trialist Association
(ANITA) 95:966–73. Randomized Trial. Int J Radiat Oncol Biol Phys 2008:72;696–701. 42. Park JO, Kim SW, Ahn JS i sur.
Phase III trial of two versus four addi- 21. Bradley JD, Paulus R, Graham MV i sur. Phase II trial of postoperative
tional cycles in patients who are nonprogressive after two cycles of adjuvant paclitaxel/carboplatin and thoracic
radiotherapy in resected platinum-based chemotherapy in non small-cell lung cancer. J Clin stage II and IIIA non-small-
cell lung cancer: promising long-term Oncol 2007;25:5233–9. results of the Radiation Therapy Oncology Group–RTOG 9705. J
Clin 43. Rosell R, Carceremy E, Gervais R i sur. Erlotinib versus standard che- Oncol 2005:343;3480–7. motherapy as
first-line treatment for European patients with advanced 22. Butts CA, Ding K, Seymour L i sur. Randomized phase III
trial of EGFR mutation-positive non-small-cell lung cancer (EURTAC): a vinorelbine plus cisplatin compared with
observation in completely multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; resected stage IB and II
non-small cell lung cancer: updated survival 13:239–46. analysis of JBR-10. J Clin Oncol 2009;28:29–34. 44. Yang JC, Wu
YL, Schuler M i sur. Afatinib versus cisplatin-based che- 23. Douillard JY, Rosell R, De Lena M i sur. Adjuvant
vinorelbine plus motherapy for EGFR mutation-positive lung adenocarcinoma (LUX- cisplatin versus observation in patients
with completely resected stage Lung 3 and LUX-Lung 6): analysis of overall survival data from two IB–IIIA non-small-cell
lung cancer (Adjuvant Navelbine International randomised, phase 3 trials. Lancet Oncol 2015;16(2):141–51. Trialist
Association [ANITA]): a randomised controlled trial. Lancet 45. Mok TS, Wu JL, Thongprasert S i sur. Gefi tinib or
carboplatin-pacli- Oncol 2006;7:719–27. taxel in pulmonary adenocarcinoma. N Engl J Med 2009:3;361(10): 24. Pignon JP,
Tribodet H, Scagliotti GV i sur. Lung adjuvant cisplatin 46. Zhou C, Wu JL, Chen G i sur. Erlotinib versus chemotherapy
as fi rst- evaluation: a pooled analysis by the LACE Collaborative Group. J Clin line treatment for patients with
advanced EGFR mutation-positive Oncol 2008;26:3552–9. non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre,
25. Strauss GM, Herndon JE 2nd, Maddaus MA i sur. Adjuvant paclitaxel open-label, randomised, phase 3 study. Lancet
Oncol 2011;12(8): plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the
Cancer and Leukemia Group B, 47. Gridelli C, De Marinis F, Di Maio M i sur. Gefi tinib as fi rst-line treat- Radiation
Therapy Oncology Group, and North Central Cancer Treat- ment for patients with advanced non-small-cell lung cancer with
acti- ment Group Study G

40. [outcome] score -40
analysis. J Natl Cancer Inst 2013;105:595–605. 27. Delbaldo C, Michiels S, Syz N i sur. Benefi ts of adding a drug to a
single 49. Seto T, Kato T, Nishio M i sur. Erlotinib alone or with bevacizumab as agent or a 2-agent chemotherapy
regimen in advanced non-small-cell fi rst-line therapy in patients with advanced non-squamous non-small- lung cancer. A
meta analysis. JAMA 2004;292:470–84. cell lung cancer harbouring EGFR mutations (JO25567): an open-la- 28. Pujol JL,
Barlesi F, Daures JP i sur. Should chemotherapy combina- bel, randomised, multicentre, phase 2 study. Lancet
2014;15:1236–44. tions for advanced non-small cell lung cancer be platinum-based? A 50. Giaccone G, Herbst RS, Manegold
C i sur. Gefi tinib in combination meta analysis of phased III randomized trials. Lung Cancer 2006;51: with gemcitabine
and cisplatin in advanced non-small-cell lung cancer: 335–45. a phase III trial–INTACT 1. J Clin Oncol 2004;22:777–84.
29. Jiang J, Liang H, Zhou X i sur. A meta-analysis of randomized con- 51. Herbst RS, Giaccone G, Schiller JH i sur.
Gefi tinib in combination with trolled trials comparing carboplatin-based to cisplatin-based chemo- paclitaxel and
carboplatin in advanced non-small-cell lung cancer: a therapy in advanced non-small cell lung cancer. Lung Cancer
2007;57: phase III trial–INTACT 2. J Clin Oncol 2004;22:785–94. 348–58. 52. Gatzemeier U, Pluzanska A, Szczesna A i sur.
Phase III study of erlo- 30. Smit EF, van Meerbeeck JP, Lianes P i sur. Three-arm randomized tinib in combination with
cisplatin and gemcitabine in advanced non- study of two cisplatin-based regimens and paclitaxel plus gemcitabine small-
cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J in advanced non-small-cell lung cancer: a phase III
trial of the Euro- Clin Oncol 2007;25:1545–52. pean Organization for Research and Treatment of Cancer Lung Cancer 53.
Shaw AT, Kim DW, Nakagawa K i sur. Crizotinib versus chemothe- Group–EORTC 08975. J Clin Oncol 2003;21:3909–17. rapy in
advanced ALK-positive lung cancer. N Engl J Med 2013;368: 31. Schiller JH, Harrington D, Belani CP i sur. Comparison of
four chemo- 2385–94. therapy regimens for advanced non-small-cell lung cancer. N Engl J 54. Solomon BJ, Mok T, Kim DW i
sur. First-line crizotinib versus chemo- Med 2002;346:92–8. therapy in ALK-positive lung cancer. N Engl J Med
2014;371:2167–77. 55. Fossella FV, DeVore R, Kerr RN i sur. Randomized phase III trial of 63. Rittmeyer A, Barlesi F,
Waterkamp D i sur. Atezolizumab versus docetaxel versus vinorelbine or ifosfamide in patients with advanced docetaxel in
patients with previously treated non-small-cell lung cancer non-small-cell lung cancer previously treated with platinum-
containing (OAK): a phase 3, open-label, multicentre randomised controlled trial. chemotherapy regimens. The TAX 320 Non
Small Cell Lung Cancer Lancet 2017;389:255–65. Study Group. J Clin Oncol 2000;18:2354–62. 64. Mok TS, Yi-Long Wu YL, Ahn
MJ i sur. Osimertinib or platinum–peme- 56. Sheperd FA, Dancey J, Ramlau R i sur. Prospective randomized trial of trexed
in EGFR T790M–positive lung cancer. N Engl J Med 2017; docetaxel versus best suportive care in patients with non small
cell lung 376:629–40. cancer previously treated with platinum-based chemotherapy. J Clin 65. Larkins E, Blumenthal GM, C

41. [population] score -41 ✅ BINGO (PIO)
er. J Clin Oncol 1999;17:2692–9. plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J 14. Curran WJ Jr,
Paulus R, Langer CJ i sur. Sequential vs. concurrent Clin Oncol 2013;31:2895–902. chemoradiation for stage III non-small
cell lung cancer: randomized 35. Sandler A, Gray R, Perry MC i sur. Paclitaxel-carboplatin alone or with phase III trial
RTOG 9410. J Natl Cancer Inst 2011;103(19):1452–60. bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:
15. Fournel P, Robinet G, Thomas P i sur. Randomized phase III trial of 36. Reck M, von Pawel J, Zatloukal P i sur.
Phase III trial of cisplatin plus sequential chemoradiotherapy compared with concurrent chemoradio- gemcitabine with
either placebo or bevacizumab as fi rst-line therapy therapy in locally advanced non-small-cell lung cancer: Groupe
Lyon- for nonsquamous non-small cell lung cancer: AVAiL. J Clin Oncol Saint-Etienne d’Oncologie Thoracique-Groupe
Français de Pneumo- Cancérologie NPC 95-01 Study. J Clin Oncol 2005;23:5910–7. 37. Sandler A, Yi J, Dahlberg S i sur.
Treatment outcomes by tumor histol- 16. Aupérin A, Le Péchoux C, Rolland E i sur. Meta-analysis of concomi- ogy in
Eastern Cooperative Group Study E4599 of bevacizumab with tant versus sequential radiochemotherapy in locally advanced
non- paclitaxel/carboplatin for advanced non-small cell lung cancer. J Tho- small cell lung cancer. J Clin Oncol
2010;28:2181–90. rac Oncol 2010;5:1416–23. 17. Brunelli A, Charloux A, Bolliger CT i sur. ERS/ESTS clinical guide- 38.
Masters GA, Temin S, Christopher G i sur. Systemic Therapy for Stage lines on fitness for radical therapy in lung cancer
patients (surgery and IV Non-Small-Cell Lung Cancer: American Society of Clinical On- chemo-radiotherapy). Eur Respir J
2009;34:17–41. cology Clinical Practice Guideline Update. J Clin Oncol 2015;33: 18. Rusch VW, Giroux DJ, Kraut MJ i sur.
Induction chemoradiation and 3488–515. surgical resection for superior sulcus non-small cell lung carcinomas: 39. Santos
FN, de Castria TB, Cruz MR, Riera R. Chemotherapy for ad- long-term results of Southwest Oncology Group Trial 9416 –
(Inter- vanced non-small cell lung cancer in the elderly population. Cochrane group Trial 0160). J Clin Oncol
2007;25:313–8. Database Syst Rev 2015;(10):CD010463. 19. Hancock JG, Rosen JE, Antonicelli A i sur. Impact of adjuvant
treat- 40. Novello S, Barlesi F, Califano R i sur. Metastatic non-small-cell lung ment for microscopic residual disease
after non-small cell lung cancer cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment surgery. Ann Thorac
Surg 2015;99(2):406–13. and follow-up. Ann Oncol 2016;27:1–27. 20. Douillard JY, Rosell R, De Lena M i sur. Impact of
postoperative radia- 41. von Plessen C, Bergman B, Andresen O i sur. Palliative chemotherapy tion therapy on survival in
patients with complete resection and stage I, beyond three courses conveys no survival or consistent quality-of-life II,
or IIIA non-small-cell lungcancer treated with adjuvant chemother- benefi ts in advanced non small-cell lung cancer. Br
J Cancer 2006; apy: the adjuvant Navelbine International Trialist Association (ANITA) 95:966–73. Randomized Trial. Int J
Radiat Oncol Biol Phys 2008:72;696–701. 42. Park JO, Kim SW, Ahn JS i sur. Phase III trial of two versus four

42. [population] score -41 ✅ BINGO (PIO)
Eur Respir J 2009;34:17–41. cology Clinical Practice Guideline Update. J Clin Oncol 2015;33: 18. Rusch VW, Giroux DJ,
Kraut MJ i sur. Induction chemoradiation and 3488–515. surgical resection for superior sulcus non-small cell lung
carcinomas: 39. Santos FN, de Castria TB, Cruz MR, Riera R. Chemotherapy for ad- long-term results of Southwest Oncology
Group Trial 9416 – (Inter- vanced non-small cell lung cancer in the elderly population. Cochrane group Trial 0160). J
Clin Oncol 2007;25:313–8. Database Syst Rev 2015;(10):CD010463. 19. Hancock JG, Rosen JE, Antonicelli A i sur. Impact of
adjuvant treat- 40. Novello S, Barlesi F, Califano R i sur. Metastatic non-small-cell lung ment for microscopic residual
disease after non-small cell lung cancer cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment surgery. Ann
Thorac Surg 2015;99(2):406–13. and follow-up. Ann Oncol 2016;27:1–27. 20. Douillard JY, Rosell R, De Lena M i sur.
Impact of postoperative radia- 41. von Plessen C, Bergman B, Andresen O i sur. Palliative chemotherapy tion therapy on
survival in patients with complete resection and stage I, beyond three courses conveys no survival or consistent
quality-of-life II, or IIIA non-small-cell lungcancer treated with adjuvant chemother- benefi ts in advanced non small-
cell lung cancer. Br J Cancer 2006; apy: the adjuvant Navelbine International Trialist Association (ANITA) 95:966–73.
Randomized Trial. Int J Radiat Oncol Biol Phys 2008:72;696–701. 42. Park JO, Kim SW, Ahn JS i sur. Phase III trial of
two versus four addi- 21. Bradley JD, Paulus R, Graham MV i sur. Phase II trial of postoperative tional cycles in
patients who are nonprogressive after two cycles of adjuvant paclitaxel/carboplatin and thoracic radiotherapy in
resected platinum-based chemotherapy in non small-cell lung cancer. J Clin stage II and IIIA non-small-cell lung cancer:
promising long-term Oncol 2007;25:5233–9. results of the Radiation Therapy Oncology Group–RTOG 9705. J Clin 43. Rosell
R, Carceremy E, Gervais R i sur. Erlotinib versus standard che- Oncol 2005:343;3480–7. motherapy as first-line treatment
for European patients with advanced 22. Butts CA, Ding K, Seymour L i sur. Randomized phase III trial of EGFR mutation-
positive non-small-cell lung cancer (EURTAC): a vinorelbine plus cisplatin compared with observation in completely
multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; resected stage IB and II non-small cell lung
cancer: updated survival 13:239–46. analysis of JBR-10. J Clin Oncol 2009;28:29–34. 44. Yang JC, Wu YL, Schuler M i sur.
Afatinib versus cisplatin-based che- 23. Douillard JY, Rosell R, De Lena M i sur. Adjuvant vinorelbine plus motherapy
for EGFR mutation-positive lung adenocarcinoma (LUX- cisplatin versus observation in patients with completely resected
stage Lung 3 and LUX-Lung 6): analysis of overall survival data from two IB–IIIA non-small-cell lung cancer (Adjuvant
Navelbine International randomised, phase 3 trials. Lancet Oncol 2015;16(2):141–51. Trialist Association [ANITA]): a
randomised controlled trial. Lancet 45. Mok TS, Wu JL, Thongprasert S i sur. Gefi tinib or carboplatin-pacli- Oncol
2006;7:719–27. taxel in pulmonary adenocarcinoma. N Engl J Med 2009:3;361(10): 24. Pignon JP, Tribodet H, Scagliotti GV
i sur.

43. [intervention] score -41
e patients with advanced-stage non-small-cell lung cancer. in stage III non-small cell lung cancer. Lancet Oncol
2008;9:636–48. J Clin Oncol 2008;26:3543–51. 13. Furuse K, Fukuoka M, Kawahara M i sur. Phase III study of concurrent
34. Paz-Ares LG, de Marinis F, Dediu M i sur. PARAMOUNT: final overall versus sequential thoracic radiotherapy in
combination with mito- survival results of the phase III study of maintenance pemetrexed ver- mycin, vindesine, and
cisplatin in unresectable stage III non-small-cell sus placebo immediately after induction treatment with pemetrexed
lung cancer. J Clin Oncol 1999;17:2692–9. plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J 14.
Curran WJ Jr, Paulus R, Langer CJ i sur. Sequential vs. concurrent Clin Oncol 2013;31:2895–902. chemoradiation for stage
III non-small cell lung cancer: randomized 35. Sandler A, Gray R, Perry MC i sur. Paclitaxel-carboplatin alone or with
phase III trial RTOG 9410. J Natl Cancer Inst 2011;103(19):1452–60. bevacizumab for non-small-cell lung cancer. N Engl J
Med 2006;355: 15. Fournel P, Robinet G, Thomas P i sur. Randomized phase III trial of 36. Reck M, von Pawel J, Zatloukal
P i sur. Phase III trial of cisplatin plus sequential chemoradiotherapy compared with concurrent chemoradio- gemcitabine
with either placebo or bevacizumab as fi rst-line therapy therapy in locally advanced non-small-cell lung cancer: Groupe
Lyon- for nonsquamous non-small cell lung cancer: AVAiL. J Clin Oncol Saint-Etienne d’Oncologie Thoracique-Groupe
Français de Pneumo- Cancérologie NPC 95-01 Study. J Clin Oncol 2005;23:5910–7. 37. Sandler A, Yi J, Dahlberg S i sur.
Treatment outcomes by tumor histol- 16. Aupérin A, Le Péchoux C, Rolland E i sur. Meta-analysis of concomi- ogy in
Eastern Cooperative Group Study E4599 of bevacizumab with tant versus sequential radiochemotherapy in locally advanced
non- paclitaxel/carboplatin for advanced non-small cell lung cancer. J Tho- small cell lung cancer. J Clin Oncol
2010;28:2181–90. rac Oncol 2010;5:1416–23. 17. Brunelli A, Charloux A, Bolliger CT i sur. ERS/ESTS clinical guide- 38.
Masters GA, Temin S, Christopher G i sur. Systemic Therapy for Stage lines on fitness for radical therapy in lung cancer
patients (surgery and IV Non-Small-Cell Lung Cancer: American Society of Clinical On- chemo-radiotherapy). Eur Respir J
2009;34:17–41. cology Clinical Practice Guideline Update. J Clin Oncol 2015;33: 18. Rusch VW, Giroux DJ, Kraut MJ i sur.
Induction chemoradiation and 3488–515. surgical resection for superior sulcus non-small cell lung carcinomas: 39. Santos
FN, de Castria TB, Cruz MR, Riera R. Chemotherapy for ad- long-term results of Southwest Oncology Group Trial 9416 –
(Inter- vanced non-small cell lung cancer in the elderly population. Cochrane group Trial 0160). J Clin Oncol
2007;25:313–8. Database Syst Rev 2015;(10):CD010463. 19. Hancock JG, Rosen JE, Antonicelli A i sur. Impact of adjuvant
treat- 40. Novello S, Barlesi F, Califano R i sur. Metastatic non-small-cell lung ment for microscopic residual disease
after non-small cell lung cancer cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment surgery. Ann Thorac
Surg 2015;99(2):406–13. and follow-up. Ann Oncol 2016;27:1–27. 20. Douillard JY, Rosell R, De Lena M i sur. Impact of
postop

44. [intervention] score -41 ✅ BINGO (PIO)
ervation in completely multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; resected stage IB and II
non-small cell lung cancer: updated survival 13:239–46. analysis of JBR-10. J Clin Oncol 2009;28:29–34. 44. Yang JC, Wu
YL, Schuler M i sur. Afatinib versus cisplatin-based che- 23. Douillard JY, Rosell R, De Lena M i sur. Adjuvant
vinorelbine plus motherapy for EGFR mutation-positive lung adenocarcinoma (LUX- cisplatin versus observation in patients
with completely resected stage Lung 3 and LUX-Lung 6): analysis of overall survival data from two IB–IIIA non-small-cell
lung cancer (Adjuvant Navelbine International randomised, phase 3 trials. Lancet Oncol 2015;16(2):141–51. Trialist
Association [ANITA]): a randomised controlled trial. Lancet 45. Mok TS, Wu JL, Thongprasert S i sur. Gefi tinib or
carboplatin-pacli- Oncol 2006;7:719–27. taxel in pulmonary adenocarcinoma. N Engl J Med 2009:3;361(10): 24. Pignon JP,
Tribodet H, Scagliotti GV i sur. Lung adjuvant cisplatin 46. Zhou C, Wu JL, Chen G i sur. Erlotinib versus chemotherapy
as fi rst- evaluation: a pooled analysis by the LACE Collaborative Group. J Clin line treatment for patients with
advanced EGFR mutation-positive Oncol 2008;26:3552–9. non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre,
25. Strauss GM, Herndon JE 2nd, Maddaus MA i sur. Adjuvant paclitaxel open-label, randomised, phase 3 study. Lancet
Oncol 2011;12(8): plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the
Cancer and Leukemia Group B, 47. Gridelli C, De Marinis F, Di Maio M i sur. Gefi tinib as fi rst-line treat- Radiation
Therapy Oncology Group, and North Central Cancer Treat- ment for patients with advanced non-small-cell lung cancer with
acti- ment Group Study Groups. J Clin Oncol 2008;26(31):5043–51. vating epidermal growth factor receptor mutation:
Review of the evi- 26. Sederholm C, Hillerdal G, Lambert K i sur. Phase III trial of gem- dence. Lung Cancer
2011;71(3):249–57. citabine plus carboplatin versus single-agent gemcitabine in the treat- 48. Lee CK, Brown C, Gralla
RJ i sur. Impact of EGFR inhibitor in non- ment of locally advanced or metastatic non-small-cell lung cancer. The small
cell lung cancer on progression-free and overall survival: a meta- Swedish Lung Cancer Study Group. J Clin Oncol
2005;23:8380–8. analysis. J Natl Cancer Inst 2013;105:595–605. 27. Delbaldo C, Michiels S, Syz N i sur. Benefi ts of
adding a drug to a single 49. Seto T, Kato T, Nishio M i sur. Erlotinib alone or with bevacizumab as agent or a 2-agent
chemotherapy regimen in advanced non-small-cell fi rst-line therapy in patients with advanced non-squamous non-small-
lung cancer. A meta analysis. JAMA 2004;292:470–84. cell lung cancer harbouring EGFR mutations (JO25567): an open-la-
28. Pujol JL, Barlesi F, Daures JP i sur. Should chemotherapy combina- bel, randomised, multicentre, phase 2 study.
Lancet 2014;15:1236–44. tions for advanced non-small cell lung cancer be platinum-based? A 50. Giaccone G, Herbst RS,
Manegold C i sur. Gefi tinib in combination meta analysis of phased III randomized trials. Lung Cancer 2006;51: with
gemcitabine and cisplatin in advanced non-small-cell lung cancer: 335–45. a phase III trial–INTACT 1. J Clin Oncol
2004;22:777–84. 29. J

45. [comparator] score -41 ✅ BINGO (ICO)
rvi svakih 8 – 12 tjedana prvih 12 mjeseci, svaka sis of individual participant data. Lancet 2014;383(9928):1561–71. 10.
Higgins K, Chino JP, Marks LB i sur. Preoperative chemotherapy ver- 3 – 6 mjeseci 2. i 3. godinu, zatim svakih 4 – 8
mjeseci tije- sus preoperative chemoradiotherapy for stage III (N2) non-small-cell kom 4. i 5. godine, potom svakih 6 –
12 mjeseci. Praćenje lung cancer. Int J Radiat Oncol Biol Phys 2009;75(5):1462–7. 11. Albain KS, Swann RS, Rusch VW i
sur. Radiotherapy plus chemothera- 32. Scagliotti GV, Hanna N, Fossella F i sur. The differential effi cacy of py with
or without surgical resection for stage III non-small cell lung pemetrexed according to NSCLC histology: a review of two
phase III cancer: a phase III randomised controlled trial. Lancet 2009;374: studies. Oncologist 2009;14:253–63. 379–86.
33. Scagliotti GV, Parikh P, von Pawel J i sur. Phase III study comparing 12. Thomas M, Rübe C, Hoffknecht P i sur.
Effect of preoperative chemo- cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemo- radiation in addition
to preoperative chemotherapy: a randomised trial therapy-naive patients with advanced-stage non-small-cell lung cancer.
in stage III non-small cell lung cancer. Lancet Oncol 2008;9:636–48. J Clin Oncol 2008;26:3543–51. 13. Furuse K, Fukuoka
M, Kawahara M i sur. Phase III study of concurrent 34. Paz-Ares LG, de Marinis F, Dediu M i sur. PARAMOUNT: final
overall versus sequential thoracic radiotherapy in combination with mito- survival results of the phase III study of
maintenance pemetrexed ver- mycin, vindesine, and cisplatin in unresectable stage III non-small-cell sus placebo
immediately after induction treatment with pemetrexed lung cancer. J Clin Oncol 1999;17:2692–9. plus cisplatin for
advanced nonsquamous non-small-cell lung cancer. J 14. Curran WJ Jr, Paulus R, Langer CJ i sur. Sequential vs.
concurrent Clin Oncol 2013;31:2895–902. chemoradiation for stage III non-small cell lung cancer: randomized 35. Sandler
A, Gray R, Perry MC i sur. Paclitaxel-carboplatin alone or with phase III trial RTOG 9410. J Natl Cancer Inst
2011;103(19):1452–60. bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 15. Fournel P, Robinet G,
Thomas P i sur. Randomized phase III trial of 36. Reck M, von Pawel J, Zatloukal P i sur. Phase III trial of cisplatin
plus sequential chemoradiotherapy compared with concurrent chemoradio- gemcitabine with either placebo or bevacizumab as
fi rst-line therapy therapy in locally advanced non-small-cell lung cancer: Groupe Lyon- for nonsquamous non-small cell
lung cancer: AVAiL. J Clin Oncol Saint-Etienne d’Oncologie Thoracique-Groupe Français de Pneumo- Cancérologie NPC 95-01
Study. J Clin Oncol 2005;23:5910–7. 37. Sandler A, Yi J, Dahlberg S i sur. Treatment outcomes by tumor histol- 16.
Aupérin A, Le Péchoux C, Rolland E i sur. Meta-analysis of concomi- ogy in Eastern Cooperative Group Study E4599 of
bevacizumab with tant versus sequential radiochemotherapy in locally advanced non- paclitaxel/carboplatin for advanced
non-small cell lung cancer. J Tho- small cell lung cancer. J Clin Oncol 2010;28:2181–90. rac Oncol 2010;5:1416–23. 17.
Brunelli A, Charloux A, Bolliger CT i sur. ERS/ESTS clinical guide- 38. Masters GA, Temin S, Christopher G i sur.
Systemic Therap

46. [comparator] score -41 ✅ BINGO (ICO)
studies. Oncologist 2009;14:253–63. 379–86. 33. Scagliotti GV, Parikh P, von Pawel J i sur. Phase III study comparing
12. Thomas M, Rübe C, Hoffknecht P i sur. Effect of preoperative chemo- cisplatin plus gemcitabine with cisplatin plus
pemetrexed in chemo- radiation in addition to preoperative chemotherapy: a randomised trial therapy-naive patients with
advanced-stage non-small-cell lung cancer. in stage III non-small cell lung cancer. Lancet Oncol 2008;9:636–48. J Clin
Oncol 2008;26:3543–51. 13. Furuse K, Fukuoka M, Kawahara M i sur. Phase III study of concurrent 34. Paz-Ares LG, de
Marinis F, Dediu M i sur. PARAMOUNT: final overall versus sequential thoracic radiotherapy in combination with mito-
survival results of the phase III study of maintenance pemetrexed ver- mycin, vindesine, and cisplatin in unresectable
stage III non-small-cell sus placebo immediately after induction treatment with pemetrexed lung cancer. J Clin Oncol
1999;17:2692–9. plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J 14. Curran WJ Jr, Paulus R, Langer
CJ i sur. Sequential vs. concurrent Clin Oncol 2013;31:2895–902. chemoradiation for stage III non-small cell lung
cancer: randomized 35. Sandler A, Gray R, Perry MC i sur. Paclitaxel-carboplatin alone or with phase III trial RTOG
9410. J Natl Cancer Inst 2011;103(19):1452–60. bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355: 15.
Fournel P, Robinet G, Thomas P i sur. Randomized phase III trial of 36. Reck M, von Pawel J, Zatloukal P i sur. Phase
III trial of cisplatin plus sequential chemoradiotherapy compared with concurrent chemoradio- gemcitabine with either
placebo or bevacizumab as fi rst-line therapy therapy in locally advanced non-small-cell lung cancer: Groupe Lyon- for
nonsquamous non-small cell lung cancer: AVAiL. J Clin Oncol Saint-Etienne d’Oncologie Thoracique-Groupe Français de
Pneumo- Cancérologie NPC 95-01 Study. J Clin Oncol 2005;23:5910–7. 37. Sandler A, Yi J, Dahlberg S i sur. Treatment
outcomes by tumor histol- 16. Aupérin A, Le Péchoux C, Rolland E i sur. Meta-analysis of concomi- ogy in Eastern
Cooperative Group Study E4599 of bevacizumab with tant versus sequential radiochemotherapy in locally advanced non-
paclitaxel/carboplatin for advanced non-small cell lung cancer. J Tho- small cell lung cancer. J Clin Oncol
2010;28:2181–90. rac Oncol 2010;5:1416–23. 17. Brunelli A, Charloux A, Bolliger CT i sur. ERS/ESTS clinical guide- 38.
Masters GA, Temin S, Christopher G i sur. Systemic Therapy for Stage lines on fitness for radical therapy in lung cancer
patients (surgery and IV Non-Small-Cell Lung Cancer: American Society of Clinical On- chemo-radiotherapy). Eur Respir J
2009;34:17–41. cology Clinical Practice Guideline Update. J Clin Oncol 2015;33: 18. Rusch VW, Giroux DJ, Kraut MJ i sur.
Induction chemoradiation and 3488–515. surgical resection for superior sulcus non-small cell lung carcinomas: 39. Santos
FN, de Castria TB, Cruz MR, Riera R. Chemotherapy for ad- long-term results of Southwest Oncology Group Trial 9416 –
(Inter- vanced non-small cell lung cancer in the elderly population. Cochrane group Trial 0160). J Clin Oncol
2007;25:313–8. Database Syst Rev 2015;(10):CD010463. 19. Hancock JG, Rosen JE, Antonicelli A i sur. Impact of adjuvant
treat- 40. Novello S,

47. [outcome] score -41
čenje što većeg broja bolesnika s karci- 1. Incidencija raka u Hrvatskoj 2014. Bilten br. 39. Zagreb: Hrvatski zavod za
javno zdravstvo; 2016. nomom pluća u klinička istraživanja. 2. Goldstraw P, Chansky K, Crowley J i sur. The IASLC Lung
Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings Preporuke za kontrolu i praćenje in the
Forthcoming (Eighth) Edition of the TNM Classifi cation for Lung Cancer. J Thorac Oncol 2016;11(1):39–51. Nakon
radikalnoga kirurškog zahvata 3. Ginsberg RJ, Rubinstein LV. Randomised trial of lobectomy versus /adjuvantnog
liječenja70 limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995;60:
615–22. Klinički pregled, KKS, DKS, SE i osnovne biokemijske 4. Scott WJ, Howington J, Feigenberg S i sur. Treatment of
non-small cel pretrage krvi napraviti svaka 3 do 4 mjeseca prve 2 godine, lung cancer stage I and stage II: ACCP
evidence-based clinical practice guidelines (2. izd.). Chest 2007;132:234S–42S. svakih 6 mjeseci od 3. do 5. godine,
potom 1x na godinu. CT 5. Darling GE, Allen MS, Decker PA i sur. Randomized trial of mediasti- pluća (rendgensko
snimanje) svakih 6 mjeseci prve 2 godine, nal lymph node sampling versus complete lymphadenectomy during zatim 1x na
godinu. CT (UZ) abdomena 1x na go dinu. pulmonary resection in the patient with N0 or N1 (less than hilar) Ostale
pretrage prema kliničkoj indikaciji (PET samo non-small cell carcinoma: results of the American College of Surgery
Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg 2011;141(3): prema preporuci multidisciplinarnog tima). 6. Baumann
P, Nyman J, Hoyer M i sur. Outcome in a prospective phase Diseminirana/neresektabilna lokalno uznapredovala II trial of
medically inoperable stage I non-small-cell lung cancer pa- bolest u fazi aktivnog liječenja tients treated with
stereotactic body radiotherapy. J Clin Oncol 2009; Kontrola učinka liječenja svakih 6 – 8 tjedana (rendgen- 27:3290–6.
7. Scagliotti GV, Pastorino U, Vansteenkiste JF i sur. Randomized phase ska snimka/CT pluća, UZ/CT abdomena).41 Ostale
pretra- III study of surgery alone or surgery plus preoperative cisplatin and ge prema kliničkoj indikaciji (PET nije
indiciran, iznimno gemcitabine in stages IB to IIIA non-small cell lung cancer. J Clin On- prema preporuci
multidisciplinarnog tima). col 2012;30:172–8. 8. Gilligan D, Nicolson M, Smith I i sur. Preoperative chemotherapy in
Diseminirana/neresektabilna lokalno uznapredovala patients with resectable non-small cell lung cancer: results of the
MRC bolest – pauza u liječenju, praćenje radi pravodobne LU22/NVALT 2/EORTC 08012 multicentre randomised trial and up-
date of systematic review. Lancet 2007;369:1929–37. detekcije progresije bolesti 9. NSCLC Meta-analysis Collaborative
Group. Preoperative chemothera- Klinički pregled, KKS, DKS, SE i osnovne biokemijske py for non-small-cell lung cancer:
a systematic review and meta-analy- pretrage krvi svakih 8 – 12 tjedana prvih 12 mjeseci, svaka sis of individual
participant data. Lancet 2014;383(9928):1561–71. 10. Higgins K, Chino JP, Marks LB i sur. Preoperative chemotherapy ver-
3 – 6 mjeseci 2. i 3. godinu, zatim svakih 4 – 8 mjeseci tije- sus preoperative chemoradiotherapy for stage III (N2)
non-small-cell kom 4. i 5. godine, potom sva

48. [outcome] score -41
P, Robinet G, Thomas P i sur. Randomized phase III trial of 36. Reck M, von Pawel J, Zatloukal P i sur. Phase III trial
of cisplatin plus sequential chemoradiotherapy compared with concurrent chemoradio- gemcitabine with either placebo or
bevacizumab as fi rst-line therapy therapy in locally advanced non-small-cell lung cancer: Groupe Lyon- for nonsquamous
non-small cell lung cancer: AVAiL. J Clin Oncol Saint-Etienne d’Oncologie Thoracique-Groupe Français de Pneumo-
Cancérologie NPC 95-01 Study. J Clin Oncol 2005;23:5910–7. 37. Sandler A, Yi J, Dahlberg S i sur. Treatment outcomes by
tumor histol- 16. Aupérin A, Le Péchoux C, Rolland E i sur. Meta-analysis of concomi- ogy in Eastern Cooperative Group
Study E4599 of bevacizumab with tant versus sequential radiochemotherapy in locally advanced non- paclitaxel/carboplatin
for advanced non-small cell lung cancer. J Tho- small cell lung cancer. J Clin Oncol 2010;28:2181–90. rac Oncol
2010;5:1416–23. 17. Brunelli A, Charloux A, Bolliger CT i sur. ERS/ESTS clinical guide- 38. Masters GA, Temin S,
Christopher G i sur. Systemic Therapy for Stage lines on fitness for radical therapy in lung cancer patients (surgery
and IV Non-Small-Cell Lung Cancer: American Society of Clinical On- chemo-radiotherapy). Eur Respir J 2009;34:17–41.
cology Clinical Practice Guideline Update. J Clin Oncol 2015;33: 18. Rusch VW, Giroux DJ, Kraut MJ i sur. Induction
chemoradiation and 3488–515. surgical resection for superior sulcus non-small cell lung carcinomas: 39. Santos FN, de
Castria TB, Cruz MR, Riera R. Chemotherapy for ad- long-term results of Southwest Oncology Group Trial 9416 – (Inter-
vanced non-small cell lung cancer in the elderly population. Cochrane group Trial 0160). J Clin Oncol 2007;25:313–8.
Database Syst Rev 2015;(10):CD010463. 19. Hancock JG, Rosen JE, Antonicelli A i sur. Impact of adjuvant treat- 40.
Novello S, Barlesi F, Califano R i sur. Metastatic non-small-cell lung ment for microscopic residual disease after non-
small cell lung cancer cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment surgery. Ann Thorac Surg
2015;99(2):406–13. and follow-up. Ann Oncol 2016;27:1–27. 20. Douillard JY, Rosell R, De Lena M i sur. Impact of
postoperative radia- 41. von Plessen C, Bergman B, Andresen O i sur. Palliative chemotherapy tion therapy on survival in
patients with complete resection and stage I, beyond three courses conveys no survival or consistent quality-of-life II,
or IIIA non-small-cell lungcancer treated with adjuvant chemother- benefi ts in advanced non small-cell lung cancer. Br
J Cancer 2006; apy: the adjuvant Navelbine International Trialist Association (ANITA) 95:966–73. Randomized Trial. Int J
Radiat Oncol Biol Phys 2008:72;696–701. 42. Park JO, Kim SW, Ahn JS i sur. Phase III trial of two versus four addi- 21.
Bradley JD, Paulus R, Graham MV i sur. Phase II trial of postoperative tional cycles in patients who are nonprogressive
after two cycles of adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected platinum-based chemotherapy in
non small-cell lung cancer. J Clin stage II and IIIA non-small-cell lung cancer: promising long-term Oncol
2007;25:5233–9. results of the Radiation Therapy Oncology Group–RTOG 9705. J Clin 43. Rosell R, Carceremy E, Gervais R i
sur. Erlotinib versus standard

49. [outcome] score -41
ndomised, multicentre, phase 2 study. Lancet 2014;15:1236–44. tions for advanced non-small cell lung cancer be platinum-
based? A 50. Giaccone G, Herbst RS, Manegold C i sur. Gefi tinib in combination meta analysis of phased III randomized
trials. Lung Cancer 2006;51: with gemcitabine and cisplatin in advanced non-small-cell lung cancer: 335–45. a phase III
trial–INTACT 1. J Clin Oncol 2004;22:777–84. 29. Jiang J, Liang H, Zhou X i sur. A meta-analysis of randomized con- 51.
Herbst RS, Giaccone G, Schiller JH i sur. Gefi tinib in combination with trolled trials comparing carboplatin-based to
cisplatin-based chemo- paclitaxel and carboplatin in advanced non-small-cell lung cancer: a therapy in advanced non-
small cell lung cancer. Lung Cancer 2007;57: phase III trial–INTACT 2. J Clin Oncol 2004;22:785–94. 348–58. 52.
Gatzemeier U, Pluzanska A, Szczesna A i sur. Phase III study of erlo- 30. Smit EF, van Meerbeeck JP, Lianes P i sur.
Three-arm randomized tinib in combination with cisplatin and gemcitabine in advanced non- study of two cisplatin-based
regimens and paclitaxel plus gemcitabine small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J in
advanced non-small-cell lung cancer: a phase III trial of the Euro- Clin Oncol 2007;25:1545–52. pean Organization for
Research and Treatment of Cancer Lung Cancer 53. Shaw AT, Kim DW, Nakagawa K i sur. Crizotinib versus chemothe-
Group–EORTC 08975. J Clin Oncol 2003;21:3909–17. rapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368: 31.
Schiller JH, Harrington D, Belani CP i sur. Comparison of four chemo- 2385–94. therapy regimens for advanced non-small-
cell lung cancer. N Engl J 54. Solomon BJ, Mok T, Kim DW i sur. First-line crizotinib versus chemo- Med 2002;346:92–8.
therapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167–77. 55. Fossella FV, DeVore R, Kerr RN i sur. Randomized
phase III trial of 63. Rittmeyer A, Barlesi F, Waterkamp D i sur. Atezolizumab versus docetaxel versus vinorelbine or
ifosfamide in patients with advanced docetaxel in patients with previously treated non-small-cell lung cancer non-small-
cell lung cancer previously treated with platinum-containing (OAK): a phase 3, open-label, multicentre randomised
controlled trial. chemotherapy regimens. The TAX 320 Non Small Cell Lung Cancer Lancet 2017;389:255–65. Study Group. J
Clin Oncol 2000;18:2354–62. 64. Mok TS, Yi-Long Wu YL, Ahn MJ i sur. Osimertinib or platinum–peme- 56. Sheperd FA,
Dancey J, Ramlau R i sur. Prospective randomized trial of trexed in EGFR T790M–positive lung cancer. N Engl J Med 2017;
docetaxel versus best suportive care in patients with non small cell lung 376:629–40. cancer previously treated with
platinum-based chemotherapy. J Clin 65. Larkins E, Blumenthal GM, Chen H i sur. FDA Approval: Alectinib for Oncol
2000;18:2095–103. the treatment of metastatic, ALK-positive non-small cell lung cancer 57. Hanna N, Sheperd FA, Fossella
FV i sur. Randomized phase III trial of following crizotinib. Clin Cancer Res 2016;22:5171–6. pemetrexed versus
docetaxel in patients with non-small-cell lung 66. Khozin S, Blumenthal GM, Zhang L i sur. FDA approval: ceritinib for
cancer previously treated with chemotherapy. J Clin Oncol 2004;22: the treatment of metastatic anaplastic lymphoma
kinase-positive non- 1

50. [outcome] score -41
Herbst RS, Giaccone G, Schiller JH i sur. Gefi tinib in combination with trolled trials comparing carboplatin-based to
cisplatin-based chemo- paclitaxel and carboplatin in advanced non-small-cell lung cancer: a therapy in advanced non-
small cell lung cancer. Lung Cancer 2007;57: phase III trial–INTACT 2. J Clin Oncol 2004;22:785–94. 348–58. 52.
Gatzemeier U, Pluzanska A, Szczesna A i sur. Phase III study of erlo- 30. Smit EF, van Meerbeeck JP, Lianes P i sur.
Three-arm randomized tinib in combination with cisplatin and gemcitabine in advanced non- study of two cisplatin-based
regimens and paclitaxel plus gemcitabine small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J in
advanced non-small-cell lung cancer: a phase III trial of the Euro- Clin Oncol 2007;25:1545–52. pean Organization for
Research and Treatment of Cancer Lung Cancer 53. Shaw AT, Kim DW, Nakagawa K i sur. Crizotinib versus chemothe-
Group–EORTC 08975. J Clin Oncol 2003;21:3909–17. rapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368: 31.
Schiller JH, Harrington D, Belani CP i sur. Comparison of four chemo- 2385–94. therapy regimens for advanced non-small-
cell lung cancer. N Engl J 54. Solomon BJ, Mok T, Kim DW i sur. First-line crizotinib versus chemo- Med 2002;346:92–8.
therapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167–77. 55. Fossella FV, DeVore R, Kerr RN i sur. Randomized
phase III trial of 63. Rittmeyer A, Barlesi F, Waterkamp D i sur. Atezolizumab versus docetaxel versus vinorelbine or
ifosfamide in patients with advanced docetaxel in patients with previously treated non-small-cell lung cancer non-small-
cell lung cancer previously treated with platinum-containing (OAK): a phase 3, open-label, multicentre randomised
controlled trial. chemotherapy regimens. The TAX 320 Non Small Cell Lung Cancer Lancet 2017;389:255–65. Study Group. J
Clin Oncol 2000;18:2354–62. 64. Mok TS, Yi-Long Wu YL, Ahn MJ i sur. Osimertinib or platinum–peme- 56. Sheperd FA,
Dancey J, Ramlau R i sur. Prospective randomized trial of trexed in EGFR T790M–positive lung cancer. N Engl J Med 2017;
docetaxel versus best suportive care in patients with non small cell lung 376:629–40. cancer previously treated with
platinum-based chemotherapy. J Clin 65. Larkins E, Blumenthal GM, Chen H i sur. FDA Approval: Alectinib for Oncol
2000;18:2095–103. the treatment of metastatic, ALK-positive non-small cell lung cancer 57. Hanna N, Sheperd FA, Fossella
FV i sur. Randomized phase III trial of following crizotinib. Clin Cancer Res 2016;22:5171–6. pemetrexed versus
docetaxel in patients with non-small-cell lung 66. Khozin S, Blumenthal GM, Zhang L i sur. FDA approval: ceritinib for
cancer previously treated with chemotherapy. J Clin Oncol 2004;22: the treatment of metastatic anaplastic lymphoma
kinase-positive non- 1589–97. small cell lung cancer. Clin Cancer Res 2015;21(11):2436–9. 58. Nagano T, Kim YH, Goto K i
sur. Re-challenge chemotherapy for re- 67. Shepherd FA, Pereira JR, Ciuleanu T i sur. Erlotinib in Previously lapsed
non-small-cell lung cancer. Lung Cancer 2010;69(3):315–8. Treated Non-Small-Cell Lung Cancer. N Engl J Med 2005;353: 59.
Reck M, Kaiser R, Mellemgaard A i sur. Docetaxel plus nintedanib ver- 123–32. sus docetaxel plus placebo in patients
with previously treated

51. [outcome] score -41
portive care in patients with non small cell lung 376:629–40. cancer previously treated with platinum-based
chemotherapy. J Clin 65. Larkins E, Blumenthal GM, Chen H i sur. FDA Approval: Alectinib for Oncol 2000;18:2095–103. the
treatment of metastatic, ALK-positive non-small cell lung cancer 57. Hanna N, Sheperd FA, Fossella FV i sur. Randomized
phase III trial of following crizotinib. Clin Cancer Res 2016;22:5171–6. pemetrexed versus docetaxel in patients with
non-small-cell lung 66. Khozin S, Blumenthal GM, Zhang L i sur. FDA approval: ceritinib for cancer previously treated
with chemotherapy. J Clin Oncol 2004;22: the treatment of metastatic anaplastic lymphoma kinase-positive non- 1589–97.
small cell lung cancer. Clin Cancer Res 2015;21(11):2436–9. 58. Nagano T, Kim YH, Goto K i sur. Re-challenge
chemotherapy for re- 67. Shepherd FA, Pereira JR, Ciuleanu T i sur. Erlotinib in Previously lapsed non-small-cell lung
cancer. Lung Cancer 2010;69(3):315–8. Treated Non-Small-Cell Lung Cancer. N Engl J Med 2005;353: 59. Reck M, Kaiser R,
Mellemgaard A i sur. Docetaxel plus nintedanib ver- 123–32. sus docetaxel plus placebo in patients with previously
treated non- 68. Tsao MN, Lloyd N, Wong RK i sur. Whole brain radiotherapy for the small-cell lung cancer (LUME-Lung 1):
a phase 3, double-blind, ran- treatment of newly diagnosed multiple brain metastases. Cochrane Da- domised controlled
trial. Lancet 2014;15:143–55. tabase Syst Rev 2012;4:CD003869. 60. Borghaei H, Paz-Ares L, Horn L i sur. Nivolumab
versus Docetaxel in 69. Temel JS, Greer JA, Muzikansky A i sur. Early palliative care for pa- Advanced Nonsquamous Non-
Small-Cell Lung Cancer. N Engl J Med tients with metastatic non-small-cell lung cancer. N Engl J Med 2010; 61. Brahmer
J, Reckamp KL, Baas P i sur. Nivolumab versus docetaxel in 70. Vansteenkiste J, Crinò L, Dooms C i sur. 2nd ESMO
Consensus Con- advanced squamous-cell non-small-cell lung cancer. N Engl J Med ference on Lung Cancer: early-stage non-
small-cell lung cancer con- 2015;373(2):123–35. sensus on diagnosis, treatment and follow-up. Ann Oncol 2014;25: 62.
Herbst RS, Baas P, Kim DW i sur. Pembrolizumab versus docetaxel for 1462–74. previously treated, PD-L1-positive,
advanced non-small-cell lung can- 71. Samaržija M, Gugić D, Radić J i sur. Kliničke upute za dijagnozu, cer
(KEYNOTE-010): a randomised controlled trial. Lancet 2016; liječenje i praćenje bolesnika oboljelih od karcinoma pluća
nemalih 387(10027):1540–50. stanica. Liječ Vjesn 2011;133:361–5.

52. [intervention] score -42
zumab as agent or a 2-agent chemotherapy regimen in advanced non-small-cell fi rst-line therapy in patients with
advanced non-squamous non-small- lung cancer. A meta analysis. JAMA 2004;292:470–84. cell lung cancer harbouring EGFR
mutations (JO25567): an open-la- 28. Pujol JL, Barlesi F, Daures JP i sur. Should chemotherapy combina- bel, randomised,
multicentre, phase 2 study. Lancet 2014;15:1236–44. tions for advanced non-small cell lung cancer be platinum-based? A
50. Giaccone G, Herbst RS, Manegold C i sur. Gefi tinib in combination meta analysis of phased III randomized trials.
Lung Cancer 2006;51: with gemcitabine and cisplatin in advanced non-small-cell lung cancer: 335–45. a phase III
trial–INTACT 1. J Clin Oncol 2004;22:777–84. 29. Jiang J, Liang H, Zhou X i sur. A meta-analysis of randomized con- 51.
Herbst RS, Giaccone G, Schiller JH i sur. Gefi tinib in combination with trolled trials comparing carboplatin-based to
cisplatin-based chemo- paclitaxel and carboplatin in advanced non-small-cell lung cancer: a therapy in advanced non-
small cell lung cancer. Lung Cancer 2007;57: phase III trial–INTACT 2. J Clin Oncol 2004;22:785–94. 348–58. 52.
Gatzemeier U, Pluzanska A, Szczesna A i sur. Phase III study of erlo- 30. Smit EF, van Meerbeeck JP, Lianes P i sur.
Three-arm randomized tinib in combination with cisplatin and gemcitabine in advanced non- study of two cisplatin-based
regimens and paclitaxel plus gemcitabine small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J in
advanced non-small-cell lung cancer: a phase III trial of the Euro- Clin Oncol 2007;25:1545–52. pean Organization for
Research and Treatment of Cancer Lung Cancer 53. Shaw AT, Kim DW, Nakagawa K i sur. Crizotinib versus chemothe-
Group–EORTC 08975. J Clin Oncol 2003;21:3909–17. rapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368: 31.
Schiller JH, Harrington D, Belani CP i sur. Comparison of four chemo- 2385–94. therapy regimens for advanced non-small-
cell lung cancer. N Engl J 54. Solomon BJ, Mok T, Kim DW i sur. First-line crizotinib versus chemo- Med 2002;346:92–8.
therapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167–77. 55. Fossella FV, DeVore R, Kerr RN i sur. Randomized
phase III trial of 63. Rittmeyer A, Barlesi F, Waterkamp D i sur. Atezolizumab versus docetaxel versus vinorelbine or
ifosfamide in patients with advanced docetaxel in patients with previously treated non-small-cell lung cancer non-small-
cell lung cancer previously treated with platinum-containing (OAK): a phase 3, open-label, multicentre randomised
controlled trial. chemotherapy regimens. The TAX 320 Non Small Cell Lung Cancer Lancet 2017;389:255–65. Study Group. J
Clin Oncol 2000;18:2354–62. 64. Mok TS, Yi-Long Wu YL, Ahn MJ i sur. Osimertinib or platinum–peme- 56. Sheperd FA,
Dancey J, Ramlau R i sur. Prospective randomized trial of trexed in EGFR T790M–positive lung cancer. N Engl J Med 2017;
docetaxel versus best suportive care in patients with non small cell lung 376:629–40. cancer previously treated with
platinum-based chemotherapy. J Clin 65. Larkins E, Blumenthal GM, Chen H i sur. FDA Approval: Alectinib for Oncol
2000;18:2095–103. the treatment of metastatic, ALK-positive non-small cell lung cancer 57. Hanna N, Sheperd FA, Fossella
FV i sur. Randomized pha

53. [outcome] score -42
nirana/neresektabilna lokalno uznapredovala II trial of medically inoperable stage I non-small-cell lung cancer pa-
bolest u fazi aktivnog liječenja tients treated with stereotactic body radiotherapy. J Clin Oncol 2009; Kontrola učinka
liječenja svakih 6 – 8 tjedana (rendgen- 27:3290–6. 7. Scagliotti GV, Pastorino U, Vansteenkiste JF i sur. Randomized
phase ska snimka/CT pluća, UZ/CT abdomena).41 Ostale pretra- III study of surgery alone or surgery plus preoperative
cisplatin and ge prema kliničkoj indikaciji (PET nije indiciran, iznimno gemcitabine in stages IB to IIIA non-small cell
lung cancer. J Clin On- prema preporuci multidisciplinarnog tima). col 2012;30:172–8. 8. Gilligan D, Nicolson M, Smith I
i sur. Preoperative chemotherapy in Diseminirana/neresektabilna lokalno uznapredovala patients with resectable non-small
cell lung cancer: results of the MRC bolest – pauza u liječenju, praćenje radi pravodobne LU22/NVALT 2/EORTC 08012
multicentre randomised trial and up- date of systematic review. Lancet 2007;369:1929–37. detekcije progresije bolesti 9.
NSCLC Meta-analysis Collaborative Group. Preoperative chemothera- Klinički pregled, KKS, DKS, SE i osnovne biokemijske
py for non-small-cell lung cancer: a systematic review and meta-analy- pretrage krvi svakih 8 – 12 tjedana prvih 12
mjeseci, svaka sis of individual participant data. Lancet 2014;383(9928):1561–71. 10. Higgins K, Chino JP, Marks LB i
sur. Preoperative chemotherapy ver- 3 – 6 mjeseci 2. i 3. godinu, zatim svakih 4 – 8 mjeseci tije- sus preoperative
chemoradiotherapy for stage III (N2) non-small-cell kom 4. i 5. godine, potom svakih 6 – 12 mjeseci. Praćenje lung
cancer. Int J Radiat Oncol Biol Phys 2009;75(5):1462–7. 11. Albain KS, Swann RS, Rusch VW i sur. Radiotherapy plus
chemothera- 32. Scagliotti GV, Hanna N, Fossella F i sur. The differential effi cacy of py with or without surgical
resection for stage III non-small cell lung pemetrexed according to NSCLC histology: a review of two phase III cancer: a
phase III randomised controlled trial. Lancet 2009;374: studies. Oncologist 2009;14:253–63. 379–86. 33. Scagliotti GV,
Parikh P, von Pawel J i sur. Phase III study comparing 12. Thomas M, Rübe C, Hoffknecht P i sur. Effect of preoperative
chemo- cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemo- radiation in addition to preoperative
chemotherapy: a randomised trial therapy-naive patients with advanced-stage non-small-cell lung cancer. in stage III
non-small cell lung cancer. Lancet Oncol 2008;9:636–48. J Clin Oncol 2008;26:3543–51. 13. Furuse K, Fukuoka M, Kawahara
M i sur. Phase III study of concurrent 34. Paz-Ares LG, de Marinis F, Dediu M i sur. PARAMOUNT: final overall versus
sequential thoracic radiotherapy in combination with mito- survival results of the phase III study of maintenance
pemetrexed ver- mycin, vindesine, and cisplatin in unresectable stage III non-small-cell sus placebo immediately after
induction treatment with pemetrexed lung cancer. J Clin Oncol 1999;17:2692–9. plus cisplatin for advanced nonsquamous
non-small-cell lung cancer. J 14. Curran WJ Jr, Paulus R, Langer CJ i sur. Sequential vs. concurrent Clin Oncol
2013;31:2895–902. chemoradiation for stage III non-small cell lung cancer: randomized 35. Sandler A, Gray R, Perry MC i
sur. Paclitaxel

54. [population] score -43
krvi napraviti svaka 3 do 4 mjeseca prve 2 godine, lung cancer stage I and stage II: ACCP evidence-based clinical
practice guidelines (2. izd.). Chest 2007;132:234S–42S. svakih 6 mjeseci od 3. do 5. godine, potom 1x na godinu. CT 5.
Darling GE, Allen MS, Decker PA i sur. Randomized trial of mediasti- pluća (rendgensko snimanje) svakih 6 mjeseci prve 2
godine, nal lymph node sampling versus complete lymphadenectomy during zatim 1x na godinu. CT (UZ) abdomena 1x na go
dinu. pulmonary resection in the patient with N0 or N1 (less than hilar) Ostale pretrage prema kliničkoj indikaciji (PET
samo non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac
Cardiovasc Surg 2011;141(3): prema preporuci multidisciplinarnog tima). 6. Baumann P, Nyman J, Hoyer M i sur. Outcome in
a prospective phase Diseminirana/neresektabilna lokalno uznapredovala II trial of medically inoperable stage I non-
small-cell lung cancer pa- bolest u fazi aktivnog liječenja tients treated with stereotactic body radiotherapy. J Clin
Oncol 2009; Kontrola učinka liječenja svakih 6 – 8 tjedana (rendgen- 27:3290–6. 7. Scagliotti GV, Pastorino U,
Vansteenkiste JF i sur. Randomized phase ska snimka/CT pluća, UZ/CT abdomena).41 Ostale pretra- III study of surgery
alone or surgery plus preoperative cisplatin and ge prema kliničkoj indikaciji (PET nije indiciran, iznimno gemcitabine
in stages IB to IIIA non-small cell lung cancer. J Clin On- prema preporuci multidisciplinarnog tima). col
2012;30:172–8. 8. Gilligan D, Nicolson M, Smith I i sur. Preoperative chemotherapy in Diseminirana/neresektabilna
lokalno uznapredovala patients with resectable non-small cell lung cancer: results of the MRC bolest – pauza u
liječenju, praćenje radi pravodobne LU22/NVALT 2/EORTC 08012 multicentre randomised trial and up- date of systematic
review. Lancet 2007;369:1929–37. detekcije progresije bolesti 9. NSCLC Meta-analysis Collaborative Group. Preoperative
chemothera- Klinički pregled, KKS, DKS, SE i osnovne biokemijske py for non-small-cell lung cancer: a systematic review
and meta-analy- pretrage krvi svakih 8 – 12 tjedana prvih 12 mjeseci, svaka sis of individual participant data. Lancet
2014;383(9928):1561–71. 10. Higgins K, Chino JP, Marks LB i sur. Preoperative chemotherapy ver- 3 – 6 mjeseci 2. i 3.
godinu, zatim svakih 4 – 8 mjeseci tije- sus preoperative chemoradiotherapy for stage III (N2) non-small-cell kom 4. i
5. godine, potom svakih 6 – 12 mjeseci. Praćenje lung cancer. Int J Radiat Oncol Biol Phys 2009;75(5):1462–7. 11. Albain
KS, Swann RS, Rusch VW i sur. Radiotherapy plus chemothera- 32. Scagliotti GV, Hanna N, Fossella F i sur. The
differential effi cacy of py with or without surgical resection for stage III non-small cell lung pemetrexed according
to NSCLC histology: a review of two phase III cancer: a phase III randomised controlled trial. Lancet 2009;374: studies.
Oncologist 2009;14:253–63. 379–86. 33. Scagliotti GV, Parikh P, von Pawel J i sur. Phase III study comparing 12. Thomas
M, Rübe C, Hoffknecht P i sur. Effect of preoperative chemo- cisplatin plus gemcitabine with cisplatin plus pemetrexed
in chemo- radiation in addition to preoperative chemotherapy: a randomised trial therapy-naive patients with advanced-
stage non-small-cell lung can

55. [intervention] score -43
IH OD RAKA PLUĆA NEMALIH STANICA GUIDELINES FOR DIAGNOSIS, TREATMENT AND MONITORING PATIENTS WITH NON-SMALL CELL LUNG
CANCER MIROSLAV SAMARŽIJA, MARKO JAKOPOVIĆ, MARIJO BOBAN, LIDIJA BOŠKOVIĆ, INGRID BELAC LOVASIĆ, ANTONIO JURETIĆ, DAMIR
GUGIĆ, JASNA RADIĆ, SVEN SEIWERTH, SNJEŽANA TOMIĆ, KSENIJA LUČIN, SANJA PLEŠTINA, MIHOVIL ROGLIĆ, JOŠKO JURIČIĆ, SILVANA
SMOJVER JEŽEK, DINKO STANČIĆ-ROKOTOV, IVICAMAŽURANIĆ, SUZANA KUKULJ, KREŠIMIR DOLIĆ, DRAGAN ARAR, MELITA KUKULJAN,
EDUARD VRDOLJAK* Deskriptori: Karcinom pluća nemalih stanica – dijagnoza, liječenje, patologija; Tumorski stadij;
Smjernice; Hrvatska Sažetak. Rak pluća najučestalija je zloćudna bolest u muškaraca, a pri vrhu je učestalosti i u žena.
Među oboljelima 85% čine bolesnici s rakom pluća nemalih stanica. S obzirom na agresivnu prirodu ove bolesti i lošu
prognozu ako se ne dijagnosticira u ranom stadiju bolesti, vrlo je važno defi nirati i provoditi standardizirani pristup
u dijagnostici, liječenju i praćenju ovih bolesnika. Metode liječenja uključuju kirurgiju, kemoterapiju, radioterapiju,
ciljanu biološku terapiju i imunoterapiju ovisno o stadiju bolesti, biološkim obilježjima tumora i općem stanju
bolesnika. Descriptors: C arcinnoma, non-small-cell lung – diagnosis, pathology, therapy; Neoplasm staging; Practice
guidelines as topic; Croatia Summary. Lung cancer is the most common male cancer, and one of the most common female
cancers. Non-small cell lung cancers account for 85% of lung cancers. Due to the aggressiveness of the disease and bad
prognosis if it is not diagnosed early, it is important to defi ne and implement standardized approach for diagnostics,
treatment and monitoring of these patients. Treatment modalities include surgery, chemotherapy, radiotherapy, targeted
biologic therapy and immunotherapy according to the stage, specifi c tumour histological subtype and patient condition.
Liječ Vjesn 2017;139:365–371 Smjernice za dijagnozu, liječenje i praćenje bolesnika * Klinika za plućne bolesti
Jordanovac, Medicinski fakultet Sveučilišta oboljelih od raka pluća nemalih stanica napravilo je Hrvat- u Zagrebu, KBC
Zagreb (akademik Miroslav Samaržija, dr. med.; prof. sko onkološko društvo Hrvatskoga liječničkog zbora, a re- dr. sc.
Marko Jakopović, dr. med.; doc. dr. sc. Sanja Pleština, dr. med.; prim. zultat su angažmana i suradnje vodećih
stručnjaka u Hrvat- Mihovil Roglić, dr. med.; prof. dr. sc. Dinko Stančić-Rokotov, dr. med.; prof. dr. sc. Ivica
Mažuranić, dr. med.; doc. dr. sc. Suzana Kukulj, dr. med.), skoj na područjima onkologije, pulmologije, kirurgije, pato-
Klinika za onkologiju i radioterapiju, Medicinski fakultet Sveučilišta u logije, radiologije i citologije. Izrada uputa
nije fi nancijski Splitu, KBC Split (doc. dr. sc. Marijo Boban, dr. med.; mr. sc. Lidija potpomognuta. Osnovni ciljevi
ovih smjernica jesu pobolj- Bošković, dr. med.; prof. dr. sc. Eduard Vrdoljak, dr. med.), Klinika za radioterapiju i
onkologiju, Medicinski fakultet Sveučilišta u Rijeci, šanje kvalitete i standardizacija postupaka dijagnostike, li- KBC
Rijeka (doc. dr. sc. Ingrid Belac Lova sić, dr. med.), Klinika za onko- ječenja i praćenja bolesnika oboljelih od
karcinoma pluća logiju, Medicinski fakultet Sveučilišta u Zagrebu, KBC Zagreb (prof. nemalih stanica. Sve preporuke u
uputama razine su

56. [intervention] score -43
nih deskriptivnih studija, risne kod opstrukcije dišnih putova (terapija laserom, po- poput usporednih studija,
korelacijskih studija ili pri- stavljanje stenta, krioterapija, brahiterapija). Postavljanje kaza bolesnika stenta
katkad se rabi kod sindroma gornje šuplje vene, a IV – Dokaz proizašao iz izvješća ili mišljenja odbora struč-
pleurodeza ili postavljanje torakalnog drena kod recidivira- njaka ili iz kliničkog iskustva nedvojbenog autoriteta
jućih pleuralnih izljeva. ili obojega Suportivna terapija Ove su smjernice nadopuna kliničkih uputa za dijagnozu, Kod
svih bolesnika s uznapredovalim karcinomom pluća liječenje i praćenje bolesnika oboljelih od raka pluća nema- savjetuje
se što prije započeti primjenom suportivne tera- lih stanica objavljenih 2011. godini.71 pije.69 Klinička istraživanja L
I T E R A T U R A Savjetuje se uključenje što većeg broja bolesnika s karci- 1. Incidencija raka u Hrvatskoj 2014.
Bilten br. 39. Zagreb: Hrvatski zavod za javno zdravstvo; 2016. nomom pluća u klinička istraživanja. 2. Goldstraw P,
Chansky K, Crowley J i sur. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings
Preporuke za kontrolu i praćenje in the Forthcoming (Eighth) Edition of the TNM Classifi cation for Lung Cancer. J
Thorac Oncol 2016;11(1):39–51. Nakon radikalnoga kirurškog zahvata 3. Ginsberg RJ, Rubinstein LV. Randomised trial of
lobectomy versus /adjuvantnog liječenja70 limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study
Group. Ann Thorac Surg 1995;60: 615–22. Klinički pregled, KKS, DKS, SE i osnovne biokemijske 4. Scott WJ, Howington J,
Feigenberg S i sur. Treatment of non-small cel pretrage krvi napraviti svaka 3 do 4 mjeseca prve 2 godine, lung cancer
stage I and stage II: ACCP evidence-based clinical practice guidelines (2. izd.). Chest 2007;132:234S–42S. svakih 6
mjeseci od 3. do 5. godine, potom 1x na godinu. CT 5. Darling GE, Allen MS, Decker PA i sur. Randomized trial of
mediasti- pluća (rendgensko snimanje) svakih 6 mjeseci prve 2 godine, nal lymph node sampling versus complete
lymphadenectomy during zatim 1x na godinu. CT (UZ) abdomena 1x na go dinu. pulmonary resection in the patient with N0 or
N1 (less than hilar) Ostale pretrage prema kliničkoj indikaciji (PET samo non-small cell carcinoma: results of the
American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg 2011;141(3): prema preporuci
multidisciplinarnog tima). 6. Baumann P, Nyman J, Hoyer M i sur. Outcome in a prospective phase
Diseminirana/neresektabilna lokalno uznapredovala II trial of medically inoperable stage I non-small-cell lung cancer
pa- bolest u fazi aktivnog liječenja tients treated with stereotactic body radiotherapy. J Clin Oncol 2009; Kontrola
učinka liječenja svakih 6 – 8 tjedana (rendgen- 27:3290–6. 7. Scagliotti GV, Pastorino U, Vansteenkiste JF i sur.
Randomized phase ska snimka/CT pluća, UZ/CT abdomena).41 Ostale pretra- III study of surgery alone or surgery plus
preoperative cisplatin and ge prema kliničkoj indikaciji (PET nije indiciran, iznimno gemcitabine in stages IB to IIIA
non-small cell lung cancer. J Clin On- prema preporuci multidisciplinarnog tima). col 2012;30:172–8. 8. Gilligan D,
Nicolson M, Smith I i sur. Preoperative chemotherapy in Diseminirana/neresektabi

57. [intervention] score -43
6;22:5171–6. pemetrexed versus docetaxel in patients with non-small-cell lung 66. Khozin S, Blumenthal GM, Zhang L i
sur. FDA approval: ceritinib for cancer previously treated with chemotherapy. J Clin Oncol 2004;22: the treatment of
metastatic anaplastic lymphoma kinase-positive non- 1589–97. small cell lung cancer. Clin Cancer Res 2015;21(11):2436–9.
58. Nagano T, Kim YH, Goto K i sur. Re-challenge chemotherapy for re- 67. Shepherd FA, Pereira JR, Ciuleanu T i sur.
Erlotinib in Previously lapsed non-small-cell lung cancer. Lung Cancer 2010;69(3):315–8. Treated Non-Small-Cell Lung
Cancer. N Engl J Med 2005;353: 59. Reck M, Kaiser R, Mellemgaard A i sur. Docetaxel plus nintedanib ver- 123–32. sus
docetaxel plus placebo in patients with previously treated non- 68. Tsao MN, Lloyd N, Wong RK i sur. Whole brain
radiotherapy for the small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, ran- treatment of newly diagnosed
multiple brain metastases. Cochrane Da- domised controlled trial. Lancet 2014;15:143–55. tabase Syst Rev
2012;4:CD003869. 60. Borghaei H, Paz-Ares L, Horn L i sur. Nivolumab versus Docetaxel in 69. Temel JS, Greer JA,
Muzikansky A i sur. Early palliative care for pa- Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med tients
with metastatic non-small-cell lung cancer. N Engl J Med 2010; 61. Brahmer J, Reckamp KL, Baas P i sur. Nivolumab versus
docetaxel in 70. Vansteenkiste J, Crinò L, Dooms C i sur. 2nd ESMO Consensus Con- advanced squamous-cell non-small-cell
lung cancer. N Engl J Med ference on Lung Cancer: early-stage non-small-cell lung cancer con- 2015;373(2):123–35. sensus
on diagnosis, treatment and follow-up. Ann Oncol 2014;25: 62. Herbst RS, Baas P, Kim DW i sur. Pembrolizumab versus
docetaxel for 1462–74. previously treated, PD-L1-positive, advanced non-small-cell lung can- 71. Samaržija M, Gugić D,
Radić J i sur. Kliničke upute za dijagnozu, cer (KEYNOTE-010): a randomised controlled trial. Lancet 2016; liječenje i
praćenje bolesnika oboljelih od karcinoma pluća nemalih 387(10027):1540–50. stanica. Liječ Vjesn 2011;133:361–5.

58. [intervention] score -43
bert K i sur. Phase III trial of gem- dence. Lung Cancer 2011;71(3):249–57. citabine plus carboplatin versus single-
agent gemcitabine in the treat- 48. Lee CK, Brown C, Gralla RJ i sur. Impact of EGFR inhibitor in non- ment of locally
advanced or metastatic non-small-cell lung cancer. The small cell lung cancer on progression-free and overall survival:
a meta- Swedish Lung Cancer Study Group. J Clin Oncol 2005;23:8380–8. analysis. J Natl Cancer Inst 2013;105:595–605. 27.
Delbaldo C, Michiels S, Syz N i sur. Benefi ts of adding a drug to a single 49. Seto T, Kato T, Nishio M i sur.
Erlotinib alone or with bevacizumab as agent or a 2-agent chemotherapy regimen in advanced non-small-cell fi rst-line
therapy in patients with advanced non-squamous non-small- lung cancer. A meta analysis. JAMA 2004;292:470–84. cell lung
cancer harbouring EGFR mutations (JO25567): an open-la- 28. Pujol JL, Barlesi F, Daures JP i sur. Should chemotherapy
combina- bel, randomised, multicentre, phase 2 study. Lancet 2014;15:1236–44. tions for advanced non-small cell lung
cancer be platinum-based? A 50. Giaccone G, Herbst RS, Manegold C i sur. Gefi tinib in combination meta analysis of
phased III randomized trials. Lung Cancer 2006;51: with gemcitabine and cisplatin in advanced non-small-cell lung
cancer: 335–45. a phase III trial–INTACT 1. J Clin Oncol 2004;22:777–84. 29. Jiang J, Liang H, Zhou X i sur. A meta-
analysis of randomized con- 51. Herbst RS, Giaccone G, Schiller JH i sur. Gefi tinib in combination with trolled trials
comparing carboplatin-based to cisplatin-based chemo- paclitaxel and carboplatin in advanced non-small-cell lung cancer:
a therapy in advanced non-small cell lung cancer. Lung Cancer 2007;57: phase III trial–INTACT 2. J Clin Oncol
2004;22:785–94. 348–58. 52. Gatzemeier U, Pluzanska A, Szczesna A i sur. Phase III study of erlo- 30. Smit EF, van
Meerbeeck JP, Lianes P i sur. Three-arm randomized tinib in combination with cisplatin and gemcitabine in advanced non-
study of two cisplatin-based regimens and paclitaxel plus gemcitabine small-cell lung cancer: the Tarceva Lung Cancer
Investigation Trial. J in advanced non-small-cell lung cancer: a phase III trial of the Euro- Clin Oncol
2007;25:1545–52. pean Organization for Research and Treatment of Cancer Lung Cancer 53. Shaw AT, Kim DW, Nakagawa K i
sur. Crizotinib versus chemothe- Group–EORTC 08975. J Clin Oncol 2003;21:3909–17. rapy in advanced ALK-positive lung
cancer. N Engl J Med 2013;368: 31. Schiller JH, Harrington D, Belani CP i sur. Comparison of four chemo- 2385–94.
therapy regimens for advanced non-small-cell lung cancer. N Engl J 54. Solomon BJ, Mok T, Kim DW i sur. First-line
crizotinib versus chemo- Med 2002;346:92–8. therapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167–77. 55.
Fossella FV, DeVore R, Kerr RN i sur. Randomized phase III trial of 63. Rittmeyer A, Barlesi F, Waterkamp D i sur.
Atezolizumab versus docetaxel versus vinorelbine or ifosfamide in patients with advanced docetaxel in patients with
previously treated non-small-cell lung cancer non-small-cell lung cancer previously treated with platinum-containing
(OAK): a phase 3, open-label, multicentre randomised controlled trial. chemotherapy regimens. The TAX 320 Non Small Cell
Lung Cancer Lancet 2017;389:255–65. Study

59. [population] score -48
hase III trial of 36. Reck M, von Pawel J, Zatloukal P i sur. Phase III trial of cisplatin plus sequential
chemoradiotherapy compared with concurrent chemoradio- gemcitabine with either placebo or bevacizumab as fi rst-line
therapy therapy in locally advanced non-small-cell lung cancer: Groupe Lyon- for nonsquamous non-small cell lung cancer:
AVAiL. J Clin Oncol Saint-Etienne d’Oncologie Thoracique-Groupe Français de Pneumo- Cancérologie NPC 95-01 Study. J Clin
Oncol 2005;23:5910–7. 37. Sandler A, Yi J, Dahlberg S i sur. Treatment outcomes by tumor histol- 16. Aupérin A, Le
Péchoux C, Rolland E i sur. Meta-analysis of concomi- ogy in Eastern Cooperative Group Study E4599 of bevacizumab with
tant versus sequential radiochemotherapy in locally advanced non- paclitaxel/carboplatin for advanced non-small cell
lung cancer. J Tho- small cell lung cancer. J Clin Oncol 2010;28:2181–90. rac Oncol 2010;5:1416–23. 17. Brunelli A,
Charloux A, Bolliger CT i sur. ERS/ESTS clinical guide- 38. Masters GA, Temin S, Christopher G i sur. Systemic Therapy
for Stage lines on fitness for radical therapy in lung cancer patients (surgery and IV Non-Small-Cell Lung Cancer:
American Society of Clinical On- chemo-radiotherapy). Eur Respir J 2009;34:17–41. cology Clinical Practice Guideline
Update. J Clin Oncol 2015;33: 18. Rusch VW, Giroux DJ, Kraut MJ i sur. Induction chemoradiation and 3488–515. surgical
resection for superior sulcus non-small cell lung carcinomas: 39. Santos FN, de Castria TB, Cruz MR, Riera R.
Chemotherapy for ad- long-term results of Southwest Oncology Group Trial 9416 – (Inter- vanced non-small cell lung
cancer in the elderly population. Cochrane group Trial 0160). J Clin Oncol 2007;25:313–8. Database Syst Rev
2015;(10):CD010463. 19. Hancock JG, Rosen JE, Antonicelli A i sur. Impact of adjuvant treat- 40. Novello S, Barlesi F,
Califano R i sur. Metastatic non-small-cell lung ment for microscopic residual disease after non-small cell lung cancer
cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment surgery. Ann Thorac Surg 2015;99(2):406–13. and
follow-up. Ann Oncol 2016;27:1–27. 20. Douillard JY, Rosell R, De Lena M i sur. Impact of postoperative radia- 41. von
Plessen C, Bergman B, Andresen O i sur. Palliative chemotherapy tion therapy on survival in patients with complete
resection and stage I, beyond three courses conveys no survival or consistent quality-of-life II, or IIIA non-small-cell
lungcancer treated with adjuvant chemother- benefi ts in advanced non small-cell lung cancer. Br J Cancer 2006; apy: the
adjuvant Navelbine International Trialist Association (ANITA) 95:966–73. Randomized Trial. Int J Radiat Oncol Biol Phys
2008:72;696–701. 42. Park JO, Kim SW, Ahn JS i sur. Phase III trial of two versus four addi- 21. Bradley JD, Paulus R,
Graham MV i sur. Phase II trial of postoperative tional cycles in patients who are nonprogressive after two cycles of
adjuvant paclitaxel/carboplatin and thoracic radiotherapy in resected platinum-based chemotherapy in non small-cell lung
cancer. J Clin stage II and IIIA non-small-cell lung cancer: promising long-term Oncol 2007;25:5233–9. results of the
Radiation Therapy Oncology Group–RTOG 9705. J Clin 43. Rosell R, Carceremy E, Gervais R i sur. Erlotinib versus standard
che- Oncol 2005:343;3480–7.

60. [population] score -48
IDELINES FOR DIAGNOSIS, TREATMENT AND MONITORING PATIENTS WITH NON-SMALL CELL LUNG CANCER MIROSLAV SAMARŽIJA, MARKO
JAKOPOVIĆ, MARIJO BOBAN, LIDIJA BOŠKOVIĆ, INGRID BELAC LOVASIĆ, ANTONIO JURETIĆ, DAMIR GUGIĆ, JASNA RADIĆ, SVEN
SEIWERTH, SNJEŽANA TOMIĆ, KSENIJA LUČIN, SANJA PLEŠTINA, MIHOVIL ROGLIĆ, JOŠKO JURIČIĆ, SILVANA SMOJVER JEŽEK, DINKO
STANČIĆ-ROKOTOV, IVICAMAŽURANIĆ, SUZANA KUKULJ, KREŠIMIR DOLIĆ, DRAGAN ARAR, MELITA KUKULJAN, EDUARD VRDOLJAK*
Deskriptori: Karcinom pluća nemalih stanica – dijagnoza, liječenje, patologija; Tumorski stadij; Smjernice; Hrvatska
Sažetak. Rak pluća najučestalija je zloćudna bolest u muškaraca, a pri vrhu je učestalosti i u žena. Među oboljelima 85%
čine bolesnici s rakom pluća nemalih stanica. S obzirom na agresivnu prirodu ove bolesti i lošu prognozu ako se ne
dijagnosticira u ranom stadiju bolesti, vrlo je važno defi nirati i provoditi standardizirani pristup u dijagnostici,
liječenju i praćenju ovih bolesnika. Metode liječenja uključuju kirurgiju, kemoterapiju, radioterapiju, ciljanu biološku
terapiju i imunoterapiju ovisno o stadiju bolesti, biološkim obilježjima tumora i općem stanju bolesnika. Descriptors: C
arcinnoma, non-small-cell lung – diagnosis, pathology, therapy; Neoplasm staging; Practice guidelines as topic; Croatia
Summary. Lung cancer is the most common male cancer, and one of the most common female cancers. Non-small cell lung
cancers account for 85% of lung cancers. Due to the aggressiveness of the disease and bad prognosis if it is not
diagnosed early, it is important to defi ne and implement standardized approach for diagnostics, treatment and
monitoring of these patients. Treatment modalities include surgery, chemotherapy, radiotherapy, targeted biologic
therapy and immunotherapy according to the stage, specifi c tumour histological subtype and patient condition. Liječ
Vjesn 2017;139:365–371 Smjernice za dijagnozu, liječenje i praćenje bolesnika * Klinika za plućne bolesti Jordanovac,
Medicinski fakultet Sveučilišta oboljelih od raka pluća nemalih stanica napravilo je Hrvat- u Zagrebu, KBC Zagreb
(akademik Miroslav Samaržija, dr. med.; prof. sko onkološko društvo Hrvatskoga liječničkog zbora, a re- dr. sc. Marko
Jakopović, dr. med.; doc. dr. sc. Sanja Pleština, dr. med.; prim. zultat su angažmana i suradnje vodećih stručnjaka u
Hrvat- Mihovil Roglić, dr. med.; prof. dr. sc. Dinko Stančić-Rokotov, dr. med.; prof. dr. sc. Ivica Mažuranić, dr. med.;
doc. dr. sc. Suzana Kukulj, dr. med.), skoj na područjima onkologije, pulmologije, kirurgije, pato- Klinika za
onkologiju i radioterapiju, Medicinski fakultet Sveučilišta u logije, radiologije i citologije. Izrada uputa nije fi
nancijski Splitu, KBC Split (doc. dr. sc. Marijo Boban, dr. med.; mr. sc. Lidija potpomognuta. Osnovni ciljevi ovih
smjernica jesu pobolj- Bošković, dr. med.; prof. dr. sc. Eduard Vrdoljak, dr. med.), Klinika za radioterapiju i
onkologiju, Medicinski fakultet Sveučilišta u Rijeci, šanje kvalitete i standardizacija postupaka dijagnostike, li- KBC
Rijeka (doc. dr. sc. Ingrid Belac Lova sić, dr. med.), Klinika za onko- ječenja i praćenja bolesnika oboljelih od
karcinoma pluća logiju, Medicinski fakultet Sveučilišta u Zagrebu, KBC Zagreb (prof. nemalih stanica. Sve preporuke u
uputama razine su dokaza dr. sc. Antonio Juretić,

